Lazydays Holdings, Inc. 52110H209 US52110H2094 07/03/2025 Election of Class A director nominee to serve a three-year term expiring at the 2028 Annual Meeting of Stockholders or until her successor has been duly elected and qualified: Susan Scarola DIRECTOR ELECTIONS ISSUER 44.000000 0 AGAINST 44.000000 AGAINST Lazydays Holdings, Inc. 52110H209 US52110H2094 07/03/2025 Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 44.000000 0 FOR 44.000000 FOR Lazydays Holdings, Inc. 52110H209 US52110H2094 07/03/2025 Approval, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 44.000000 0 FOR 44.000000 FOR Lazydays Holdings, Inc. 52110H209 US52110H2094 07/03/2025 Approval of an amendment to our 2018 Long-Term Incentive Plan (the "2018 Plan") to increase the number of authorized shares of our common stock par value $0.0001 per share ("common stock"), that may be issued under the 2018 Plan by 12,000,000 (before giving effect to any reverse stock split). COMPENSATION ISSUER 44.000000 0 FOR 44.000000 FOR Lazydays Holdings, Inc. 52110H209 US52110H2094 07/03/2025 Approval of an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of at least 1-for-2 and up to 1-for-30, as determined by our Board of Directors in its discretion and publicly announced prior to the effectiveness of such reverse stock split, subject to the authority of the Board of Directors to abandon such amendment. CAPITAL STRUCTURE ISSUER 44.000000 0 FOR 44.000000 FOR Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Omid Farokhzad, M.D. DIRECTOR ELECTIONS ISSUER 495.000000 0 FOR 495.000000 FOR Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Meeta Gulyani DIRECTOR ELECTIONS ISSUER 495.000000 0 FOR 495.000000 FOR Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Terrance McGuire DIRECTOR ELECTIONS ISSUER 495.000000 0 WITHHOLD 495.000000 AGAINST Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Robert Langer, Sc.D. DIRECTOR ELECTIONS ISSUER 495.000000 0 FOR 495.000000 FOR Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Dipchand (Deep) Nishar DIRECTOR ELECTIONS ISSUER 495.000000 0 WITHHOLD 495.000000 AGAINST Seer, Inc. 81578P106 US81578P1066 07/07/2025 Election of Directors: Nicolas Roelofs, Ph.D. DIRECTOR ELECTIONS ISSUER 495.000000 0 WITHHOLD 495.000000 AGAINST Seer, Inc. 81578P106 US81578P1066 07/07/2025 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending O December 31, 2025. AUDIT-RELATED ISSUER 495.000000 0 FOR 495.000000 FOR BlackRock Credit Allocation Income Trust 092508100 US0925081004 07/11/2025 To Elect Board Member Nominees: Cynthia L. Egan DIRECTOR ELECTIONS ISSUER 290333.000000 0 WITHHOLD 7302.341100 AGAINST FOR 283030.658900 FOR BlackRock Credit Allocation Income Trust 092508100 US0925081004 07/11/2025 To Elect Board Member Nominees: Robert Fairbairn DIRECTOR ELECTIONS ISSUER 290333.000000 0 WITHHOLD 6240.819610 AGAINST FOR 284092.180390 FOR BlackRock Credit Allocation Income Trust 092508100 US0925081004 07/11/2025 To Elect Board Member Nominees: Stayce D. Harris DIRECTOR ELECTIONS ISSUER 290333.000000 0 WITHHOLD 7242.577160 AGAINST FOR 283090.422840 FOR iCAD, Inc. 44934S206 US44934S2068 07/14/2025 To adopt the Agreement and Plan of Merger, dated April 15, 2025, by and among RadNet, Inc., a Delaware corporation ("RadNet"), Trio Merger Sub, Inc., a wholly-owned subsidiary of RadNet and a Delaware corporation ("Merger Sub"), and iCAD, Inc. ("iCAD") (as it may be amended from time to time, the "Merger Agreement"), under which, upon the terms and subject to the conditions set forth therein, Merger Sub will merge with and into iCAD (the "Merger"), with iCAD surviving as a whollyowned subsidiary of RadNet (the "Merger Agreement Proposal"). EXTRAORDINARY TRANSACTIONS ISSUER 130.000000 0 FOR 130.000000 FOR iCAD, Inc. 44934S206 US44934S2068 07/14/2025 To approve, by non-binding advisory vote, the compensation that may be paid or become payable to iCAD's named executive officers that is based on or otherwise related to the Merger (the "Advisory Compensation Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 130.000000 0 FOR 130.000000 FOR iCAD, Inc. 44934S206 US44934S2068 07/14/2025 To adjourn the special meeting (the "Special Meeting") to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting (the "Adjournment Proposal"). CORPORATE GOVERNANCE ISSUER 130.000000 0 FOR 130.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To elect two (2) directors to the Board of Directors as Class II directors: Lawrence Firestone DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To elect two (2) directors to the Board of Directors as Class II directors: David Keys DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve an advisory resolution approving executive compensation for fiscal year 2024. SECTION 14A SAY-ON-PAY VOTES ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve an advisory resolution on the frequency of advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 1.000000 0 ONE YEAR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve an amendment to our Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from two hundred fifty-million (250,000,000) shares to five hundred million (500,000,000). CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve the amendment and restatement of the 22nd Century Group, Inc. 2021 Omnibus Incentive Plan which shall increase the number of shares authorized for issuance by five million (5,000,000). COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve an amendment to our Articles of Incorporation, as amended, to effect a reverse stock split of our outstanding common stock at a ratio between 1-for-2 and 1-for-100, to be determined at the discretion of our Board of Directors (the "Reverse Split"), for the purpose of complying with the Nasdaq Listing Rules, subject to the Board's discretion to abandon such amendment. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve the Amended Warrants dated October 24, 2024 and the shares issuable upon exercise of the warrants pursuant to Rule 5635(d) of the Nasdaq Stock Market. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve the Warrants dated May 1, 2025 and the shares issuable upon exercise of the warrants pursuant to Rule 5635(d) of the Nasdaq Stock Market. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve an amendment to the outstanding convertible Debentures (the "JGB Amendment") pursuant to Rules 5635(b) and 5635(d) of the Nasdaq Stock Market. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To ratify the appointment of Freed Maxick CPAs, P.C. as our independent registered public accountants for fiscal year 2025. AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 07/15/2025 To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of Proposals 4, 5, 6, 7, 8, 9 and/or 10. CORPORATE GOVERNANCE ISSUER 1.000000 0 FOR 1.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To approve the issuance of shares of Ikena common stock to (i) the securityholders of Inmagene, pursuant to the terms of the Merger Agreement, and (ii) certain investors in the Ikena concurrent financing, pursuant to the terms of the subscription agreements, which will (a) represent more than 20% of the shares of Ikena common stock outstanding immediately prior to the merger and (b) result in the change of control of Ikena, Ikena pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively EXTRAORDINARY TRANSACTIONS ISSUER 161.000000 0 FOR 161.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To approve an amendment to Ikena's fifth amended and restated certificate of incorporation to effect a reverse stock split of Ikena's issued and outstanding common stock at a ratio in the range from 1:5 to 1:15, inclusive, with the final ratio to be mutually agreed to by Ikena and Inmagene CAPITAL STRUCTURE ISSUER 161.000000 0 FOR 161.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To elect three Class I directors to the Ikena board of directors to hold office until the 2028 Ikena annual meeting and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: lain Dukes D.Phil. DIRECTOR ELECTIONS ISSUER 161.000000 0 WITHHOLD 161.000000 AGAINST Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To elect three Class I directors to the Ikena board of directors to hold office until the 2028 Ikena annual meeting and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Maria Koehler, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 161.000000 0 FOR 161.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To elect three Class I directors to the Ikena board of directors to hold office until the 2028 Ikena annual meeting and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Otello Stampacchia, Ph.D. DIRECTOR ELECTIONS ISSUER 161.000000 0 WITHHOLD 161.000000 AGAINST Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To ratify the appointment of Ernst & Young LLP as Ikena's independent registered public accounting firm for the fiscal year ending December 31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the merger is completed AUDIT-RELATED ISSUER 161.000000 0 FOR 161.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To approve the 2025 Equity Incentive Plan, which will become effective on the date immediately following the consummation of the merger and is contingent on the completion of the merger COMPENSATION ISSUER 161.000000 0 AGAINST 161.000000 AGAINST Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To approve the 2025 Employee Stock Purchase Plan, which will become effective on the date immediately following the consummation of the merger and is contingent on the completion of the merger COMPENSATION ISSUER 161.000000 0 FOR 161.000000 FOR Ikena Oncology, Inc. 45175G207 US45175G2075 07/15/2025 To approve an adjournment of the Ikena annual meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1 and/or Proposal No. 2 CORPORATE GOVERNANCE ISSUER 161.000000 0 FOR 161.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 The election of two Class III directors to serve for a term of three years until Oportun's 2028 annual meeting of stockholders and until their successors are duly elected and qualified: Nominees RECOMMENDED by the Board of Directors: Carlos Minetti DIRECTOR ELECTIONS ISSUER 124.000000 0 FOR 124.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 The election of two Class III directors to serve for a term of three years until Oportun's 2028 annual meeting of stockholders and until their successors are duly elected and qualified: Nominees RECOMMENDED by the Board of Directors: Raul Vazquez DIRECTOR ELECTIONS ISSUER 124.000000 0 FOR 124.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 To approve an amendment of Oportun's Certificate of Incorporation to eliminate supermajority voting provisions and make certain other administrative changes. CORPORATE GOVERNANCE ISSUER 124.000000 0 FOR 124.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 To approve an amendment of Oportun's Certificate of Incorporation to declassify the Board of Directors and provide for the annual election of directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 124.000000 0 FOR 124.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 To approve, on a non-binding advisory basis, Oportun's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 124.000000 0 FOR 124.000000 FOR Oportun Financial Corporation 68376D104 US68376D1046 07/18/2025 To ratify the appointment of Deloitte & Touche LLP as Oportun's independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 124.000000 0 FOR 124.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Hila Karah DIRECTOR ELECTIONS ISSUER 80.000000 0 AGAINST 80.000000 AGAINST DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Dennis Matheis DIRECTOR ELECTIONS ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Dennis M. McGrath DIRECTOR ELECTIONS ISSUER 80.000000 0 AGAINST 80.000000 AGAINST DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Erez Raphael DIRECTOR ELECTIONS ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Yoav Shaked DIRECTOR ELECTIONS ISSUER 80.000000 0 AGAINST 80.000000 AGAINST DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Lawrence Leisure DIRECTOR ELECTIONS ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 Election of Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Lawrence Leisure, Yoav Shaked and Adam K. Stern to hold office until the 2026 Annual Meeting of Stockholders or their successors are elected and qualified or until their earlier resignation or removal: Adam K. Stern DIRECTOR ELECTIONS ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 To ratify the appointment by the Audit Committee of the Company's Board of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 To consider and vote to amend the Company's 2020 Equity Compensation Plan, as amended. COMPENSATION ISSUER 80.000000 0 AGAINST 80.000000 AGAINST DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 To authorize the Board to amend the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued and outstanding shares of common stock, $0.0001 par value per share (the "Common Stock"), at a ratio of not less than two (2) to one (1) and not greater than twenty-five (25) to one (1), to be implemented no later than September 15, 2025, as determined by the Board in its sole discretion; CAPITAL STRUCTURE ISSUER 80.000000 0 FOR 80.000000 FOR DarioHealth Corp. 23725P308 US23725P3082 07/23/2025 To approve an amendment to the Certificate of Incorporation of the Company to increase the number of authorized Common Stock from one hundred sixty million (160,000,000) shares, $0.0001 par value per share, to four hundred million (400,000,000) shares, $0.0001 par value per share; and CAPITAL STRUCTURE ISSUER 80.000000 0 AGAINST 80.000000 AGAINST GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Election of the following four nominees as directors for a one-year term: Michael Breen DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Election of the following four nominees as directors for a one-year term: Charles J. Casamento DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Election of the following four nominees as directors for a one-year term: Hilary Kramer DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Election of the following four nominees as directors for a one-year term: David C. Mun-Gavin DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Ratification of the appointment of Weinberg & Company, P.A. as the Company's independent public accountants for the year ending December 31, 2025. AUDIT-RELATED ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Approval of the non-binding advisory vote approving a resolution approving the compensation of the Company's executives as disclosed in the Company's Proxy Statement for the Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Approval, pursuant to Rule 5635 of The Nasdaq Stock Market LLC, of the issuance of 19.99% or more of the Company's outstanding shares of Common Stock in connection with (a) the Securities Purchase Agreement, including the shares issuable upon conversion of shares of Series L Preferred Stock and exercise of the warrants, and (b) the Common Shares Purchase Agreement. CAPITAL STRUCTURE ISSUER 3.000000 0 FOR 3.000000 FOR GT Biopharma, Inc. 36254L308 US36254L3087 07/24/2025 Approval of Amendment No. 1 to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan increasing the number of shares available for future awards thereunder by 583,334 shares of Common Stock. COMPENSATION ISSUER 3.000000 0 AGAINST 3.000000 AGAINST Kirkland's, Inc. 497498105 US4974981056 07/24/2025 To approve, an Amendment to the Amended and Restated Charter of Kirkland's, Inc. to declassify the Board of Directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of five directors, each for a term of one year, if Proposal 1 is Approved: Eric L. Schwartzman DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of five directors, each for a term of one year, if Proposal 1 is Approved: Amy E. Sullivan DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of five directors, each for a term of one year, if Proposal 1 is Approved: Neely J. Tamminga DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of five directors, each for a term of one year, if Proposal 1 is Approved: Tamara R. Ward DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of five directors, each for a term of one year, if Proposal 1 is Approved: Steven C. Woodward DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of two Class I directors, Tamara R. Ward and Steven C. Woodward, elect one Class II director, Eric L. Schwartzman, and elect one Class III director, Neely J. Tamminga, if Proposal 1 is Not Approved: Eric L. Schwartzman DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of two Class I directors, Tamara R. Ward and Steven C. Woodward, elect one Class II director, Eric L. Schwartzman, and elect one Class III director, Neely J. Tamminga, if Proposal 1 is Not Approved: Neely J. Tamminga DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of two Class I directors, Tamara R. Ward and Steven C. Woodward, elect one Class II director, Eric L. Schwartzman, and elect one Class III director, Neely J. Tamminga, if Proposal 1 is Not Approved: Tamara R. Ward DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Election of two Class I directors, Tamara R. Ward and Steven C. Woodward, elect one Class II director, Eric L. Schwartzman, and elect one Class III director, Neely J. Tamminga, if Proposal 1 is Not Approved: Steven C. Woodward DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 To approve an Amendment of the Company's Amended and Restated 2002 Equity Incentive Plan to increase the number of shares available for issuance under that Plan. COMPENSATION ISSUER 74.000000 0 AGAINST 74.000000 AGAINST Kirkland's, Inc. 497498105 US4974981056 07/24/2025 To approve, an Amendment to the Amended and Restated Charter of Kirkland's, Inc. to change the name of the Company from "Kirkland's, Inc." to "The Brand House Collective, Inc." CORPORATE GOVERNANCE ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 To approve, on an advisory basis, compensation for our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 74.000000 0 FOR 74.000000 FOR Kirkland's, Inc. 497498105 US4974981056 07/24/2025 Ratification of the selection of Ernst & Young LLP as our Independent Registered Public Accounting Firm for fiscal 2025. AUDIT-RELATED ISSUER 74.000000 0 FOR 74.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Jaswinder Pal Singh DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Monique Bonner DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Andrew Burton DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Todd Ford DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Alison Gleeson DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: John Pagliuca DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Elizabeth Theophille DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 Election of Directors: Samuel Wilson DIRECTOR ELECTIONS ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 To ratify the appointment of Grant Thornton LLP as 8x8, Inc.'s independent registered public accounting firm for the fiscal year ending March 31, 2026. AUDIT-RELATED ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 To approve, through an advisory vote, 8x8, Inc.'s executive compensation for the fiscal year ended March 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 To approve an amendment to the 8x8, Inc.'s Amended and Restated 1996 Employee Stock Purchase Plan to increase the number of shares of common stock available for issuance thereunder by 6,000,000 shares. COMPENSATION ISSUER 1327.000000 0 FOR 1327.000000 FOR 8x8, Inc. 282914100 US2829141009 07/25/2025 To approve an amendment to the 8x8, Inc.'s 2022 Equity Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 8,500,000 shares. COMPENSATION ISSUER 1327.000000 0 AGAINST 1327.000000 AGAINST Acutus Medical, Inc. 005111109 US0051111096 07/28/2025 Elect Director Andrew ElBardissi DIRECTOR ELECTIONS ISSUER 113.000000 0 WITHHOLD 113.000000 AGAINST HOOKIPA Pharma Inc. 43906K209 US43906K2096 07/29/2025 To approve the sale of certain assets of HOOKIPA Pharma Inc. pursuant to the Asset Purchase Agreement dated May 21, 2025, by and among HOOKIPA Pharma Inc., Hookipa Biotech GmbH and Gilead Sciences, Inc. (the "Asset Sale Proposal"). EXTRAORDINARY TRANSACTIONS ISSUER 11.000000 0 FOR 11.000000 FOR HOOKIPA Pharma Inc. 43906K209 US43906K2096 07/29/2025 To approve the liquidation and dissolution of HOOKIPA Pharma Inc. (the "Dissolution") and the Plan of Dissolution, which, if approved, will authorize HOOKIPA Pharma Inc. to dissolve and liquidate as described in the Plan of Dissolution (the "Dissolution Proposal"). The Dissolution is conditioned on approval of the Asset Sale Proposal. EXTRAORDINARY TRANSACTIONS ISSUER 11.000000 0 FOR 11.000000 FOR HOOKIPA Pharma Inc. 43906K209 US43906K2096 07/29/2025 To approve one or more adjournments of the Special Meeting from time to time, if necessary, to solicit additional proxies in the event that there are insufficient shares present virtually or represented by proxy voting in favor of the Asset Sale Proposal or the Dissolution Proposal. CORPORATE GOVERNANCE ISSUER 11.000000 0 FOR 11.000000 FOR Carisma Therapeutics Inc. 14216R101 US14216R1014 08/05/2025 To adopt and approve an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our Board of Directors, without further approval or authorization of our stockholders (the "Reverse Split Proposal"). CAPITAL STRUCTURE ISSUER 59.000000 0 FOR 59.000000 FOR Carisma Therapeutics Inc. 14216R101 US14216R1014 08/05/2025 To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Reverse Split Proposal. CORPORATE GOVERNANCE ISSUER 59.000000 0 FOR 59.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The election of the following nominees to the Company's Board of Directors to serve until the 2026 Annual Meeting of Stockholders: Stavros G. Vizirgianakis DIRECTOR ELECTIONS ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The election of the following nominees to the Company's Board of Directors to serve until the 2026 Annual Meeting of Stockholders: Charles D. Goodwin DIRECTOR ELECTIONS ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The election of the following nominees to the Company's Board of Directors to serve until the 2026 Annual Meeting of Stockholders: Lawrence J. Waldman DIRECTOR ELECTIONS ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The election of the following nominees to the Company's Board of Directors to serve until the 2026 Annual Meeting of Stockholders: Minnie Baylor-Henry DIRECTOR ELECTIONS ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The election of the following nominees to the Company's Board of Directors to serve until the 2026 Annual Meeting of Stockholders: Wendy Levine DIRECTOR ELECTIONS ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The ratification of RSM US LLP as the Company's independent public accountants for the year ending December 31, 2025. AUDIT-RELATED ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The approval of a non-binding advisory proposal approving a resolution supporting the compensation of named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 185.000000 0 FOR 185.000000 FOR Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The approval of a non-binding advisory vote on the frequency of an advisory vote on compensation of named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 185.000000 0 ONE YEAR 185.000000 AGAINST Apyx Medical Corporation 03837C106 US03837C1062 08/07/2025 The approval to adopt the amendment to the Company's Certificate of Incorporation to delete the text of Article EIGHTH and replace with "Intentionally Omitted". CORPORATE GOVERNANCE ISSUER 185.000000 0 FOR 185.000000 FOR Aterian, Inc. 02156U200 US02156U2006 08/12/2025 To elect Arturo Rodriguez as a Class III director to serve until our 2028 Annual Meeting of Stockholders: Arturo Rodriguez DIRECTOR ELECTIONS ISSUER 12.000000 0 AGAINST 12.000000 AGAINST Aterian, Inc. 02156U200 US02156U2006 08/12/2025 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 12.000000 0 FOR 12.000000 FOR Aterian, Inc. 02156U200 US02156U2006 08/12/2025 To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our of Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 12.000000 0 ONE YEAR 12.000000 AGAINST Aterian, Inc. 02156U200 US02156U2006 08/12/2025 To ratify the appointment of UHY LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 12.000000 0 FOR 12.000000 FOR Kalaris Therapeutics, Inc. 482929106 US4829291065 08/12/2025 The election of two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Srinivas Akkaraju, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 7.000000 0 WITHHOLD 7.000000 AGAINST Kalaris Therapeutics, Inc. 482929106 US4829291065 08/12/2025 The election of two Class II directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Andrew Oxtoby DIRECTOR ELECTIONS ISSUER 7.000000 0 WITHHOLD 7.000000 AGAINST Kalaris Therapeutics, Inc. 482929106 US4829291065 08/12/2025 The ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 7.000000 0 FOR 7.000000 FOR GrafTech International Ltd. 384313607 US3843136074 08/14/2025 Approve an amendment to the Company's Amended and Restated Certificate of Incorporation to, at the discretion of the Board of Directors, effect a reverse stock split of the Company's issued common stock, par value $0.01 per share, at a ratio of not less than one-for-seven (1-for-7) and not greater than one-for-fifteen (1-for-15), with the final ratio within such range to be determined at the discretion of the Board of Directors, and a reduction in the number of authorized shares of common stock and preferred stock, par value $0.01 per share, by a corresponding proportion. CAPITAL STRUCTURE ISSUER 2345.000000 0 FOR 2345.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Daniel Aghion DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Miriam Kidron DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Nadav Kidron DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Dr. Arie Mayer DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Yehuda Reznick DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Leonard Sank DIRECTOR ELECTIONS ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To re-elect the following directors of the Company to hold office until our next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal: Benjamin Shapiro DIRECTOR ELECTIONS ISSUER 212.000000 0 AGAINST 212.000000 AGAINST Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2025 fiscal year: AUDIT-RELATED ISSUER 212.000000 0 FOR 212.000000 FOR Oramed Pharmaceuticals Inc. 68403P203 US68403P2039 08/19/2025 To consider and approve an amendment to the Company's Amended and Restated 2019 Stock Incentive Plan: COMPENSATION ISSUER 212.000000 0 AGAINST 212.000000 AGAINST Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: Marco Fregenal DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: Scott Flanders DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: David Hood DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: Stephen Murray DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: Adam Rothstein DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 Election of Directors: Jennifer Venable DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 To approve an amendment to the Fathom Holdings Inc. 2019 Omnibus Stock Incentive Plan to increase the share reserve by one million three hundred thousand (1,300,000) shares of common stock. COMPENSATION ISSUER 36.000000 0 AGAINST 36.000000 AGAINST Fathom Holdings Inc. 31189V109 US31189V1098 08/20/2025 To ratify the selection of Deloitte & Touche LLP, an independent registered public accounting firm, as the auditor of the Company for the year ending December 31, 2025. AUDIT-RELATED ISSUER 36.000000 0 FOR 36.000000 FOR Vor Biopharma Inc. 929033207 US9290332074 08/25/2025 To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock issuable by the Company upon exercise of the Warrants (as defined in the proxy statement). CAPITAL STRUCTURE ISSUER 113.000000 0 FOR 113.000000 FOR Vor Biopharma Inc. 929033207 US9290332074 08/25/2025 To approve a series of alternate amendments to the Company's Certificate of Incorporation, as amended, to effect, at the option of the Board of Directors, a reverse stock split of the common stock into a lesser number of outstanding shares at a ratio in the range of 1-for-5 to 1-for-30, inclusive, with such ratio to be determined by the Board of Directors in its sole discretion. CAPITAL STRUCTURE ISSUER 113.000000 0 FOR 113.000000 FOR Vor Biopharma Inc. 929033207 US9290332074 08/25/2025 To approve the amendment and restatement of the Company's Amended and Restated 2021 Equity Incentive Plan to, among other things, (i) increase the number of shares of the Company's common stock reserved for issuance thereunder by 25,000,000 shares and (ii) decrease the number of shares that will automatically be added to the share reserve thereunder on January 1 of each calendar year from five percent (5%) to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year through and including calendar year 2035. COMPENSATION ISSUER 113.000000 0 AGAINST 113.000000 AGAINST Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Roy H. Chestnutt DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Robert Deutschman DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Holly Hess Groos DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Mohan S. Gyani DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Jeffrey Karish DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Mollie V. Spilman DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: Michelle Sterling DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 Election of Directors: William G. Stone III DIRECTOR ELECTIONS ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 To approve, in a non-binding advisory vote, the compensation of our named executive officers, commonly referred to as "Say-on-pay." SECTION 14A SAY-ON-PAY VOTES ISSUER 1060.000000 0 FOR 1060.000000 FOR Digital Turbine, Inc. 25400W102 US25400W1027 08/26/2025 To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026. AUDIT-RELATED ISSUER 1060.000000 0 FOR 1060.000000 FOR Vincerx Pharma, Inc. 92731L304 US92731L3042 08/27/2025 To approve the liquidation and dissolution of Vincerx Pharma, Inc. (the "Company") in accordance with Section 275 of the Delaware General Corporation Law and pursuant to the plan of liquidation and dissolution which, if approved, will authorize the Company's board of directors to liquidate and dissolve the Company in accordance with the plan of liquidation and dissolution (the "Dissolution Proposal"). EXTRAORDINARY TRANSACTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Vincerx Pharma, Inc. 92731L304 US92731L3042 08/27/2025 To adjourn the special meeting to a later date, if necessary or appropriate, to allow for the solicitation of additional proxies in the event that there are not sufficient votes at the time of the special meeting to approval the Dissolution Proposal. CORPORATE GOVERNANCE ISSUER 4.000000 0 FOR 4.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Director Election Proposal - to elect five directors to serve on our Board of Directors until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Steven F. Urvan DIRECTOR ELECTIONS ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Director Election Proposal - to elect five directors to serve on our Board of Directors until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Christos Tsentas DIRECTOR ELECTIONS ISSUER 515.000000 0 AGAINST 515.000000 AGAINST Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Director Election Proposal - to elect five directors to serve on our Board of Directors until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Wayne Walker DIRECTOR ELECTIONS ISSUER 515.000000 0 AGAINST 515.000000 AGAINST Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Director Election Proposal - to elect five directors to serve on our Board of Directors until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Houman Akhavan DIRECTOR ELECTIONS ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Director Election Proposal - to elect five directors to serve on our Board of Directors until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified: David Douglas DIRECTOR ELECTIONS ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Auditor Ratification Proposal - to ratify the appointment of Withum Smith & Brown, P.C. as our independent registered public accounting firm for the fiscal year ending March 31, 2026; AUDIT-RELATED ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Incentive Plan Proposal - to approve the Outdoor Holding Company 2025 Long-Term Incentive Plan; COMPENSATION ISSUER 515.000000 0 AGAINST 515.000000 AGAINST Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Warrant Share Issuance Proposal - to approve, for the purpose of complying with the applicable rules of the Nasdaq Capital Market ("Nasdaq" and such rules, the "Nasdaq Rules"), including but not limited to Nasdaq Rule 5635(b) and (d), the issuance of a warrant (the "Additional Warrant") and the issuance of up to 13,000,000 shares of our Common Stock upon exercise of the Additional Warrant to an affiliated designee of Steven F. Urvan, Chairman of the Board and our Chief Executive Officer, pursuant to the Settlement Agreement (as defined in the accompanying Proxy Statement) that became effective on May 30, 2025; CAPITAL STRUCTURE ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Reverse Stock Split Proposal - to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio in the range of 1-for-5 to 1-for-10 (the "Reverse Stock Split"), with the exact ratio to be determined at the discretion of the Board, to be effected at such time and date, if at all, as determined by the Board, but in any case prior to the one-year anniversary of the date on which the Reverse Stock Split is approved by the Company's stockholders at the Annual Meeting; CAPITAL STRUCTURE ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Say-on-Pay Proposal - to approve, on an advisory basis, the compensation of the Company's named executive officers, as described in the Proxy Statement; and SECTION 14A SAY-ON-PAY VOTES ISSUER 515.000000 0 FOR 515.000000 FOR Outdoor Holding Company 00175J107 US00175J1079 08/29/2025 Say-on-Frequency Proposal - to approve, on an advisory basis, the frequency of future advisory votes on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 515.000000 0 ONE YEAR 515.000000 AGAINST XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 Elect 5 nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified: John Simard DIRECTOR ELECTIONS ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 Elect 5 nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified: Thomas Kundig DIRECTOR ELECTIONS ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 Elect 5 nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified: Craig Rademaker DIRECTOR ELECTIONS ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 Elect 5 nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified: Tevi D. Troy DIRECTOR ELECTIONS ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 Elect 5 nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified: David Soffer DIRECTOR ELECTIONS ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 To ratify the selection by the Audit Committee of the Board of Directors of Whitley Penn LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 90.000000 0 FOR 90.000000 FOR XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 90.000000 0 AGAINST 90.000000 AGAINST XBiotech Inc. 98400H102 CA98400H1029 08/29/2025 To approve the Company's 2025 Equity Incentive Plan. COMPENSATION ISSUER 90.000000 0 AGAINST 90.000000 AGAINST Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Margaret M. FitzPatrick, M.A. DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Ann M. Cunningham, MBA DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Joanne Curley, Ph.D. DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Mary L. Rotunno, J.D. DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Jon S. Saxe, J.D., LL.M. DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 ELECTION OF DIRECTORS: To elect six directors to the Company's Board of Directors, each to serve until the Company's next annual meeting of stockholders, or until her or his respective successor is elected and qualified: Shawn K. Singh, J.D. DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers (NEOS). SECTION 14A SAY-ON-PAY VOTES ISSUER 38.000000 0 FOR 38.000000 FOR Vistagen Therapeutics, Inc. 92840H400 US92840H4002 09/09/2025 To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for our fiscal year ending March 31, 2026. AUDIT-RELATED ISSUER 38.000000 0 FOR 38.000000 FOR Inseego Corp. 45782B302 US45782B3024 09/10/2025 Elect two directors to serve until the 2028 Annual Meeting of Stockholders.: Brian Miller DIRECTOR ELECTIONS ISSUER 49.000000 0 FOR 49.000000 FOR Inseego Corp. 45782B302 US45782B3024 09/10/2025 Elect two directors to serve until the 2028 Annual Meeting of Stockholders.: George Mulhern DIRECTOR ELECTIONS ISSUER 49.000000 0 FOR 49.000000 FOR Inseego Corp. 45782B302 US45782B3024 09/10/2025 Ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 49.000000 0 FOR 49.000000 FOR Inseego Corp. 45782B302 US45782B3024 09/10/2025 Approve, in an advisory vote, the compensation paid to the Company's named executive officers, as presented in the proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 49.000000 0 FOR 49.000000 FOR BeyondSpring Inc. G10830100 KYG108301006 09/15/2025 To Ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025 AUDIT-RELATED ISSUER 133.000000 0 FOR 133.000000 FOR Vaxart, Inc. 92243A200 US92243A2006 09/19/2025 To adopt and approve (i) an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of issued shares of the Company's common stock into a lesser number of shares by a ratio of not less than 1-for-5 and not more than 1-for-20, with the exact ratio to be set within this range by the board of directors of the Company in its sole discretion, and (ii) if and when the reverse stock split is effected, to decrease the number of authorized shares of common stock of the Company in a proportion equal to that of the associated reverse stock split. CAPITAL STRUCTURE ISSUER 715.000000 0 FOR 715.000000 FOR Big 5 Sporting Goods Corporation 08915P101 US08915P1012 09/26/2025 To approve and adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "merger agreement"), dated as of June 29, 2025, by and among Big 5 Sporting Goods Corporation, Worldwide Sports Group Holdings LLC ("parent"), WSG Merger LLC ("merger sub"), and, to guarantee certain limited obligations of parent and merger sub, Worldwide Golf Group LLC, and the merger of the merger sub with and into Big 5 Sporting Goods Corporation (the "merger"); EXTRAORDINARY TRANSACTIONS ISSUER 123.000000 0 FOR 123.000000 FOR Big 5 Sporting Goods Corporation 08915P101 US08915P1012 09/26/2025 To approve, on an advisory (non-binding) basis, the compensation that may become payable to Big 5 Sporting Goods Corporation's named executive officers in connection with the merger; and SECTION 14A SAY-ON-PAY VOTES ISSUER 123.000000 0 AGAINST 123.000000 AGAINST Big 5 Sporting Goods Corporation 08915P101 US08915P1012 09/26/2025 To approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve the proposal to approve and adopt the merger agreement and the merger. CORPORATE GOVERNANCE ISSUER 123.000000 0 FOR 123.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 09/29/2025 Approval of an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board of Directors, a reverse stock split of our common stock (with a proportionate reduction in the authorized number of shares of common stock) at a ratio in the range of 1-for-10 to 1-for-20. CAPITAL STRUCTURE ISSUER 5152.000000 0 FOR 5152.000000 FOR LivePerson, Inc. 538146309 US5381463091 10/02/2025 To approve an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, (i) to effect a reverse stock spit of the Company's common stock, subject to the Company's Board of Directors' discretion, at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of the Company's Board of Directors, without further approval or authorization of the Company's stockholders, prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company's stockholders at the Special Meeting and (ii) if and when the reverse stock split is effected, to decrease the number of authorized shares of the Company's common stock in the same ratio as is selected for the reverse stock split. CAPITAL STRUCTURE ISSUER 775.000000 0 FOR 775.000000 FOR LivePerson, Inc. 538146309 US5381463091 10/02/2025 To approve an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock by a factor of 1.5x, which would result in the conversion of the Company's outstanding Series B Preferred Stock into 23,217,594 shares of common stock (prior to giving effect to any reverse stock split approved pursuant to Proposal 1). CAPITAL STRUCTURE ISSUER 775.000000 0 FOR 775.000000 FOR Mallinckrodt plc 10/08/2025 Approve the change of the name of Mallinckrodt from Mallinckrodt plc to Keenova Therapeutics plc. OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Mallinckrodt plc 10/08/2025 Approve the sub-division of the Preferred Shares of US$0.01 each in the authorized share capital of Mallinckrodt into Preferred Shares of US $0.001 each OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Mallinckrodt plc 10/08/2025 Approve a variation and increase in the authorized share capital of Mallinckrodt, which following the approval of Resolution 2(a) above will stand at US$10,000,000 and E25,000 divided into 500,000,000 Ordinary Shares of US $0.01 each, 5,000,000,000 Preferred Shares of US$0.001 each and 25,000 Ordinary A Shares of E1.00 each, by the creation of 2,995,000,000,000 new Preferred Shares of US$0.001 each, such that the authorized share capital of Mallinckrodt shall be US$3,005,000,000 and E25,000 divided into 500,000,000 Ordinary Shares of US$0.01 each, 3,000,000,000,000 Preferred Shares of US$0.001 each and 25,000 Ordinary A Shares of E1.00 each. OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Mallinckrodt plc 10/08/2025 Approve the authority to adjourn the EGM to another time or place if necessary or appropriate to effect particular steps. OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 10/13/2025 To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of convertible senior unsecured promissory notes due 2031 held by several non-affiliated purchasers, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of common stock issued and outstanding prior to such issuance. CAPITAL STRUCTURE ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 10/13/2025 To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of common stock issued and outstanding prior to such issuance. CAPITAL STRUCTURE ISSUER 1100.000000 0 FOR 1100.000000 FOR Eos Energy Enterprises, Inc. 29415C101 US29415C1018 10/16/2025 To approve, for purposes of complying with Nasdaq Listing Rules, including, but not limited to, Rule 5635, the Company's Issuance of shares of the Company's Common Stock to the Affiliated Purchasers upon redemption or conversion of the Notes pursuant to the Indenture as supplemented by the First Supplemental Indenture. CAPITAL STRUCTURE ISSUER 259.000000 0 FOR 259.000000 FOR Eos Energy Enterprises, Inc. 29415C101 US29415C1018 10/16/2025 To approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for the approval of Proposal 1 or the absence of a quorum. CORPORATE GOVERNANCE ISSUER 259.000000 0 FOR 259.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 10/16/2025 Nasdaq Proposal. Approval, for purposes of Nasdaq listing rule 5635(d), of the issuance of shares of our common stock underlying the common warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated July 17, 2025, in an amount that, together with the other shares of common stock issued pursuant to such Securities Purchase Agreement, may equal or exceed 20% of our common stock outstanding. CAPITAL STRUCTURE ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 10/16/2025 Adjournment Proposal. Approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1. CORPORATE GOVERNANCE ISSUER 34.000000 0 FOR 34.000000 FOR Beam Global 07373B109 US07373B1098 10/21/2025 Election of Directors: Anthony Posawatz DIRECTOR ELECTIONS ISSUER 52.000000 0 FOR 52.000000 FOR Beam Global 07373B109 US07373B1098 10/21/2025 Election of Directors: Judy Krandel DIRECTOR ELECTIONS ISSUER 52.000000 0 FOR 52.000000 FOR Beam Global 07373B109 US07373B1098 10/21/2025 Election of Directors: George Syllantavos DIRECTOR ELECTIONS ISSUER 52.000000 0 FOR 52.000000 FOR Beam Global 07373B109 US07373B1098 10/21/2025 Election of Directors: Desmond Wheatley DIRECTOR ELECTIONS ISSUER 52.000000 0 FOR 52.000000 FOR Beam Global 07373B109 US07373B1098 10/21/2025 Approve, on a non-binding advisory basis, the compensation of our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 52.000000 0 AGAINST 52.000000 AGAINST Beam Global 07373B109 US07373B1098 10/21/2025 Ratify the appointment of CBIZ CPAs P.C. as our independent registered public accountants for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 52.000000 0 FOR 52.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Travis Washko DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Vincent Puccio DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Mark Carrington DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Michael Freed DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Michael Dunn DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To elect six directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified (the "Election of Directors Proposal"): Loic Gautier DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Society Pass Incorporated 83370P201 US83370P2011 10/21/2025 To ratify the appointment of Onestop Assurance PAC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 (the "Auditor Ratification Proposal"). AUDIT-RELATED ISSUER 2.000000 0 FOR 2.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Barry M. Monheit DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Bradley T. Favreau DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Mary E. Gallagher DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Gregory J. Gluchowski DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Luis G. Marconi DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 ELECTION OF DIRECTORS: To elect as directors each of the nominees listed below to serve until their successors are elected and qualified at the 2026 Annual Meeting of Stockholders, subject to their earlier death, resignation, disqualification, or removal: Brian D. Murphy DIRECTOR ELECTIONS ISSUER 84.000000 0 FOR 84.000000 FOR American Outdoor Brands, Inc. 02875D109 US02875D1090 10/27/2025 To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent registered public accountant of our company for the fiscal year ending April 30, 2026. AUDIT-RELATED ISSUER 84.000000 0 FOR 84.000000 FOR CoreCard Corporation 45816D100 US45816D1000 10/28/2025 Proposal (the "Merger Agreement Proposal") to adopt the Agreement and Plan of Merger, dated July 30, 2025 (as it may be amended from time to time, the "Merger Agreement"), a copy of which is attached as Annex A to the proxy statement/prospectus relating to the Special Meeting, among CoreCard Corporation ("CoreCard"), Euronet Worldwide, Inc. ("Euronet") and Genesis Merger Sub Inc., a wholly owned subsidiary of Euronet ("Merger Sub"), providing for the merger of Merger Sub with and into CoreCard (the "Merger"). EXTRAORDINARY TRANSACTIONS ISSUER 43.000000 0 FOR 43.000000 FOR CoreCard Corporation 45816D100 US45816D1000 10/28/2025 Proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to CoreCard's named executive officers that is based on or otherwise relates to the Merger (the "Advisory Compensation Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 43.000000 0 FOR 43.000000 FOR CoreCard Corporation 45816D100 US45816D1000 10/28/2025 Proposal to approve one or more adjournments of the Special Meeting, if necessary or appropriate, to permit solicitation of additional votes or proxies if there are not sufficient votes to approve the Merger Agreement Proposal (the "Adjournment Proposal"). CORPORATE GOVERNANCE ISSUER 43.000000 0 FOR 43.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Election of Directors: Lockie Andrews DIRECTOR ELECTIONS ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Election of Directors: Nancy Benacci DIRECTOR ELECTIONS ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Election of Directors: Susan Lintonsmith DIRECTOR ELECTIONS ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Election of Directors: Michael Mansbach DIRECTOR ELECTIONS ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Election of Directors: Michael J. Merriman DIRECTOR ELECTIONS ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Advisory vote on the compensation of the Company's named executive officers (the "Say-on-Pay Vote"). SECTION 14A SAY-ON-PAY VOTES ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm. AUDIT-RELATED ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Approval of the Amended and Restated 1991 Contributory Stock Purchase Plan. COMPENSATION ISSUER 12.000000 0 FOR 12.000000 FOR Regis Corporation 758932206 US7589322061 10/28/2025 Advisory ratification of the extension of the Tax Benefits Preservation Plan. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 12.000000 0 FOR 12.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Emma S. Battle DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Francis S. Blake DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Albert P. Carey DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Edmund M. Ingle DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Kenneth G. Langone DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Suzanne M. Present DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Rhonda L. Ramlo DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Election of directors: Eva T. Zlotnicka DIRECTOR ELECTIONS ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Advisory vote to approve UNIFI's named executive officer compensation in fiscal 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Approval of the Second Amendment to the Unifi, Inc. Second Amended and Restated 2013 Incentive Compensation Plan to increase the number of shares of UNIFI's common stock reserved for issuance by 1,240,000 shares. COMPENSATION ISSUER 81.000000 0 FOR 81.000000 FOR Unifi, Inc. 904677200 US9046772003 10/28/2025 Ratification of the appointment of KPMG LLP to serve as UNIFI's independent registered public accounting firm for fiscal 2026 AUDIT-RELATED ISSUER 81.000000 0 FOR 81.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To elect three Class I directors named in the accompanying proxy statement to serve until our 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Anne B. Le Grand DIRECTOR ELECTIONS ISSUER 550.000000 0 FOR 550.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To elect three Class I directors named in the accompanying proxy statement to serve until our 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Joseph E. Whitters DIRECTOR ELECTIONS ISSUER 550.000000 0 FOR 550.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To elect three Class I directors named in the accompanying proxy statement to serve until our 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Chan W. Galbato DIRECTOR ELECTIONS ISSUER 550.000000 0 FOR 550.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To approve our 2026 Equity Incentive Plan. COMPENSATION ISSUER 550.000000 0 FOR 550.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To conduct an advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 550.000000 0 FOR 550.000000 FOR Accuray Incorporated 004397105 US0043971052 11/13/2025 To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2026. AUDIT-RELATED ISSUER 550.000000 0 FOR 550.000000 FOR Mesa Air Group, Inc. 590479408 US5904794089 11/17/2025 Approve the Merger and all transactions contemplated by the Merger Agreement, including the Merger and the conversion of Mesa from a Nevada corporation to a Delaware corporation by means of a conversion, pursuant to the Plan of Conversion. EXTRAORDINARY TRANSACTIONS ISSUER 204.000000 0 FOR 204.000000 FOR Mesa Air Group, Inc. 590479408 US5904794089 11/17/2025 Approve (i) the issuance of shares of common stock of Mesa, which will represent more than 20% of the shares of Mesa common stock outstanding immediately prior to the Merger, (a) to stockholders of Republic pursuant to the terms of the Merger Agreement, dated as of April 4, 2025, and (b) in respect of the Escrow Shares, which shall ultimately be distributed to one or more of United Airlines, the Surviving Corporation, or the Pre-Merger Mesa Shareholders, pursuant to the terms of the Merger Agreement and the Three Party Agreement, and (ii) the change of control arising from the issuance of shares in connection with the Merger and the Escrow Issuance, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. EXTRAORDINARY TRANSACTIONS ISSUER 204.000000 0 FOR 204.000000 FOR Mesa Air Group, Inc. 590479408 US5904794089 11/17/2025 Approve on an advisory (non-binding) basis, certain compensation payments that will or may be made by Mesa to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 204.000000 0 FOR 204.000000 FOR Mesa Air Group, Inc. 590479408 US5904794089 11/17/2025 Approve the Republic 2025 Equity Incentive Plan. COMPENSATION ISSUER 204.000000 0 FOR 204.000000 FOR Mesa Air Group, Inc. 590479408 US5904794089 11/17/2025 Approve an adjournment of the Mesa Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals in Items 1, 2, 3, and 4. CORPORATE GOVERNANCE ISSUER 204.000000 0 FOR 204.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Reelect Ariel Halperin as Director DIRECTOR ELECTIONS ISSUER 134.000000 0 FOR 134.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Reelect Maxim Ohana as Director DIRECTOR ELECTIONS ISSUER 134.000000 0 FOR 134.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Reelect Yuval Beeri as Director DIRECTOR ELECTIONS ISSUER 134.000000 0 FOR 134.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Elect Eran Cohen as Director DIRECTOR ELECTIONS ISSUER 134.000000 0 FOR 134.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Elect Irit Ben-Dov as Director DIRECTOR ELECTIONS ISSUER 134.000000 0 FOR 134.000000 FOR Caesarstone Ltd. M20598104 IL0011259137 11/19/2025 Reappoint Kost, Forer, Gabbay & Kasierer as Auditors and Authorize Board to Fix Their Remuneration AUDIT-RELATED ISSUER 134.000000 0 FOR 134.000000 FOR iBio, Inc. 451033708 US4510337086 11/20/2025 Election of Directors: Dr. Martin Brenner DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR iBio, Inc. 451033708 US4510337086 11/20/2025 Election of Directors: Dr. Alexandra Kropotova DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR iBio, Inc. 451033708 US4510337086 11/20/2025 To ratify the appointment of Grassi & Co., CPAS, P.C. as our independent registered public accounting firm for our fiscal year ending on June 30, 2026. AUDIT-RELATED ISSUER 2.000000 0 FOR 2.000000 FOR iBio, Inc. 451033708 US4510337086 11/20/2025 To approve, on an advisory, non-binding basis, the compensation of our named executive officers ("say-on-pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 2.000000 0 FOR 2.000000 FOR iBio, Inc. 451033708 US4510337086 11/20/2025 To approve, on an advisory, non-binding basis, the frequency of future executive compensation advisory votes. SECTION 14A SAY-ON-PAY VOTES ISSUER 2.000000 0 ONE YEAR 2.000000 FOR Xilio Therapeutics, Inc. 98422T209 US98422T2096 11/21/2025 To approve a one-time repricing of certain outstanding employee stock options. COMPENSATION ISSUER 43.000000 0 AGAINST 43.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 11/21/2025 To approve the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan. COMPENSATION ISSUER 43.000000 0 AGAINST 43.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 11/21/2025 To approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 1 and/or Proposal 2. CORPORATE GOVERNANCE ISSUER 43.000000 0 AGAINST 43.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Stock Issuance Proposal: Approve, for purposes of complying with Nasdaq Listing Rules, the issuance of shares of Workhorse Common Stock, including (i) shares issuable pursuant to Rights to receive shares of Workhorse Common Stock to be issued to the 2024 Note Holder pursuant to the Repayment Agreement, (ii) shares issuable to securityholders of Motiv pursuant to the terms of the Merger Agreement, and (iii) shares issuable pursuant to the Convertible Note. EXTRAORDINARY TRANSACTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Reverse Stock Split Proposal: Approve, pursuant to Nevada Revised Statutes 78.2055, a reverse stock split of the outstanding shares of Workhorse Common Stock by a ratio of any whole number between 1-for-8 and 1-for-12, at any time prior to June 30, 2026, to be determined at the discretion of the Board of Directors of Workhorse. CAPITAL STRUCTURE ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Incentive Plan Proposal: Approve the Amended and Restated Workhorse Group 2023 Long-Term Incentive Plan, to among other things, increase the number of shares of common stock available for the grant of equity awards following the Closing by an additional 1,500,000 shares. COMPENSATION ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Charter Amendment Proposal: Approve the amendment and restatement of Workhorse's Articles of Incorporation, in the form of the Proposed Charter attached to the accompanying proxy statement as Annex G, to among other things, effect the amendments related to governance described below in Proposal No. 5. CORPORATE GOVERNANCE ISSUER 4.000000 0 AGAINST 4.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Advisory Charter Proposals: Approve, on a non-binding advisory basis, certain differences in the governance provisions set forth in the Proposed Charter, as compared to our Current Charter, which are being presented in accordance with the requirements of the U.S. Securities and Exchange Commission as three separate sub-proposals CORPORATE GOVERNANCE ISSUER 4.000000 0 AGAINST 4.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 increase the number of authorized shares of common stock to 100.0 million shares; CAPITAL STRUCTURE ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 opt out of Sections 78.378 to 78.3793, inclusive, of the Nevada Revised Statutes, referred to as the Control Share Act; and SHAREHOLDER RIGHTS AND DEFENSES ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 add exclusive forum and waiver of jury trial provisions. SHAREHOLDER RIGHTS AND DEFENSES CORPORATE GOVERNANCE ISSUER 4.000000 0 AGAINST 4.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Raymond J. Chess DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Richard "Rick" Dauch DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Jacqueline A. Dedo DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Pamela S. Mader DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: William Quigley DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Austin Scott Miller DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Dr. Jean Botti DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Director Election Proposal: Approve the election of eight directors to serve on the Board of Directors of Workhorse until the 2026 annual meeting of stockholders of Workhorse, or until such directors' successors have been duly elected and qualified, or until such directors' earlier death, resignation, retirement or removal: Alan S. Henricks DIRECTOR ELECTIONS ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Say-on-Pay Proposal: Approve, on an advisory basis, the compensation of Workhorse's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4.000000 0 AGAINST 4.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Auditor Ratification Proposal: Ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs as Workhorse's independent auditors for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 4.000000 0 FOR 4.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 11/25/2025 The Adjournment Proposal: A proposal to allow the adjournment of the meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Stock Issuance Proposal, the Reverse Stock Split Proposal, the Incentive Plan Proposal or the Charter Amendment Proposal or in the event that the Company determines that one or more of the closing conditions under the Merger Agreement is not satisfied or waived. CORPORATE GOVERNANCE ISSUER 4.000000 0 FOR 4.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Bryant R. Riley DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Thomas J. Kelleher DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Robert L. Antin DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Tammy Brandt DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Robert D'Agostino DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Renee E. LaBran DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Randall E. Paulson DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To elect eight (8) directors to hold office for a one-year term to expire at the Company's 2026 Annual Meeting of Stockholders or until their successors are elected and duly qualified: Mimi K. Walters DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To ratify the selection of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 118.000000 0 FOR 118.000000 FOR B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 118.000000 0 AGAINST 118.000000 AGAINST B. Riley Financial, Inc. 05580M108 US05580M1080 12/01/2025 To vote, on an advisory basis, on the frequency of holding an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 118.000000 0 ONE YEAR 118.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 12/05/2025 Approval of an amendment to the Company's certificate of incorporation, as amended, to effect (i) a reverse stock split of the Company's outstanding shares of common stock at a specific ratio, ranging from 1-for-10 to 1-for-30, to be determined by the Company's board of directors in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue from 250,000,000 shares to 25,000,000 shares. CAPITAL STRUCTURE ISSUER 29.000000 0 FOR 29.000000 FOR PAVmed Inc. 70387R502 US70387R5028 12/05/2025 Approval of the adjournment of the special meeting to the extent there are insufficient votes at the special meeting to approve the foregoing proposal. CORPORATE GOVERNANCE ISSUER 29.000000 0 FOR 29.000000 FOR Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Election of Class I Director: Neil Weiner DIRECTOR ELECTIONS ISSUER 60.000000 0 WITHHOLD 60.000000 AGAINST Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 60.000000 0 FOR 60.000000 FOR Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Approval of an amendment to the 2020 Equity Incentive Plan to increase the number of shares of Class A common stock reserved thereunder by 1,000,000 shares. COMPENSATION ISSUER 60.000000 0 AGAINST 60.000000 AGAINST Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Approval, on a non-binding advisory basis, of the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 60.000000 0 FOR 60.000000 FOR Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Approval, on a non-binding advisory basis, of the frequency of future advisory votes on the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 60.000000 0 ONE YEAR 60.000000 AGAINST Nu Ride, Inc. 54405Q209 US54405Q2093 12/11/2025 Approval of an amendment to the NOL Protective Provisions in the Third Amended and Restated Certificate of Incorporation. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 60.000000 0 AGAINST 60.000000 AGAINST Scilex Holding Company 80880W205 US80880W2052 12/11/2025 Proposal to approve the repricing of certain stock options issued under the Scilex Holding Company 2022 Equity Incentive Plan, as amended, that are held by eligible service providers of the Company (the "Option Repricing Proposal"); and COMPENSATION ISSUER 14.000000 0 AGAINST 14.000000 AGAINST Scilex Holding Company 80880W205 US80880W2052 12/11/2025 Proposal to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Option Repricing Proposal. CORPORATE GOVERNANCE ISSUER 14.000000 0 AGAINST 14.000000 AGAINST Stitch Fix, Inc. 860897107 US8608971078 12/11/2025 Election of Directors: Kofi Amoo-Gottfried DIRECTOR ELECTIONS ISSUER 949.000000 0 WITHHOLD 949.000000 AGAINST Stitch Fix, Inc. 860897107 US8608971078 12/11/2025 Election of Directors: Timothy Baxter DIRECTOR ELECTIONS ISSUER 949.000000 0 WITHHOLD 949.000000 AGAINST Stitch Fix, Inc. 860897107 US8608971078 12/11/2025 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 949.000000 0 AGAINST 949.000000 AGAINST Stitch Fix, Inc. 860897107 US8608971078 12/11/2025 Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending August 1, 2026. AUDIT-RELATED ISSUER 949.000000 0 FOR 949.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To elect four directors to hold office until the next annual meeting and until their respective successors are elected and qualified or until each of their earlier resignation or removal: George Oliva DIRECTOR ELECTIONS ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To elect four directors to hold office until the next annual meeting and until their respective successors are elected and qualified or until each of their earlier resignation or removal: Brett Moyer DIRECTOR ELECTIONS ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To elect four directors to hold office until the next annual meeting and until their respective successors are elected and qualified or until each of their earlier resignation or removal: Gene Jones DIRECTOR ELECTIONS ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To elect four directors to hold office until the next annual meeting and until their respective successors are elected and qualified or until each of their earlier resignation or removal: Tod Browndorf DIRECTOR ELECTIONS ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To ratify the appointment of Simon & Edward, LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To approve an amendment to the Company's Amended and Restated Articles of Incorporation, as amended, to effect a reverse stock split of the Company's common stock, par value $0.001 per share, at a ratio of not less than one-for-twenty and not more than one-for-fifty, with the exact ratio, timing, and implementation to be determined by the Board of Directors in its sole discretion, but no later than June 30, 2026. CAPITAL STRUCTURE ISSUER 11.000000 0 FOR 11.000000 FOR RYVYL Inc. 39366L406 US39366L4068 12/15/2025 To approve an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of our common stock from 100,000,000 to 500,000,000. CAPITAL STRUCTURE ISSUER 11.000000 0 FOR 11.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified: Tommy G. Thompson DIRECTOR ELECTIONS ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified: Cooper C. Collins DIRECTOR ELECTIONS ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified: Gail K. Naughton, Ph.D. DIRECTOR ELECTIONS ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified: Justin Roberts DIRECTOR ELECTIONS ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024; SECTION 14A SAY-ON-PAY VOTES ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 46.000000 0 ONE YEAR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 46.000000 0 FOR 46.000000 FOR TherapeuticsMD, Inc. 88338N206 US88338N2062 12/15/2025 To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; CAPITAL STRUCTURE ISSUER 46.000000 0 FOR 46.000000 FOR comScore, Inc. 20564W204 US20564W2044 12/19/2025 The approval, in accordance with Nasdaq Listing Rules 5635(b) and 5635(d), of the issuance of common stock and Series C Convertible Preferred Stock ("Series C Preferred Stock") to Charter Communications Holding Company, LLC, Liberty Broadband Corporation and Pine Investor, LLC (the "Preferred Stockholders") in accordance with the Stock Exchange Agreements between the Company and each of the Preferred Stockholders (the "Share Issuance"). CAPITAL STRUCTURE ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 12/19/2025 The approval of the Stock Exchange Agreements, the Certificate of Designations of the Series C Preferred Stock, the Stockholder Support Agreements with the Preferred Stockholders, an amendment to the Registration Rights Agreement with the Preferred Stockholders, the Second Amended and Restated Stockholders Agreement with the Preferred Stockholders, and the Exchange (as defined in the Stock Exchange Agreements) by a vote of the "disinterested stockholders" as defined in Delaware law (the "Disinterested Stockholder Approval"). EXTRAORDINARY TRANSACTIONS ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 12/19/2025 The adoption of an amendment to the Amended and Restated Certificate of Incorporation to permit the Share Issuance and authorize a sufficient number of shares of common stock and preferred stock of the Company (the "COI Amendment"). CAPITAL STRUCTURE ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 12/19/2025 The approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the Share Issuance, the Disinterested Stockholder Approval and/or the COI Amendment. CORPORATE GOVERNANCE ISSUER 20.000000 0 FOR 20.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Pamela B. Corrie DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Susie Coulter DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Pamela J. Edwards DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Franco Fogliato DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Kevin Mansell DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Marc Rey DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Wendy L. Schoppert DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 ELECTIONS OF DIRECTORS: Gail B. Tifford DIRECTOR ELECTIONS ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 284.000000 0 FOR 284.000000 FOR Fossil Group, Inc. 34988V106 US34988V1061 12/19/2025 Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending January 3, 2026. AUDIT-RELATED ISSUER 284.000000 0 FOR 284.000000 FOR Eaton Vance Limited Duration Income Fund 27828H105 US27828H1059 01/07/2026 Election of two Class II Trustees: Keith Quinton DIRECTOR ELECTIONS ISSUER 309597.000000 0 FOR 309597.000000 FOR Eaton Vance Limited Duration Income Fund 27828H105 US27828H1059 01/07/2026 Election of two Class II Trustees: Susan J. Sutherland DIRECTOR ELECTIONS ISSUER 309597.000000 0 FOR 309597.000000 FOR FORIAN INC. 34630N106 US34630N1063 01/08/2026 To approve a redomiciliation of the Company to the State of Maryland through a statutory conversion. EXTRAORDINARY TRANSACTIONS CORPORATE GOVERNANCE ISSUER 112.000000 0 AGAINST 112.000000 AGAINST FORIAN INC. 34630N106 US34630N1063 01/08/2026 To approve one or more adjournments of the Special Meeting, if necessary, to solicit proxies if there are insufficient votes at the time of the Special Meeting to approve Proposal 1. CORPORATE GOVERNANCE ISSUER 112.000000 0 AGAINST 112.000000 AGAINST Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Susan Y. Bernstein DIRECTOR ELECTIONS ISSUER 67.000000 0 FOR 67.000000 FOR Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Alan Grayson DIRECTOR ELECTIONS ISSUER 67.000000 0 FOR 67.000000 FOR Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Howard S. Jonas DIRECTOR ELECTIONS ISSUER 67.000000 0 AGAINST 67.000000 AGAINST Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Markus W. Sieger DIRECTOR ELECTIONS ISSUER 67.000000 0 FOR 67.000000 FOR Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Mark N. Stein DIRECTOR ELECTIONS ISSUER 67.000000 0 AGAINST 67.000000 AGAINST Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 Election of Directors: Michael J. Weiss DIRECTOR ELECTIONS ISSUER 67.000000 0 AGAINST 67.000000 AGAINST Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the Fiscal Year ending July 31, 2026. AUDIT-RELATED ISSUER 67.000000 0 FOR 67.000000 FOR Rafael Holdings, Inc. 75062E106 US75062E1064 01/08/2026 To approve an amendment to the Rafael Holdings, Inc. 2021 Equity Incentive that will increase the number of shares of the Company's Class B common stock available for the grant of awards thereunder by 1,000,000. COMPENSATION ISSUER 67.000000 0 AGAINST 67.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To elect the five nominees listed below to the Board of Directors: Peter Batushansky DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To elect the five nominees listed below to the Board of Directors: Leslie C.G. Campbell DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To elect the five nominees listed below to the Board of Directors: James LaCamp DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To elect the five nominees listed below to the Board of Directors: Justin Mennen DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To elect the five nominees listed below to the Board of Directors: Leah A. Solivan DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST PetMed Express, Inc. 716382106 US7163821066 01/21/2026 An advisory (non-binding) vote to approve named executive officer compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 118.000000 0 FOR 118.000000 FOR PetMed Express, Inc. 716382106 US7163821066 01/21/2026 To ratify the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the Company to serve for the 2026 fiscal year; AUDIT-RELATED ISSUER 118.000000 0 FOR 118.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 01/22/2026 Approval of an amendment to the Company's Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's outstanding shares of common stock, par value $0.0001 per share, by a ratio of any whole number between 1-for-5 and 1-for-30, the implementation and timing of which shall be subject to the discretion of the Company's Board of Directors. CAPITAL STRUCTURE ISSUER 96.000000 0 FOR 96.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 01/22/2026 Approval of adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the preceding proposal or to establish a quorum. CORPORATE GOVERNANCE ISSUER 96.000000 0 FOR 96.000000 FOR BioAtla, Inc. 09077B203 US09077B2034 01/26/2026 Approve the potential issuance of 20% or more of the aggregate number of our common stock, par value $0.0001 per share ("Common Stock"), issued and outstanding as of November 20, 2025 pursuant to the Pre-Paid Advance Agreements, dated November 20, 2025, by and between BioAtla, Inc. and each of YA II PN, Ltd., a Cayman Islands exempt limited company ("Yorkville"), Anson Investments Master Fund LP and Anson East Master Fund LP, and the Standby Equity Purchase Agreement, dated November 20, 2025, by and between BioAtla, Inc. and Yorkville, pursuant to Nasdaq Listing Rule 5635(d). CAPITAL STRUCTURE ISSUER 92.000000 0 FOR 92.000000 FOR BioAtla, Inc. 09077B203 US09077B2034 01/26/2026 Approve an amendment to our Amended and Restated Certificate of Incorporation to, at the discretion of our board of directors, effect a reverse stock split with respect to our issued and outstanding Common Stock, at any time prior to June 30, 2026, at a ratio of 1-for-5 to 1-for-20 (the "Range"), with the ratio within such Range to be determined at the discretion of our board of directors without further approval or authorization of our stockholders (the "Reverse Stock Split Proposal"). CAPITAL STRUCTURE ISSUER 92.000000 0 FOR 92.000000 FOR BioAtla, Inc. 09077B203 US09077B2034 01/26/2026 Authorize an adjournment or adjournments of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal or the Reverse Stock Split Proposal. CORPORATE GOVERNANCE ISSUER 92.000000 0 FOR 92.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 Election of three Class II Directors each to serve until the 2028 Annual Meeting of Stockholders: David Lazar DIRECTOR ELECTIONS ISSUER 6.000000 0 FOR 6.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 Election of three Class II Directors each to serve until the 2028 Annual Meeting of Stockholders: Mark Iwicki DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST KALA BIO, Inc. 483119301 US4831193010 01/30/2026 Election of three Class II Directors each to serve until the 2028 Annual Meeting of Stockholders: Todd Bazemore DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST KALA BIO, Inc. 483119301 US4831193010 01/30/2026 Approval of a non-binding advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 6.000000 0 AGAINST 6.000000 AGAINST KALA BIO, Inc. 483119301 US4831193010 01/30/2026 To ratify the appointment of HTL International, LLC as KALA BIO, Inc.'s independent public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 6.000000 0 FOR 6.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 To approve the issuance of shares of common stock of KALA BIO, Inc. upon conversion of the Series AA Convertible Preferred Stock and Series AAA Convertible Preferred Stock in accordance with Nasdaq Listing Rules 5635(b) and 5635(d). CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 To approve an amendment to KALA BIO, Inc.'s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock to 1,500,000,000. CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 To approve an amendment to KALA BIO, Inc.'s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the shares of the company's common stock at a ratio of not less than 1 for 2 and not greater than 1 for 100, with the exact exchange ratio and timing to be determined at the discretion of the Board of Directors. CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR KALA BIO, Inc. 483119301 US4831193010 01/30/2026 To approve an adjournment of the 2025 Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals at the time of the meeting, or in the absence of a quorum. CORPORATE GOVERNANCE ISSUER 6.000000 0 FOR 6.000000 FOR Noodles & Company 65540B303 US65540B3033 02/04/2026 To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's Class A common stock by a ratio in a range of 1-for-2 to 1-for-15, with such ratio to be determined by the board of directors of the Company in its discretion and with such action to be effected at such time and date, if at all, as determined by the Company's board of directors within one year after the conclusion of the Special Meeting. CAPITAL STRUCTURE ISSUER 242.000000 0 FOR 242.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Kristi Ann Matus DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Brian Krzanich DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Marianne Budnik DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Douglas Davis DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Marion Harris DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Election of six directors named in the proxy statement, each to serve for a one-year term and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal: Marcy Klevorn DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Cerence Inc. 156727109 US1567271093 02/12/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 454.000000 0 AGAINST 454.000000 AGAINST Cerence Inc. 156727109 US1567271093 02/12/2026 Ratification of the appointment of BDO USA PC as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2026. AUDIT-RELATED ISSUER 454.000000 0 FOR 454.000000 FOR Lite Strategy, Inc. 55279B301 US55279B3015 02/12/2026 To elect two directors to our Board of Directors, to serve until the expiration of their terms in fiscal year 2029 and until their successor is elected and qualified: Justin J. File DIRECTOR ELECTIONS ISSUER 33.000000 0 FOR 33.000000 FOR Lite Strategy, Inc. 55279B301 US55279B3015 02/12/2026 To elect two directors to our Board of Directors, to serve until the expiration of their terms in fiscal year 2029 and until their successor is elected and qualified: Joshua Riezman DIRECTOR ELECTIONS ISSUER 33.000000 0 FOR 33.000000 FOR Lite Strategy, Inc. 55279B301 US55279B3015 02/12/2026 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 33.000000 0 FOR 33.000000 FOR Lite Strategy, Inc. 55279B301 US55279B3015 02/12/2026 To ratify the appointment of CBIZ CPAs, an independent registered public accounting firm, as our independent auditors for the fiscal year ending June 30, 2026. AUDIT-RELATED ISSUER 33.000000 0 FOR 33.000000 FOR Lite Strategy, Inc. 55279B301 US55279B3015 02/12/2026 To approve the Lite Strategy, Inc.'s 2026 Omnibus Equity Compensation Plan (the 2026 Equity Plan) COMPENSATION ISSUER 33.000000 0 FOR 33.000000 FOR Aemetis, Inc. 00770K202 US00770K2024 02/18/2026 Decrease of Authorized Preferred Stock. Approve an amendment to our Certificate of Incorporation to decrease the number of authorized shares of our preferred stock, par value $0.001 per share, from 65,000,000 to 5,000,000 shares. CAPITAL STRUCTURE ISSUER 161.000000 0 FOR 161.000000 FOR Aemetis, Inc. 00770K202 US00770K2024 02/18/2026 Increase of Authorized Common Stock. Approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock, par value $0.001 per share, from 80,000,000 to 140,000,000 shares. CAPITAL STRUCTURE ISSUER 161.000000 0 FOR 161.000000 FOR Aemetis, Inc. 00770K202 US00770K2024 02/18/2026 Adjourn the Special Meeting. Approve the adjournment of the Special Meeting to a later date or dates, in the Company's discretion, to permit further solicitation and voting of proxies if there are not sufficient votes to approve Proposal 1 or Proposal 2. CORPORATE GOVERNANCE ISSUER 161.000000 0 FOR 161.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 02/20/2026 To approve an amendment to our Articles of Incorporation, as amended, to effect a reverse stock split of our outstanding common stock at a ratio between 1-for-2 and 1-for-200, to be determined at the discretion of our Board of Directors (the "Reverse Split"), for the purpose of complying with the Nasdaq Listing Rules, subject to the Board's discretion to abandon such amendment. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 02/20/2026 To approve sections of the Series A Convertible Preferred Stock (the "Series A Preferred") that could cause shares of common stock to be issued below the Nasdaq Minimum Price in accordance with Nasdaq Listing Rules. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 02/20/2026 To approve an amendment to 10,028,302 outstanding warrants issued in August 2025 to add anti-dilution provisions (the "August Warrants") in accordance with Nasdaq Listing Rules. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 02/20/2026 To approve a potential future offering in accordance with Nasdaq Listing Rules. CAPITAL STRUCTURE ISSUER 1.000000 0 AGAINST 1.000000 AGAINST 22nd Century Group, Inc. 90137F707 US90137F7078 02/20/2026 To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of Proposals 1, 2, 3 or 4. CORPORATE GOVERNANCE ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 02/23/2026 Adoption and approval of an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within a range of not less than 1-for-2 and not greater than 1-for-30, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors, without further approval or authorization of our stockholders. CAPITAL STRUCTURE ISSUER 43.000000 0 FOR 43.000000 FOR Xilio Therapeutics, Inc. 98422T209 US98422T2096 02/23/2026 Approval of an adjournment of the special meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 1 described above. CORPORATE GOVERNANCE ISSUER 43.000000 0 FOR 43.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 03/06/2026 To approve a proposed amendment to the Harvard Bioscience, Inc. Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding shares of common stock, $0.01 par value per share, at a ratio of between 1-for-5 and 1-for-15. CAPITAL STRUCTURE ISSUER 234.000000 0 FOR 234.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 03/06/2026 To authorize an adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1. CORPORATE GOVERNANCE ISSUER 234.000000 0 FOR 234.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Bruce T. Crawford DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Michael J. Hildebrandt DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Mark R. Quinlan DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Mary Jane Raymond DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Lloyd A. Sprung DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Kenneth Traub DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Election of Directors: Lawrence J. Waldman DIRECTOR ELECTIONS ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Approval, on an advisory basis, of the compensation of our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal 2026. AUDIT-RELATED ISSUER 152.000000 0 FOR 152.000000 FOR Comtech Telecommunications Corp. 205826209 US2058262096 03/09/2026 Approval of an amendment to the Company's 2023 Equity and Incentive Plan, as amended (the "2023 Plan") to increase the number of shares of Common Stock available under the 2023 Plan. COMPENSATION ISSUER 152.000000 0 FOR 152.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Curtis L. Begle DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Bruce Brown DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Michael S. Curless DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Thomas M. Fahnemann DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Kevin M. Fogarty DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Mary D. Hall DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Samantha J. Marnick DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: C. Rick Rickertsen DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Election of Directors: Thomas E. Salmon DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Proposal to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending September 26, 2026. AUDIT-RELATED ISSUER 20.000000 0 FOR 20.000000 FOR Magnera Corporation 55939A107 US55939A1079 03/09/2026 Advisory approval of the Company's named executive officer compensation for the fiscal year ended September 27, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 20.000000 0 FOR 20.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 03/11/2026 Stock Issuance Proposal: To consider and vote upon a proposal to approve, for purposes of complying with Sections 712 and 713 of the NYSE American LLC Listed Company Guide, the issuance to Nexus Capital Management, LP of up to 110,000 shares of a newly created series of preferred stock, the Series A Preferred Stock of the Company, par value $0.001 per share, in a private placement and the issuance of the underlying shares of the Company's common stock (the "Nexus Investment"), the proceeds of which will be used for the acquisition by the Company of Navitas LLC and Global Superfoods Corp. (the "Navitas Acquisition" and together with the Nexus Investment, the "Transactions"). EXTRAORDINARY TRANSACTIONS ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 03/11/2026 Compensation Proposal: To approve, on a non-binding, advisory basis, certain compensation that may be paid or become payable to the Company's named executive officers in connection with the Transactions. SECTION 14A SAY-ON-PAY VOTES ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 03/11/2026 Adjournment Proposal: To consider and vote upon a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Stock Issuance Proposal. This proposal will only be presented at the Special Meeting if there are not sufficient votes to approve the Stock Issuance Proposal. CORPORATE GOVERNANCE ISSUER 37.000000 0 FOR 37.000000 FOR Advantage Solutions Inc. 00791N201 US00791N2018 03/16/2026 To approve amendments to our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our Class A common stock, par value $0.0001 per share (the "Common Stock"), at a ratio ranging from any whole number between 1-for-10 and 1-for-25, inclusive, with such ratio to be determined at the discretion of our Board of Directors (the "Board") and reduce the number of authorized shares of Common Stock and unissued authorized shares of our preferred stock, no par value (the "Preferred Stock"), subject to the Board's authority to determine when to file the amendment and to abandon the other amendments notwithstanding prior stockholder approval of such amendments. CAPITAL STRUCTURE ISSUER 455.000000 0 FOR 455.000000 FOR Advantage Solutions Inc. 00791N201 US00791N2018 03/16/2026 To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1. CORPORATE GOVERNANCE ISSUER 455.000000 0 FOR 455.000000 FOR Curis, Inc. 231269408 US2312694084 03/17/2026 To adopt and approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our capital stock from 73,343,750 to 288,757,150 and the number of authorized shares of our common stock from 68,343,750 to 283,757,150. CAPITAL STRUCTURE ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 03/17/2026 To approve, in accordance with Nasdaq Listing Rules 5635(c) and (d), the issuance of shares of our common stock upon the conversion of our Series B Preferred Stock and upon the exercise of our Series A Warrants, Series B Warrants and Series C Warrants (or, in certain circumstances, upon the exercise of Pre-Funded Warrants). CAPITAL STRUCTURE ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 03/17/2026 To approve our 2026 Incentive Plan. COMPENSATION ISSUER 25.000000 0 AGAINST 25.000000 AGAINST Curis, Inc. 231269408 US2312694084 03/17/2026 To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the adoption and approval of Proposal 1, Proposal 2 and/or Proposal 3. CORPORATE GOVERNANCE ISSUER 25.000000 0 FOR 25.000000 FOR The Brand House Collective, Inc. 497498105 US4974981056 03/17/2026 To adopt the Agreement and Plan of Merger, dated as of November 24, 2025, by and among The Brand House Collective, Inc., Bed Bath & Beyond, Inc. and Knight Merger Sub II, Inc., a wholly owned subsidiary of Bed Bath & Beyond, Inc. (such proposal, the "Merger Proposal"); EXTRAORDINARY TRANSACTIONS ISSUER 74.000000 0 FOR 74.000000 FOR The Brand House Collective, Inc. 497498105 US4974981056 03/17/2026 To approve on an advisory (non-binding) basis the compensation that may be paid or become payable to The Brand House Collective, Inc.'s named executive officers that is based on or otherwise relates to the merger (the "Merger-Related Compensation Proposal"); and SECTION 14A SAY-ON-PAY VOTES ISSUER 74.000000 0 FOR 74.000000 FOR The Brand House Collective, Inc. 497498105 US4974981056 03/17/2026 To approve one or more adjournments of the Special Meeting to a later date or dates, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Merger Proposal (the "Adjournment Proposal"). CORPORATE GOVERNANCE ISSUER 74.000000 0 FOR 74.000000 FOR LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To approve the issuance of 5,502,402 shares of common stock, par value $0.0001 per share, or the common stock, pursuant to the exercise of a pre-funded warrant, or the Sermonix Pre-Funded Warrant, held by Sermonix Pharmaceuticals, Inc., or Sermonix, in accordance with Nasdaq Rule 5635(a)(2). CAPITAL STRUCTURE ISSUER 19.000000 0 AGAINST 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To approve the issuance of shares of common stock to Sermonix pursuant to an exercise of the Sermonix Pre-Funded Warrant if, immediately following such exercise, Sermonix, together with its affiliates and any other persons whose beneficial ownership of shares of common stock would be aggregated with Sermonix for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, would beneficially own in excess of 19.99% of our outstanding common stock, in accordance with Nasdaq Rule 5635(b). CAPITAL STRUCTURE ISSUER 19.000000 0 AGAINST 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To approve the issuance of shares of common stock to Perceptive Advisors or its affiliates pursuant to the exercise of warrants if, immediately following such exercise, Perceptive Advisors, together with its affiliates and any other persons whose beneficial ownership of shares of common stock would be aggregated with Perceptive Advisors for purposes of Section 13(d) of the Exchange Act, would beneficially own in excess of 19.99% of our outstanding common stock, in accordance with Nasdaq Rule 5635(b). CAPITAL STRUCTURE ISSUER 19.000000 0 AGAINST 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To approve the LeonaBio, Inc. 2026 Equity Incentive Plan. COMPENSATION ISSUER 19.000000 0 AGAINST 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To amend our amended and restated certificate of incorporation to increase the number of authorized shares of common stock. CAPITAL STRUCTURE ISSUER 19.000000 0 AGAINST 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 03/18/2026 To adjourn the Special Meeting, if necessary or appropriate in the view of the board of directors, including to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to adopt any of Proposal 1, Proposal 2, Proposal 3, Proposal 4 or Proposal 5. CORPORATE GOVERNANCE ISSUER 19.000000 0 AGAINST 19.000000 AGAINST BioAtla, Inc. 09077B203 US09077B2034 03/23/2026 Approve and adopt the Agreement and Plan of Merger by and between BioAtla, Inc. (the "Company") and its wholly owned subsidiary, BA Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Company (the "Merger Proposal"). CORPORATE GOVERNANCE ISSUER 92.000000 0 FOR 92.000000 FOR BioAtla, Inc. 09077B203 US09077B2034 03/23/2026 Authorize an adjournment or adjournments of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the Merger Proposal. CORPORATE GOVERNANCE ISSUER 92.000000 0 FOR 92.000000 FOR PAVmed Inc. 70387R502 US70387R5028 03/27/2026 Approval, for the purposes of Nasdaq Listing Rule 5635, of (i) the issuance of shares of the Company's common stock upon conversion of 60,000 shares of the Company's Series D Convertible Preferred Stock sold in a private placement consummated on February 3, 2026 and underlying the Warrants to purchase Series D Convertible Preferred Stock sold in the private placement, and (ii) the issuance of shares of the Company's common stock pursuant to the Amended and Restated Senior Secured Convertible Note issued by the Company in connection with the redemption of certain of its preferred stock and the refinancing of certain of its debt on February 3, 2026. CAPITAL STRUCTURE ISSUER 1.000000 0 FOR 1.000000 FOR PAVmed Inc. 70387R502 US70387R5028 03/27/2026 Approval of an amendment to the Company's certificate of incorporation, as amended, to permit the removal of any director, with or without cause, by the affirmative vote of the holders of a majority of the Company's outstanding voting power. CORPORATE GOVERNANCE ISSUER 1.000000 0 AGAINST 1.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 03/27/2026 Approval of an amendment to the Company's 2014 Long-Term Incentive Equity Plan to increase the total number of shares of the Company's common stock available thereunder by an addition 1,500,000 shares, from 213,517 shares to 1,713,517 shares. COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 03/27/2026 Approval of the adjournment of the special meeting to the extent there are insufficient votes at the special meeting to approve the foregoing proposals. CORPORATE GOVERNANCE ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Pasha Sarraf DIRECTOR ELECTIONS ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Peter A. Kiener DIRECTOR ELECTIONS ISSUER 183.000000 0 WITHHOLD 183.000000 AGAINST Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Frank Morich DIRECTOR ELECTIONS ISSUER 183.000000 0 WITHHOLD 183.000000 AGAINST Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Pamela Garzone DIRECTOR ELECTIONS ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Patrick Verheyen DIRECTOR ELECTIONS ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The election of seven nominees to our board of directors: Jill Broadfoot DIRECTOR ELECTIONS ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 183.000000 0 FOR 183.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 04/13/2026 The adoption and approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-30 and not more than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors without further approval or authorization of our stockholders. CAPITAL STRUCTURE ISSUER 183.000000 0 FOR 183.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified: Sujata Dayal DIRECTOR ELECTIONS ISSUER 287.000000 0 FOR 287.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified: John Fowler, Jr. DIRECTOR ELECTIONS ISSUER 287.000000 0 FOR 287.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified: Zsolt Harsanyi, Ph.D. DIRECTOR ELECTIONS ISSUER 287.000000 0 FOR 287.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified: Joseph Papa DIRECTOR ELECTIONS ISSUER 287.000000 0 FOR 287.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 287.000000 0 FOR 287.000000 FOR Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To hold, on an advisory basis, a vote to approve the 2025 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 287.000000 0 AGAINST 287.000000 AGAINST Emergent BioSolutions Inc. 29089Q105 US29089Q1058 04/29/2026 To approve an amendment to the Emergent BioSolutions Inc Amended and Restated Stock Incentive Plan to increase the number of shares of common stock for the grant of awards under the plan. COMPENSATION ISSUER 287.000000 0 AGAINST 287.000000 AGAINST Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Election of Directors: Samuel L. Barker, Ph.D. DIRECTOR ELECTIONS ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Election of Directors: Christopher J. Sobecki DIRECTOR ELECTIONS ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Election of Directors: Judith L. Swain, M.D. DIRECTOR ELECTIONS ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Ratification and approval of the Company's Seventh Amended and Restated Certificate of Incorporation CAPITAL STRUCTURE ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Approval of the Company's 2026 Equity Incentive Plan COMPENSATION ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Approval of the Company's 2026 Non-Employee Directors' Equity Incentive Plan COMPENSATION ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Advisory vote to approve the compensation paid to the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 408.000000 0 FOR 408.000000 FOR Lexicon Pharmaceuticals, Inc. 528872302 US5288723027 04/30/2026 Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 AUDIT-RELATED ISSUER 408.000000 0 FOR 408.000000 FOR The E.W. Scripps Company 811054402 US8110544025 05/04/2026 Election of Directors: Marcellus W. Alexander, Jr. DIRECTOR ELECTIONS ISSUER 335.000000 0 FOR 335.000000 FOR The E.W. Scripps Company 811054402 US8110544025 05/04/2026 Election of Directors: Burton F. Jablin DIRECTOR ELECTIONS ISSUER 335.000000 0 FOR 335.000000 FOR The E.W. Scripps Company 811054402 US8110544025 05/04/2026 Election of Directors: Nishat A. Mehta DIRECTOR ELECTIONS ISSUER 335.000000 0 FOR 335.000000 FOR The E.W. Scripps Company 811054402 US8110544025 05/04/2026 Election of Directors: Kim Williams DIRECTOR ELECTIONS ISSUER 335.000000 0 WITHHOLD 335.000000 AGAINST The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Turki Saleh A. AlRajhi DIRECTOR ELECTIONS ISSUER 161.000000 0 AGAINST 161.000000 AGAINST The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Hussan Arshad DIRECTOR ELECTIONS ISSUER 161.000000 0 FOR 161.000000 FOR The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Douglas Edwards DIRECTOR ELECTIONS ISSUER 161.000000 0 FOR 161.000000 FOR The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Kim Roy DIRECTOR ELECTIONS ISSUER 161.000000 0 AGAINST 161.000000 AGAINST The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Muhammad Asif Seemab DIRECTOR ELECTIONS ISSUER 161.000000 0 AGAINST 161.000000 AGAINST The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Rhys Summerton DIRECTOR ELECTIONS ISSUER 161.000000 0 FOR 161.000000 FOR The Children's Place, Inc. 168905107 US1689051076 05/06/2026 Election of Directors: Muhammad Umair DIRECTOR ELECTIONS ISSUER 161.000000 0 AGAINST 161.000000 AGAINST The Children's Place, Inc. 168905107 US1689051076 05/06/2026 To ratify the appointment of BDO USA, P.C. as the independent registered public accounting firm of The Children's Place, Inc. for fiscal 2026. AUDIT-RELATED ISSUER 161.000000 0 FOR 161.000000 FOR The Children's Place, Inc. 168905107 US1689051076 05/06/2026 To approve an increase of 1,200,000 shares of Common Stock available for issuance under the Company's 2011 Equity Incentive Plan. COMPENSATION ISSUER 161.000000 0 FOR 161.000000 FOR The Children's Place, Inc. 168905107 US1689051076 05/06/2026 To approve, by non-binding vote, executive compensation as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 161.000000 0 FOR 161.000000 FOR 1stdibs.com, Inc. 320551104 US3205511047 05/07/2026 The election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Matthew R. Cohler DIRECTOR ELECTIONS ISSUER 106.000000 0 FOR 106.000000 FOR 1stdibs.com, Inc. 320551104 US3205511047 05/07/2026 The election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Andrew G. Robb DIRECTOR ELECTIONS ISSUER 106.000000 0 WITHHOLD 106.000000 AGAINST 1stdibs.com, Inc. 320551104 US3205511047 05/07/2026 The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 106.000000 0 FOR 106.000000 FOR GrafTech International Ltd. 384313607 US3843136074 05/07/2026 Election of Directors: Jean-Marc Germain DIRECTOR ELECTIONS ISSUER 234.000000 0 FOR 234.000000 FOR GrafTech International Ltd. 384313607 US3843136074 05/07/2026 Election of Directors: Henry R. Keizer DIRECTOR ELECTIONS ISSUER 234.000000 0 FOR 234.000000 FOR GrafTech International Ltd. 384313607 US3843136074 05/07/2026 Ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for 2026. AUDIT-RELATED ISSUER 234.000000 0 FOR 234.000000 FOR GrafTech International Ltd. 384313607 US3843136074 05/07/2026 Approve, on an advisory basis, our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 234.000000 0 FOR 234.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: John B. Wood DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: David Borland DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: Maj. Gen. (ret) John W. Maluda DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: Bonnie Carroll DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: Derrick D. Dockery DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: Brad Jacobs DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ELECTION OF DIRECTORS: To elect seven Directors to the Board of Directors to serve until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified: Fredrick D. Schaufeld DIRECTOR ELECTIONS ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM: To ratify the selection of PricewaterhouseCoopers LLP to serve as the Company's independent registered public accounting firm. AUDIT-RELATED ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 AMENDMENT TO THE AMENDED AND RESTATED 2016 OMNIBUS LONG-TERM INCENTIVE PLAN: To approve Amendment No. 2 to the Amended and Restated 2016 Omnibus Long-Term Incentive Plan of the Company, substantially in the form attached hereto as Exhibit A (the "Plan Amendment"). COMPENSATION ISSUER 238.000000 0 FOR 238.000000 FOR Telos Corporation 87969B101 US87969B1017 05/07/2026 ADVISORY VOTE ON EXECUTIVE COMPENSATION: To approve, on an advisory basis, the compensation of the Company's named executive officers or "say-on-pay". SECTION 14A SAY-ON-PAY VOTES ISSUER 238.000000 0 FOR 238.000000 FOR Retractable Technologies, Inc. 76129W105 US76129W1053 05/08/2026 Election of Three Class 2 Directors: Thomas J. Shaw DIRECTOR ELECTIONS ISSUER 103.000000 0 FOR 103.000000 FOR Retractable Technologies, Inc. 76129W105 US76129W1053 05/08/2026 Election of Three Class 2 Directors: Walter O. Bigby, Jr. DIRECTOR ELECTIONS ISSUER 103.000000 0 FOR 103.000000 FOR Retractable Technologies, Inc. 76129W105 US76129W1053 05/08/2026 Election of Three Class 2 Directors: John W. Fort III DIRECTOR ELECTIONS ISSUER 103.000000 0 FOR 103.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Election of the following Class II Director: Nanxi Liu DIRECTOR ELECTIONS ISSUER 291.000000 0 FOR 291.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Ratification of the appointment of RSM US, LLP, an independent registered public accounting firm, as independent auditors of the Company for fiscal year 2026. AUDIT-RELATED ISSUER 291.000000 0 FOR 291.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Adoption of the 2026 CarParts.com Stock Incentive Plan. COMPENSATION ISSUER 291.000000 0 FOR 291.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Approval of an amendment to the Certificate of Incorporation of the Company, as amended, to provide for a reverse stock split of the common stock of the Company, that will be at a ratio of not less than one-for-five (1:5) and not greater than one-for-twenty (1:20), the final determination of which shall be determined by the Board, and to authorize the Board to effect the reverse stock split at their discretion. CAPITAL STRUCTURE ISSUER 291.000000 0 FOR 291.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Approval of an advisory (non-binding) resolution regarding the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 291.000000 0 FOR 291.000000 FOR CarParts.com, Inc. 14427M206 US14427M2061 05/11/2026 Approval of the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and yote of proxies in favor of the foregoing proposals. CORPORATE GOVERNANCE ISSUER 291.000000 0 FOR 291.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Dr. Kenneth D. Eichenbaum, MD, MSE DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Paul A. Gendron DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Ronald Hundzinski DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Beverly A. Huss DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Carrie Lachance DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Scott Shuda DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Election of Directors: Dr. John J. Sviokla DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Approval, on advisory basis, of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Approval of an amendment increasing the number of shares reserved under the InfuSystem Holdings, Inc. 2021 Equity Incentive Plan. COMPENSATION ISSUER 108.000000 0 FOR 108.000000 FOR InfuSystem Holdings, Inc. 45685K102 US45685K1025 05/11/2026 Ratification of the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 108.000000 0 FOR 108.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: William C. Goings DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: William Greenblatt DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: Kim Harris Jones DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: R. Chris Kreidler DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: Sonita Lontoh DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: Taryn R. Owen DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders Paul G. Reitz DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: Kristi A. Savacool DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Election of Directors: Elect 9 directors to the Board of Directors to serve until our 2027 Annual Meeting of Shareholders: William Seward DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Advisory (Non-Binding) vote Approving Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Approval of the Amendment and Restatement of the Company's 2016 Omnibus Incentive Plan COMPENSATION ISSUER 205.000000 0 FOR 205.000000 FOR TrueBlue, Inc. 89785X101 US89785X1019 05/11/2026 Ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 27, 2026 AUDIT-RELATED ISSUER 205.000000 0 FOR 205.000000 FOR AirSculpt Technologies, Inc. 009496100 US0094961002 05/12/2026 Election of Directors: Adam Feinstein DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR AirSculpt Technologies, Inc. 009496100 US0094961002 05/12/2026 Election of Directors: Thomas Aaron DIRECTOR ELECTIONS ISSUER 38.000000 0 FOR 38.000000 FOR AirSculpt Technologies, Inc. 009496100 US0094961002 05/12/2026 Election of Directors: Kenneth Higgins DIRECTOR ELECTIONS ISSUER 38.000000 0 AGAINST 38.000000 AGAINST AirSculpt Technologies, Inc. 009496100 US0094961002 05/12/2026 Ratification of the appointment of Grant Thornton as our independent registered public accounting firm for the fiscal year ending December 31, 2026 AUDIT-RELATED ISSUER 38.000000 0 FOR 38.000000 FOR Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: Monty J. Bennett DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: Amish Gupta DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: Stephen Zsigray DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: David W. Johnson DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: Frederick J. Kleisner DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 Election of Directors: Sheri L. Pantermuehl DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 To obtain advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 To ratify the appointment of BDO USA, P.C., a national public accounting firm, as the Company's independent auditors for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 10.000000 0 FOR 10.000000 FOR Ashford Hospitality Trust, Inc. 044103794 US0441037944 05/12/2026 To approve Amendment No. 6 to the Ashford Hospitality Trust, Inc. 2021 Stock Incentive Plan. COMPENSATION ISSUER 10.000000 0 FOR 10.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 Election of Directors: John Gerber DIRECTOR ELECTIONS ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 Election of Directors: Scott Bibaud DIRECTOR ELECTIONS ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 Election of Directors: Steve Shevick DIRECTOR ELECTIONS ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 Election of Directors: Duy-Loan Le DIRECTOR ELECTIONS ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 Election of Directors: Suja Ramnath DIRECTOR ELECTIONS ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 To ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the 2026 fiscal year. AUDIT-RELATED ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the Corporation's authorized common stock to 95 million shares. CAPITAL STRUCTURE ISSUER 120.000000 0 FOR 120.000000 FOR Atomera Incorporated 04965B100 US04965B1008 05/12/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement to be filed for the Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 120.000000 0 FOR 120.000000 FOR Clear Channel Outdoor Holdings, Inc. 18453H106 US18453H1068 05/12/2026 A proposal to adopt the Agreement and Plan of Merger, dated as of February 9, 2026 (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement"), by and among Clear Channel Outdoor Holdings, Inc. (the "Company"), a Delaware corporation, Madison Parent Inc., a Delaware corporation ("Parent"), and Madison Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Merger Sub will be merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger") (the "Merger Proposal"). EXTRAORDINARY TRANSACTIONS ISSUER 4259.000000 0 FOR 4259.000000 FOR Clear Channel Outdoor Holdings, Inc. 18453H106 US18453H1068 05/12/2026 A proposal to approve, on an advisory, non-binding basis, the specified compensation that will or may be paid or may become payable to the Company's named executive officers in connection with the Merger (the "Advisory Compensation Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 4259.000000 0 FOR 4259.000000 FOR Clear Channel Outdoor Holdings, Inc. 18453H106 US18453H1068 05/12/2026 A proposal to adjourn the special meeting (such meeting, including any adjournments or postponements thereof, the "Special Meeting") of the stockholders of the Company to a later date or dates, from time to time, if necessary or appropriate, to solicit additional proxies for the Merger Proposal if there are insufficient votes at the time of the Special Meeting to approve the Merger Proposal (the "Adjournment Proposal"). CORPORATE GOVERNANCE ISSUER 4259.000000 0 FOR 4259.000000 FOR Personalis, Inc. 71535D106 US71535D1063 05/12/2026 Election of Directors: Olivia K. Bloom DIRECTOR ELECTIONS ISSUER 214.000000 0 FOR 214.000000 FOR Personalis, Inc. 71535D106 US71535D1063 05/12/2026 Election of Directors: Woodrow A. Myers, Jr., M.D. DIRECTOR ELECTIONS ISSUER 214.000000 0 WITHHOLD 214.000000 AGAINST Personalis, Inc. 71535D106 US71535D1063 05/12/2026 Ratification of the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 214.000000 0 FOR 214.000000 FOR Personalis, Inc. 71535D106 US71535D1063 05/12/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 214.000000 0 FOR 214.000000 FOR Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 Election of Directors: Steven R. Mitchell DIRECTOR ELECTIONS ISSUER 263.000000 0 WITHHOLD 263.000000 AGAINST Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 Election of Directors: Donald R. Young DIRECTOR ELECTIONS ISSUER 263.000000 0 WITHHOLD 263.000000 AGAINST Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 The ratification of the appointment of KPMG LLP as Aspen Aerogels, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 263.000000 0 FOR 263.000000 FOR Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 Approval, on a non-binding, advisory basis, of the compensation of Aspen Aerogels, Inc.'s named executive officers, as disclosed in its Proxy Statement for the 2026 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 263.000000 0 AGAINST 263.000000 AGAINST Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 Approval, on a non-binding, advisory basis, of the frequency of holding an advisory vote on the compensation of Aspen Aerogels, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 263.000000 0 ONE YEAR 263.000000 FOR Aspen Aerogels, Inc. 04523Y105 US04523Y1055 05/13/2026 Approval, on a non-binding, advisory basis, of a proposal regarding the future declassification of the Board of Directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 263.000000 0 FOR 263.000000 FOR Noodles & Company 65540B303 US65540B3033 05/13/2026 Election of two Class I directors: Joseph Christina DIRECTOR ELECTIONS ISSUER 30.000000 0 FOR 30.000000 FOR Noodles & Company 65540B303 US65540B3033 05/13/2026 Election of two Class I directors: Thomas Lynch DIRECTOR ELECTIONS ISSUER 30.000000 0 FOR 30.000000 FOR Noodles & Company 65540B303 US65540B3033 05/13/2026 Advisory (non-binding) vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 30.000000 0 FOR 30.000000 FOR Noodles & Company 65540B303 US65540B3033 05/13/2026 To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 29, 2026. AUDIT-RELATED ISSUER 30.000000 0 FOR 30.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Malissia R. Clinton DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Claudia N. Drayton DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Thomas W. Erickson DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Jeffrey A. Graves DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Jim D. Kever DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Charles G. McClure, Jr. DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Kevin S. Moore DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: Vasant Padmanabhan DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The election of the nine directors named in the accompanying Proxy Statement: John J. Tracy DIRECTOR ELECTIONS ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The approval, on an advisory basis, of the compensation paid to our named executive officers in 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2026. AUDIT-RELATED ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The approval of an amendment to our Certificate of Incorporation, as amended, to increase the total number of authorized shares of our common stock, par value $0.001 per share, from 220,000,000 shares to 440,000,000 shares. CAPITAL STRUCTURE ISSUER 1453.000000 0 FOR 1453.000000 FOR 3D Systems Corporation 88554D205 US88554D2053 05/14/2026 The approval of the amendment and restatement of the 2015 Incentive Plan to increase the number of shares reserved for issuance thereunder by 4,000,000 shares and to extend the term until 2036. COMPENSATION ISSUER 1453.000000 0 AGAINST 1453.000000 AGAINST Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Mark A. Beck DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Gwendolyn M. Bingham DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Kenneth Gardner-Smith DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Stephen W. Klemash DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Teresa L. Kline DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Election of six Directors, each for a one-year term and until their respective successors are elected and qualified: Edward A. Pesicka DIRECTOR ELECTIONS ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Non-binding advisory vote to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 718.000000 0 FOR 718.000000 FOR Accendra Health, Inc. 690732102 US6907321029 05/14/2026 Approval of the Accendera Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan. COMPENSATION ISSUER 718.000000 0 FOR 718.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Marcus A. Lemonis DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Joanna C. Burkey DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Barclay F. Corbus DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: William B. Nettles, Jr. DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Debra G. Perelman DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Dr. Robert J. Shapiro DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 Election of Directors: Joseph J. Tabacco, Jr. DIRECTOR ELECTIONS ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 The approval, on an advisory (non-binding) basis, of the compensation paid by the Company to its named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 The approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock. CAPITAL STRUCTURE ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 The approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4 and/or Proposal 6. CORPORATE GOVERNANCE ISSUER 504.000000 0 FOR 504.000000 FOR Bed Bath & Beyond, Inc. 690370101 US6903701018 05/14/2026 The approval of an amendment and restatement of the Company's Amended and Restated 2005 Equity Incentive Plan. COMPENSATION ISSUER 504.000000 0 FOR 504.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To elect five Directors, each to serve for a term expiring at the 2027 Annual Meeting of Stockholders: George J. Carter DIRECTOR ELECTIONS ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To elect five Directors, each to serve for a term expiring at the 2027 Annual Meeting of Stockholders: Georgia Murray DIRECTOR ELECTIONS ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To elect five Directors, each to serve for a term expiring at the 2027 Annual Meeting of Stockholders: John N. Burke DIRECTOR ELECTIONS ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To elect five Directors, each to serve for a term expiring at the 2027 Annual Meeting of Stockholders: Dennis J. McGillicuddy DIRECTOR ELECTIONS ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To elect five Directors, each to serve for a term expiring at the 2027 Annual Meeting of Stockholders: Jennifer Bitterman DIRECTOR ELECTIONS ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To ratify the Audit Committee's appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 595.000000 0 FOR 595.000000 FOR Franklin Street Properties Corp. 35471R106 US35471R1068 05/14/2026 To approve, by non-binding vote, our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 595.000000 0 FOR 595.000000 FOR Stereotaxis, Inc. 85916J409 US85916J4094 05/14/2026 To elect each of the following directors to serve a three-year term as a Class I director until the 2029 Annual Meeting and until their respective successors are duly elected and qualified: Mr. David Benfer DIRECTOR ELECTIONS ISSUER 295.000000 0 FOR 295.000000 FOR Stereotaxis, Inc. 85916J409 US85916J4094 05/14/2026 To elect each of the following directors to serve a three-year term as a Class I director until the 2029 Annual Meeting and until their respective successors are duly elected and qualified: Dr. Arun Menawat DIRECTOR ELECTIONS ISSUER 295.000000 0 FOR 295.000000 FOR Stereotaxis, Inc. 85916J409 US85916J4094 05/14/2026 To elect each of the following directors to serve a three-year term as a Class I director until the 2029 Annual Meeting and until their respective successors are duly elected and qualified: Dr. Myriam Curet DIRECTOR ELECTIONS ISSUER 295.000000 0 FOR 295.000000 FOR Stereotaxis, Inc. 85916J409 US85916J4094 05/14/2026 To ratify the appointment of Ernst & Young, LLP as the Corporation's independent registered public accounting firm for fiscal year 2026. AUDIT-RELATED ISSUER 295.000000 0 FOR 295.000000 FOR Stereotaxis, Inc. 85916J409 US85916J4094 05/14/2026 To approve, by non-binding vote, executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 295.000000 0 FOR 295.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Election of Directors To be elected for terms expiring in 2029: Dexter Goei DIRECTOR ELECTIONS ISSUER 127.000000 0 FOR 127.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Election of Directors To be elected for terms expiring in 2029: Yaffa Krindel DIRECTOR ELECTIONS ISSUER 127.000000 0 FOR 127.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Election of Directors To be elected for terms expiring in 2029: Mark Mullen DIRECTOR ELECTIONS ISSUER 127.000000 0 FOR 127.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Election of Directors To be elected for terms expiring in 2029: Arne Wolter DIRECTOR ELECTIONS ISSUER 127.000000 0 WITHHOLD 127.000000 AGAINST Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Approve, on an advisory basis, the compensation of our named executive officers, described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 127.000000 0 AGAINST 127.000000 AGAINST Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Cast an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 127.000000 0 ONE YEAR 127.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Ratify the appointment of KPMG LLP as the independent registered public accounting firm for fiscal 2026. AUDIT-RELATED ISSUER 127.000000 0 FOR 127.000000 FOR Teads Holding Co. 69002R103 US69002R1032 05/14/2026 Adopt and approve an amendment to Teads Holding Co. Thirteenth Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued shares of common stock at a ratio within the range of 1-for-5 to 1-for-25, without reducing the authorized number of shares, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of the Board of Directors, without further approval or authorization of the Company's stockholders. CAPITAL STRUCTURE ISSUER 127.000000 0 FOR 127.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Brian L. Libman DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Norma C. Corio DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Andrew Essex DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Cory S. Gardner DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Tyson A. Pratcher DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 Election of Directors: Lance N. West DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 An advisory vote to approve the compensation of the named executive officers of the Company; and SECTION 14A SAY-ON-PAY VOTES ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Finance of America Companies Inc. 31738L206 US31738L2060 05/15/2026 The ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 10.000000 0 FOR 10.000000 FOR Biodesix, Inc. 09075X207 US09075X2071 05/19/2026 To elect the two Class III directors named in this proxy statement to hold office until the 2029 annual meeting of stockholders: Jean Franchi DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Biodesix, Inc. 09075X207 US09075X2071 05/19/2026 To elect the two Class III directors named in this proxy statement to hold office until the 2029 annual meeting of stockholders: Hany Massarany DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR Biodesix, Inc. 09075X207 US09075X2071 05/19/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 3.000000 0 AGAINST 3.000000 AGAINST Biodesix, Inc. 09075X207 US09075X2071 05/19/2026 To approve, on a non-binding advisory basis, the frequency of solicitation of advisory votes to approve named executive officer compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 3.000000 0 ONE YEAR 3.000000 FOR Biodesix, Inc. 09075X207 US09075X2071 05/19/2026 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026; AUDIT-RELATED ISSUER 3.000000 0 FOR 3.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Robert L. Antin DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Tammy Brandt DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Thomas J. Kelleher DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Renee E. LaBran DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Randall E. Paulson DIRECTOR ELECTIONS ISSUER 118.000000 0 AGAINST 118.000000 AGAINST BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Bryant R. Riley DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To elect seven (7) directors to hold office for a one-year term to expire at the Company's 2027 Annual Meeting of Stockholders or until their successors are elected and duly qualified. ELECTIONS OF DIRECTORS: Mimi K. Walters DIRECTOR ELECTIONS ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To ratify the selection of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 118.000000 0 FOR 118.000000 FOR BRC Group Holdings, Inc. 05580M108 US05580M1080 05/19/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 118.000000 0 AGAINST 118.000000 AGAINST Curis, Inc. 231269408 US2312694084 05/19/2026 Election of two Class III Directors: Martyn D. Greenacre DIRECTOR ELECTIONS ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 05/19/2026 Election of two Class III Directors: Kenneth I. Kaitin, Ph.D. DIRECTOR ELECTIONS ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 05/19/2026 To approve, on an advisory (non-binding) basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 05/19/2026 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 05/19/2026 To adopt and approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock. CAPITAL STRUCTURE ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 05/19/2026 To approve an adjournment of the annual meeting, if necessary, to solicit additional proxies in the event there are insufficient votes to approve Proposal 4. CORPORATE GOVERNANCE ISSUER 25.000000 0 FOR 25.000000 FOR Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 Election of Directors: Rodger Boehm DIRECTOR ELECTIONS ISSUER 698.000000 0 WITHHOLD 698.000000 AGAINST Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 Election of Directors: Mary Gustanski DIRECTOR ELECTIONS ISSUER 698.000000 0 WITHHOLD 698.000000 AGAINST Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 Election of Directors: Robert Knight, Jr. DIRECTOR ELECTIONS ISSUER 698.000000 0 WITHHOLD 698.000000 AGAINST Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the 2026 fiscal year ended December 31, 2026. AUDIT-RELATED ISSUER 698.000000 0 FOR 698.000000 FOR Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 To approve, on an advisory basis, compensation for the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 698.000000 0 FOR 698.000000 FOR Hyliion Holdings Corp. 449109107 US4491091074 05/19/2026 To approve an amendment to the Hyliion Holdings Co 2024 Equity Incentive Plan to increase the aggregate number of shares of common stock available for issuance thereunder by 8 million shares. COMPENSATION ISSUER 698.000000 0 AGAINST 698.000000 AGAINST Passage Bio, Inc. 702712209 US7027122099 05/19/2026 To elect two Class III directors, each to serve a three-year term through the third Annual Meeting of Stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Athena Countouriotis, M.D. DIRECTOR ELECTIONS ISSUER 11.000000 0 WITHHOLD 11.000000 AGAINST Passage Bio, Inc. 702712209 US7027122099 05/19/2026 To elect two Class III directors, each to serve a three-year term through the third Annual Meeting of Stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal: Sandip Kapadia DIRECTOR ELECTIONS ISSUER 11.000000 0 WITHHOLD 11.000000 AGAINST Passage Bio, Inc. 702712209 US7027122099 05/19/2026 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 11.000000 0 FOR 11.000000 FOR Passage Bio, Inc. 702712209 US7027122099 05/19/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 11.000000 0 FOR 11.000000 FOR Passage Bio, Inc. 702712209 US7027122099 05/19/2026 To approve, on a non-binding advisory basis, the frequency of holding future advisory votes on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 11.000000 0 ONE YEAR 11.000000 FOR Phathom Pharmaceuticals, Inc. 71722W107 US71722W1071 05/19/2026 To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta DIRECTOR ELECTIONS ISSUER 120.000000 0 WITHHOLD 120.000000 AGAINST Phathom Pharmaceuticals, Inc. 71722W107 US71722W1071 05/19/2026 To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder DIRECTOR ELECTIONS ISSUER 120.000000 0 WITHHOLD 120.000000 AGAINST Phathom Pharmaceuticals, Inc. 71722W107 US71722W1071 05/19/2026 To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse DIRECTOR ELECTIONS ISSUER 120.000000 0 WITHHOLD 120.000000 AGAINST Phathom Pharmaceuticals, Inc. 71722W107 US71722W1071 05/19/2026 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 120.000000 0 FOR 120.000000 FOR Phathom Pharmaceuticals, Inc. 71722W107 US71722W1071 05/19/2026 To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 120.000000 0 FOR 120.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Election of three Class I Directors: Dimitrios Angelis DIRECTOR ELECTIONS ISSUER 123.000000 0 FOR 123.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Election of three Class I Directors: James Chambers DIRECTOR ELECTIONS ISSUER 123.000000 0 FOR 123.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Election of three Class I Directors: Michael Serruya DIRECTOR ELECTIONS ISSUER 123.000000 0 FOR 123.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Proposal to ratify the appointment of Deloitte & Touche LLP as the Company's Independent registered public accounting firm for the fiscal year ending December 27, 2026. AUDIT-RELATED ISSUER 123.000000 0 FOR 123.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Proposal to approve, by an advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 123.000000 0 FOR 123.000000 FOR The ONE Group Hospitality, Inc. 88338K103 US88338K1034 05/19/2026 Proposal to approve an amendment to the Company's 2019 Equity Incentive Plan to increase the number of shares issuable under the 2019 Equity Incentive Plan. COMPENSATION ISSUER 123.000000 0 AGAINST 123.000000 AGAINST Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To elect each of the following Class II directors to serve on the Company's Board of Directors until the annual meeting of stockholders to be held in 2028 or until their respective successors are elected and qualified: Michael D. Burger DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To elect each of the following Class II directors to serve on the Company's Board of Directors until the annual meeting of stockholders to be held in 2028 or until their respective successors are elected and qualified: Satjiv S. Chahil DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To elect each of the following Class II directors to serve on the Company's Board of Directors until the annual meeting of stockholders to be held in 2028 or until their respective successors are elected and qualified: Sue Ann R. Hamilton DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To elect each of the following Class II directors to serve on the Company's Board of Directors until the annual meeting of stockholders to be held in 2028 or until their respective successors are elected and qualified: John Mutch DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To elect each of the following Class II directors to serve on the Company's Board of Directors until the annual meeting of stockholders to be held in 2028 or until their respective successors are elected and qualified: Eric B. Singer DIRECTOR ELECTIONS ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To adopt and approve an amendment to the Company's Restated Certificate of Incorporation, as amended, to declassify the Company's Board of Directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To adopt and approve the amendment and restatement of the Amended and Restated 2018 Equity and Incentive Compensation Plan (a) to increase the number of shares of common stock available for issuance thereunder by 375,000 shares, (b) to extend the term thereof, and (c) to incorporate other amendments thereto consistent with current compensation and governance best practices. COMPENSATION ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 74.000000 0 FOR 74.000000 FOR Universal Electronics Inc. 913483103 US9134831034 05/19/2026 To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the Company's auditors for the year ending December 31, 2026. AUDIT-RELATED ISSUER 74.000000 0 FOR 74.000000 FOR a.k.a. Brands Holding Corp. 00152K200 US00152K2006 05/20/2026 Elect Class II directors to serve on the Board until the 2029 Annual Meeting and until their successors are duly elected and qualified: Wesley Bryett DIRECTOR ELECTIONS ISSUER 4.000000 0 WITHHOLD 4.000000 AGAINST a.k.a. Brands Holding Corp. 00152K200 US00152K2006 05/20/2026 Elect Class II directors to serve on the Board until the 2029 Annual Meeting and until their successors are duly elected and qualified: Sourav Ghosh DIRECTOR ELECTIONS ISSUER 4.000000 0 WITHHOLD 4.000000 AGAINST a.k.a. Brands Holding Corp. 00152K200 US00152K2006 05/20/2026 Elect Class II directors to serve on the Board until the 2029 Annual Meeting and until their successors are duly elected and qualified: Kelly Thompson DIRECTOR ELECTIONS ISSUER 4.000000 0 WITHHOLD 4.000000 AGAINST a.k.a. Brands Holding Corp. 00152K200 US00152K2006 05/20/2026 Ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 4.000000 0 FOR 4.000000 FOR Aemetis, Inc. 00770K202 US00770K2024 05/20/2026 Election of Director. Elect Lydia I. Beebe as a member of the Board of Directors of Aemetis, Inc., to hold office for a three-year term until her successor is duly elected and qualified. DIRECTOR ELECTIONS ISSUER 161.000000 0 FOR 161.000000 FOR Aemetis, Inc. 00770K202 US00770K2024 05/20/2026 Ratification of Independent Accounting Firm. Ratify the appointment of KPMG LLP as Aemetis, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 161.000000 0 FOR 161.000000 FOR Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 Election of Directors: Amit Gupta DIRECTOR ELECTIONS ISSUER 382.000000 0 FOR 382.000000 FOR Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 Election of Directors: Jack Klinck DIRECTOR ELECTIONS ISSUER 382.000000 0 WITHHOLD 382.000000 AGAINST Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 Election of Directors: Srishti Gupta DIRECTOR ELECTIONS ISSUER 382.000000 0 WITHHOLD 382.000000 AGAINST Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 The ratification of the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 382.000000 0 FOR 382.000000 FOR Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 Approval of the Reverse Stock Split and Authorized Shares Reduction. CAPITAL STRUCTURE ISSUER 382.000000 0 FOR 382.000000 FOR Cardlytics, Inc. 14161W303 US14161W3034 05/20/2026 Advisory vote to approve compensation of named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 382.000000 0 AGAINST 382.000000 AGAINST CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified: Matthew Blank DIRECTOR ELECTIONS ISSUER 155.000000 0 WITHHOLD 155.000000 AGAINST CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified: Jonathan Huberman DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To elect three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified: Mike Nikzad DIRECTOR ELECTIONS ISSUER 155.000000 0 WITHHOLD 155.000000 AGAINST CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To approve an amendment to the CuriosityStream Inc. 2020 Omnibus Incentive Plan (the Plan) to increase the number of shares of Common Stock authorized for issuance under the Plan from 10,725,000 shares of Common Stock to 11,725,000 shares of Common Stock. COMPENSATION ISSUER 155.000000 0 AGAINST 155.000000 AGAINST CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 155.000000 0 FOR 155.000000 FOR CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 155.000000 0 AGAINST 155.000000 AGAINST CuriosityStream Inc. 23130Q107 US23130Q1076 05/20/2026 To approve, on an advisory basis, the frequency of future advisory votes on the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 155.000000 0 ONE YEAR 155.000000 FOR Gevo, Inc. 374396406 US3743964062 05/20/2026 Election of Class I Directors: James J. Barber DIRECTOR ELECTIONS ISSUER 1167.000000 0 FOR 1167.000000 FOR Gevo, Inc. 374396406 US3743964062 05/20/2026 Election of Class I Directors: Paul D. Bloom DIRECTOR ELECTIONS ISSUER 1167.000000 0 FOR 1167.000000 FOR Gevo, Inc. 374396406 US3743964062 05/20/2026 Election of Class I Directors: Patrick R. Gruber DIRECTOR ELECTIONS ISSUER 1167.000000 0 FOR 1167.000000 FOR Gevo, Inc. 374396406 US3743964062 05/20/2026 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1167.000000 0 FOR 1167.000000 FOR Gevo, Inc. 374396406 US3743964062 05/20/2026 To cast an advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1167.000000 0 AGAINST 1167.000000 AGAINST Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D. DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D. DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D. DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D. DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 205.000000 0 FOR 205.000000 FOR Inovio Pharmaceuticals, Inc. 45773H409 US45773H4092 05/20/2026 To approve an amendment and restatement of our Amended and Restated 2023 Omnibus Incentive Plan. COMPENSATION ISSUER 205.000000 0 FOR 205.000000 FOR MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 Election of the two nominees for Class II director named in the proxy statement, each to hold office until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified: Carolyn D. Beaver DIRECTOR ELECTIONS ISSUER 829.000000 0 FOR 829.000000 FOR MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 Election of the two nominees for Class II director named in the proxy statement, each to hold office until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified: Theodore L. Tewksbury, Ph.D. DIRECTOR ELECTIONS ISSUER 829.000000 0 FOR 829.000000 FOR MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 To approve, on an advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 829.000000 0 AGAINST 829.000000 AGAINST MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 829.000000 0 FOR 829.000000 FOR MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 To approve an amendment and restatement of the MaxLinear, Inc. Amended and Restated 2010 Equity Incentive Plan, including approval of a new ten-year term and an increase in the number of shares reserved thereunder by 3,204,107. COMPENSATION ISSUER 829.000000 0 AGAINST 829.000000 AGAINST MaxLinear, Inc. 57776J100 US57776J1007 05/20/2026 To approve an amendment and restatement of the MaxLinear, Inc. 2010 Employee Stock Purchase Plan to approve a new term. COMPENSATION ISSUER 829.000000 0 FOR 829.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To elect the three nominees of the Board of Directors, to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Timothy T. Goodnow DIRECTOR ELECTIONS ISSUER 257.000000 0 WITHHOLD 257.000000 AGAINST Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To elect the three nominees of the Board of Directors, to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Francine R. Kaufman DIRECTOR ELECTIONS ISSUER 257.000000 0 WITHHOLD 257.000000 AGAINST Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To elect the three nominees of the Board of Directors, to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Sharon Larkin DIRECTOR ELECTIONS ISSUER 257.000000 0 WITHHOLD 257.000000 AGAINST Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this Notice. SECTION 14A SAY-ON-PAY VOTES ISSUER 257.000000 0 FOR 257.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 257.000000 0 ONE YEAR 257.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To ratify the appointment by the Audit Committee of the Board of Directors of KPMG LLP as independent registered public accounting firm, or auditors, for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 257.000000 0 FOR 257.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To approve an amendment to the Company's amended and restated certificate of incorporation (the "Certificate of Incorporation") to increase the authorized number of shares of common stock from 70,000,000 shares to 140,000,000 shares. CAPITAL STRUCTURE ISSUER 257.000000 0 FOR 257.000000 FOR Senseonics Holdings, Inc. 81727U303 US81727U3032 05/20/2026 To approve the Senseonics Holdings, Inc. 2026 Equity Incentive Plan. COMPENSATION ISSUER 257.000000 0 FOR 257.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Matthew E. Rubel DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Ronald V. DaVella DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Jefferson Gramm DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Christopher M. Grandpre DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Sandra R.A. Karrmann DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Milind Pant DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Election of Directors: Sanjiv Razdan DIRECTOR ELECTIONS ISSUER 165.000000 0 FOR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Approval, on an advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 165.000000 0 AGAINST 165.000000 AGAINST The Joint Corp. 47973J102 US47973J1025 05/20/2026 Approval, on an advisory basis, of the frequency of an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 165.000000 0 ONE YEAR 165.000000 FOR The Joint Corp. 47973J102 US47973J1025 05/20/2026 Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 165.000000 0 FOR 165.000000 FOR Euronet Worldwide, Inc. 298736109 US2987361092 05/21/2026 Election of Class II Directors: Sara Baack DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Euronet Worldwide, Inc. 298736109 US2987361092 05/21/2026 Election of Class II Directors: Ligia Torres Fentanes DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Euronet Worldwide, Inc. 298736109 US2987361092 05/21/2026 Approval of amendments to the amended 2006 Stock Incentive Plan. COMPENSATION ISSUER 13.000000 0 FOR 13.000000 FOR Euronet Worldwide, Inc. 298736109 US2987361092 05/21/2026 Advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 13.000000 0 FOR 13.000000 FOR Euronet Worldwide, Inc. 298736109 US2987361092 05/21/2026 Ratification of the appointment of KPMG LLP as Euronet's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 13.000000 0 FOR 13.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Election of Directors: Jill Avery DIRECTOR ELECTIONS ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Election of Directors: Michael Murray DIRECTOR ELECTIONS ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Election of Directors: David Nieuwsma DIRECTOR ELECTIONS ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Election of Directors: Margaret Seif DIRECTOR ELECTIONS ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Election of Directors: Paul Walsh, Jr. DIRECTOR ELECTIONS ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Proposal to approve the amendment and restatement of the Kopin Corporation 2020 Equity Incentive Plan. COMPENSATION ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 Proposal to ratify the appointment of BDO USA as the independent registered public accounting firm of the Company for the current fiscal year ending December 26, 2026. AUDIT-RELATED ISSUER 462.000000 0 FOR 462.000000 FOR Kopin Corporation 500600101 US5006001011 05/21/2026 An advisory vote to approve the compensation of the Company's named executive officers, during the fiscal year ended December 27, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 462.000000 0 FOR 462.000000 FOR Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Election of Class I Directors: Melinda Brown DIRECTOR ELECTIONS ISSUER 9.000000 0 WITHHOLD 9.000000 AGAINST Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Election of Class I Directors: Geno Germano DIRECTOR ELECTIONS ISSUER 9.000000 0 WITHHOLD 9.000000 AGAINST Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2026. AUDIT-RELATED ISSUER 9.000000 0 FOR 9.000000 FOR Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers (commonly referred to as the "say-on-pay vote"). SECTION 14A SAY-ON-PAY VOTES ISSUER 9.000000 0 FOR 9.000000 FOR Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Approval of the amendment and restatement of the Company's 2019 Incentive Award Plan. COMPENSATION ISSUER 9.000000 0 AGAINST 9.000000 AGAINST Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Approval of an amendment to our Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation. CORPORATE GOVERNANCE ISSUER 9.000000 0 FOR 9.000000 FOR Precision BioSciences, Inc. 74019P207 US74019P2074 05/21/2026 Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals. CORPORATE GOVERNANCE ISSUER 9.000000 0 AGAINST 9.000000 AGAINST Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/21/2026 To elect one Class II Director to serve until the 2029 Annual Meeting of Stockholders: Richard Kollender DIRECTOR ELECTIONS ISSUER 86.000000 0 WITHHOLD 86.000000 AGAINST Rapid Micro Biosystems, Inc. 75340L104 US75340L1044 05/21/2026 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 86.000000 0 FOR 86.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: Ellen N. Artist DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: David Grizzle DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: Michael C. Lenz DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: Ruth Okediji DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: Barry W. Ridings DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 Election of Directors: James E. Sweetnam DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 13.000000 0 FOR 13.000000 FOR Republic Airways Holdings, Inc. 590479408 US5904794089 05/21/2026 The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 13.000000 0 FOR 13.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Election of Directors: Phillip M. Eyler DIRECTOR ELECTIONS ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Election of Directors: Julie M. Howard DIRECTOR ELECTIONS ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Election of Directors: Angel L. Mendez DIRECTOR ELECTIONS ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Approve Amendments to the Company's Articles and Bylaws to Declassify the Board SHAREHOLDER RIGHTS AND DEFENSES ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Approve an Amendment to the Company's Articles to Eliminate the Supermajority Voting Requirement in Article XIV Related to Directors CORPORATE GOVERNANCE ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Approve an Amendment to the Company's Articles to Eliminate the Supermajority Voting Requirements in Article XV Related to Approval of Certain Transactions CORPORATE GOVERNANCE ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Ratification of Appointment of Independent Registered Public Accounting Firm AUDIT-RELATED ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Advisory Vote to Approve Executive Compensation (Say on Pay) SECTION 14A SAY-ON-PAY VOTES ISSUER 260.000000 0 FOR 260.000000 FOR Sleep Number Corporation 83125X103 US83125X1037 05/21/2026 Approve Amendment to the Sleep Number Corporation 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 750,000 shares COMPENSATION ISSUER 260.000000 0 AGAINST 260.000000 AGAINST Star Holdings 85512G106 US85512G1067 05/21/2026 Election of Trustees: Nina Matis DIRECTOR ELECTIONS ISSUER 60.000000 0 WITHHOLD 60.000000 AGAINST Star Holdings 85512G106 US85512G1067 05/21/2026 Election of Trustees: Clifford De Souza DIRECTOR ELECTIONS ISSUER 60.000000 0 WITHHOLD 60.000000 AGAINST Star Holdings 85512G106 US85512G1067 05/21/2026 Election of Trustees: Richard Lieb DIRECTOR ELECTIONS ISSUER 60.000000 0 WITHHOLD 60.000000 AGAINST Star Holdings 85512G106 US85512G1067 05/21/2026 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 60.000000 0 FOR 60.000000 FOR The Cato Corporation 149205106 US1492051065 05/21/2026 ELECTION OF DIRECTORS: Dr. Pamela L. Davies DIRECTOR ELECTIONS ISSUER 117.000000 0 WITHHOLD 117.000000 AGAINST The Cato Corporation 149205106 US1492051065 05/21/2026 ELECTION OF DIRECTORS: Thomas B. Henson DIRECTOR ELECTIONS ISSUER 117.000000 0 WITHHOLD 117.000000 AGAINST The Cato Corporation 149205106 US1492051065 05/21/2026 ELECTION OF DIRECTORS: Bryan F. Kennedy DIRECTOR ELECTIONS ISSUER 117.000000 0 WITHHOLD 117.000000 AGAINST The Cato Corporation 149205106 US1492051065 05/21/2026 To approve, on a non-binding advisory basis, the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 117.000000 0 FOR 117.000000 FOR The Cato Corporation 149205106 US1492051065 05/21/2026 To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending January 30, 2027. AUDIT-RELATED ISSUER 117.000000 0 FOR 117.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Kenneth D. Tuchman DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Steven J. Anenen DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Tracy L. Bahl DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Gregory A. Conley DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Robert N. Frerichs DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Marc L. Holtzman DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 Election of Director Nominees: Gina L. Loften DIRECTOR ELECTIONS ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year 2026. AUDIT-RELATED ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 The approval, on a non-binding, advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 108.000000 0 FOR 108.000000 FOR TTEC Holdings, Inc. 89854H102 US89854H1023 05/21/2026 The approval of the redomestication of the Company from Delaware to Texas by conversion. EXTRAORDINARY TRANSACTIONS CORPORATE GOVERNANCE ISSUER 108.000000 0 AGAINST 108.000000 AGAINST Verastem, Inc. 92337C203 US92337C2035 05/21/2026 Election of Directors: Michael Bailey DIRECTOR ELECTIONS ISSUER 85.000000 0 FOR 85.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/21/2026 Election of Directors: Brian Stuglik DIRECTOR ELECTIONS ISSUER 85.000000 0 FOR 85.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/21/2026 Election of Directors: Karin Tollefson DIRECTOR ELECTIONS ISSUER 85.000000 0 FOR 85.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/21/2026 To approve the adoption of the Company's Amended and Restated 2021 Equity Incentive Plan COMPENSATION ISSUER 85.000000 0 AGAINST 85.000000 AGAINST Verastem, Inc. 92337C203 US92337C2035 05/21/2026 To approve the adoption of the Company's Amended and Restated 2018 Employee Stock Purchase Plan COMPENSATION ISSUER 85.000000 0 FOR 85.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/21/2026 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 85.000000 0 FOR 85.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/21/2026 To approve an advisory vote on the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 85.000000 0 FOR 85.000000 FOR Solo Brands, Inc. 83425V203 US83425V2034 05/22/2026 Election of Directors: Paul Furer DIRECTOR ELECTIONS ISSUER 1.000000 0 WITHHOLD 1.000000 AGAINST Solo Brands, Inc. 83425V203 US83425V2034 05/22/2026 Election of Directors: Peter Laurinaitis DIRECTOR ELECTIONS ISSUER 1.000000 0 WITHHOLD 1.000000 AGAINST Solo Brands, Inc. 83425V203 US83425V2034 05/22/2026 Ratification of the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR Solo Brands, Inc. 83425V203 US83425V2034 05/22/2026 Approval of the Solo Brands, Inc. Amended and Restated 2021 Incentive Award Plan. COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Solo Brands, Inc. 83425V203 US83425V2034 05/22/2026 Approval of an adjournment of the Annual Meeting to a later date or dates, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 3. CORPORATE GOVERNANCE ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Election of Directors. To elect two (2) directors to serve for a three-year term ending at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: William W. Smith, Jr. DIRECTOR ELECTIONS ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Election of Directors. To elect two (2) directors to serve for a three-year term ending at the 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Timothy C. Huffmyer DIRECTOR ELECTIONS ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Non-binding advisory vote to approve the compensation of named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Ratification of the appointment of SingerLewak LLP as the independent registered public accounting firm of Smith Micro Software, Inc. for the fiscal year ending December 31, 2026 AUDIT-RELATED ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Approval of an amendment to the Smith Micro Software, Inc. Amended and Restated Omnibus Equity Incentive Plan COMPENSATION ISSUER 34.000000 0 AGAINST 34.000000 AGAINST Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Nasdaq Proposal I: Approval, for purposes of Nasdaq listing rule 5635(d), of the issuance of shares of our common stock underlying the common warrants issued by us pursuant to the terms of note purchase agreements, dated September 11, 2025 and September 29, 2025, in amounts that may equal or exceed 20% of our common stock outstanding CAPITAL STRUCTURE ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Nasdaq Proposal II: Approval, for purposes of Nasdaq listing rules 5635(c) and (d), of the issuance of shares of our common stock underlying the common warrants issued by us pursuant to the terms of that certain private placement securities purchase agreement, dated November 5, 2025 CAPITAL STRUCTURE ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Approval of an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock, par value $0.001 per share, at a ratio, ranging from one-for-three (1:3) to one-for-ten (1:10), with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders CAPITAL STRUCTURE ISSUER 34.000000 0 FOR 34.000000 FOR Smith Micro Software, Inc. 832154504 US8321545043 05/26/2026 Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of Proposals 4, 5, 6, or 7 CORPORATE GOVERNANCE ISSUER 34.000000 0 AGAINST 34.000000 AGAINST Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To elect four Class III directors from the nominees described in the proxy statement: Tiffany Han DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To elect four Class III directors from the nominees described in the proxy statement: Adam Levyn DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To elect four Class III directors from the nominees described in the proxy statement: David Peacock DIRECTOR ELECTIONS ISSUER 18.000000 0 FOR 18.000000 FOR Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To elect four Class III directors from the nominees described in the proxy statement: David J. West DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To ratify the appointment of PricewaterhouseCoopers LLP as Advantage Solutions Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 18.000000 0 FOR 18.000000 FOR Advantage Solutions Inc. 00791N201 US00791N2018 05/27/2026 To approve, on an advisory (non-binding) basis, the compensation of the Advantage Solutions Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 18.000000 0 AGAINST 18.000000 AGAINST Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Martha Bejar DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Richard McBee DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Steven Sansom DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Paul Stone DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Michael Tucci DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Election of Directors: Nancy A. Walsh DIRECTOR ELECTIONS ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Approve a second amendment and restatement of the Company's Amended and Restated 2019 Performance Incentive Plan (the "Amended 2019 Plan"), including to increase the number of shares available for grant under the Amended 2019 Plan. COMPENSATION ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for fiscal year ending January 30, 2027 (fiscal year 2026). AUDIT-RELATED ISSUER 259.000000 0 FOR 259.000000 FOR Sportsman's Warehouse Holdings, Inc. 84920Y106 US84920Y1064 05/27/2026 Approve, on an advisory basis, the frequency of future advisory votes on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 259.000000 0 ONE YEAR 259.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/27/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders and until their respective successors are elected and qualified: Amy Burroughs, M.B.A. DIRECTOR ELECTIONS ISSUER 153.000000 0 WITHHOLD 153.000000 AGAINST Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/27/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders and until their respective successors are elected and qualified: Karah Parschauer, J.D. DIRECTOR ELECTIONS ISSUER 153.000000 0 WITHHOLD 153.000000 AGAINST Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/27/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders and until their respective successors are elected and qualified: Catherine Stehman-Breen, M.D. DIRECTOR ELECTIONS ISSUER 153.000000 0 WITHHOLD 153.000000 AGAINST Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/27/2026 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 153.000000 0 FOR 153.000000 FOR Tenaya Therapeutics, Inc. 87990A106 US87990A1060 05/27/2026 To amend and restate our 2021 Equity Incentive Plan to, among other things, increase the number of shares of our common stock reserved for issuance by approximately 3% of our outstanding shares and remove the annual limit of 4 million shares from the "evergreen" provision. COMPENSATION ISSUER 153.000000 0 AGAINST 153.000000 AGAINST Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Paul Anton Zevnik DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Gilbert R. Vasquez DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Martha Elena Diaz DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Fehmi Zeko DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Thomas Strickler DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Brad Bender DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 Election of Directors to serve for a term ending at the 2027 Annual Meeting of Stockholders and until a successor is duly elected and qualified: Michael Christenson DIRECTOR ELECTIONS ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 To ratify the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 To approve, on an advisory, non-binding basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 358.000000 0 FOR 358.000000 FOR Entravision Communications Corporation 29382R107 US29382R1077 05/28/2026 To approve an amendment and restatement of the Entravision Communications Corporation Amended and Restated 2004 Equity Incentive Plan (the "2004 Plan") to, among other things, increase the number of shares of the Company's Class A common stock authorized for issuance thereunder by 6,000,000 shares. COMPENSATION ISSUER 358.000000 0 AGAINST 358.000000 AGAINST Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Deirdre P. Connelly DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Ellen G. Cooper DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: William H. Cunningham DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Reginald E. Davis DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Eric G. Johnson DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Gary C. Kelly DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: M. Leanne Lachman DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Dale LeFebvre DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: James Morris DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The election of ten directors for a one-year term expiring at the 2027 Annual Meeting: Owen Ryan DIRECTOR ELECTIONS ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026. AUDIT-RELATED ISSUER 750000.000000 0 FOR 750000.000000 FOR Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 The approval of an advisory resolution on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 750000.000000 0 AGAINST 750000.000000 AGAINST Lincoln National Corporation 534187BR9 US534187BR92 05/28/2026 Shareholder proposal to amend our governing documents to provide for an independent chairman of the board. CORPORATE GOVERNANCE SECURITY HOLDER 750000.000000 0 FOR 750000.000000 AGAINST Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Dennis M. Lanfear DIRECTOR ELECTIONS ISSUER 806.000000 0 FOR 806.000000 FOR Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Mats L. Wahlstrom DIRECTOR ELECTIONS ISSUER 806.000000 0 FOR 806.000000 FOR Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 806.000000 0 FOR 806.000000 FOR Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 806.000000 0 FOR 806.000000 FOR Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To approve a reduction in the exercise price of certain outstanding stock options. COMPENSATION ISSUER 806.000000 0 AGAINST 806.000000 AGAINST Coherus Oncology, Inc. 19249H103 US19249H1032 05/29/2026 To approve an increase in the number of shares of our common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan. COMPENSATION ISSUER 806.000000 0 AGAINST 806.000000 AGAINST Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Steven Kornfeld DIRECTOR ELECTIONS ISSUER 2.000000 0 WITHHOLD 2.000000 AGAINST Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Scott Brun, M.D. DIRECTOR ELECTIONS ISSUER 2.000000 0 WITHHOLD 2.000000 AGAINST Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Paul A. Wagner, Ph.D. DIRECTOR ELECTIONS ISSUER 2.000000 0 FOR 2.000000 FOR Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 2.000000 0 FOR 2.000000 FOR Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote"). SECTION 14A SAY-ON-PAY VOTES ISSUER 2.000000 0 AGAINST 2.000000 AGAINST Forte Biosciences, Inc. 34962G208 US34962G2084 05/29/2026 The approval of the Company's Amended and Restated 2021 Equity Incentive Plan. COMPENSATION ISSUER 2.000000 0 AGAINST 2.000000 AGAINST Alpha Teknova, Inc. 02080L102 US02080L1026 06/01/2026 To elect three (3) Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Irene Davis DIRECTOR ELECTIONS ISSUER 41.000000 0 WITHHOLD 41.000000 AGAINST Alpha Teknova, Inc. 02080L102 US02080L1026 06/01/2026 To elect three (3) Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: J. Matthew Mackowski DIRECTOR ELECTIONS ISSUER 41.000000 0 WITHHOLD 41.000000 AGAINST Alpha Teknova, Inc. 02080L102 US02080L1026 06/01/2026 To elect three (3) Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Brett Robertson DIRECTOR ELECTIONS ISSUER 41.000000 0 FOR 41.000000 FOR Alpha Teknova, Inc. 02080L102 US02080L1026 06/01/2026 Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 41.000000 0 FOR 41.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 06/01/2026 The approval of, in accordance with Nasdaq Listing Rules 5635(a), (c), and (d), the issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement. CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR Cue Biopharma, Inc. 22978P205 US22978P2056 06/01/2026 The approval of the Cue Biopharma, Inc. 2026 Stock Incentive Plan. COMPENSATION ISSUER 6.000000 0 AGAINST 6.000000 AGAINST Cue Biopharma, Inc. 22978P205 US22978P2056 06/01/2026 The approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2. CORPORATE GOVERNANCE ISSUER 6.000000 0 AGAINST 6.000000 AGAINST Taysha Gene Therapies, Inc. 877619106 US8776191061 06/01/2026 To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Sean P. Nolan DIRECTOR ELECTIONS ISSUER 133.000000 0 WITHHOLD 133.000000 AGAINST Taysha Gene Therapies, Inc. 877619106 US8776191061 06/01/2026 To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Laura Sepp-Lorenzino, Ph.D. DIRECTOR ELECTIONS ISSUER 133.000000 0 WITHHOLD 133.000000 AGAINST Taysha Gene Therapies, Inc. 877619106 US8776191061 06/01/2026 To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026. AUDIT-RELATED ISSUER 133.000000 0 FOR 133.000000 FOR Taysha Gene Therapies, Inc. 877619106 US8776191061 06/01/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 133.000000 0 AGAINST 133.000000 AGAINST Taysha Gene Therapies, Inc. 877619106 US8776191061 06/01/2026 To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 133.000000 0 ONE YEAR 133.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Michael Heffernan DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Garry Neil, M.D. DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Rita Jain, M.D. DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Aaron Kantoff DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Gilla Kaplan, Ph.D. DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Kevin Lind DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To elect the seven directors nominated by our board of directors and named herein to hold office until the 2027 Annual Meeting of Stockholders: Samantha Truex DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To approve the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan; COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Avalo Therapeutics, Inc. 05338F306 US05338F3064 06/02/2026 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR Cerus Corporation 157085101 US1570851014 06/02/2026 The election of the two nominees for director named in the Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders: William M. Greenman DIRECTOR ELECTIONS ISSUER 986.000000 0 FOR 986.000000 FOR Cerus Corporation 157085101 US1570851014 06/02/2026 The election of the two nominees for director named in the Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders: Ann Lucena DIRECTOR ELECTIONS ISSUER 986.000000 0 FOR 986.000000 FOR Cerus Corporation 157085101 US1570851014 06/02/2026 The approval of an amendment and restatement of the Company's 2024 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 10 million shares and to make certain other changes thereto as described further in the accompanying Proxy Statement. COMPENSATION ISSUER 986.000000 0 AGAINST 986.000000 AGAINST Cerus Corporation 157085101 US1570851014 06/02/2026 The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 986.000000 0 FOR 986.000000 FOR Cerus Corporation 157085101 US1570851014 06/02/2026 The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 986.000000 0 FOR 986.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Nicholas Woodman DIRECTOR ELECTIONS ISSUER 755.000000 0 WITHHOLD 755.000000 AGAINST GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Tyrone Ahmad-Taylor DIRECTOR ELECTIONS ISSUER 755.000000 0 WITHHOLD 755.000000 AGAINST GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Emily S. Culp Hogue DIRECTOR ELECTIONS ISSUER 755.000000 0 FOR 755.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Michael C. Dennison DIRECTOR ELECTIONS ISSUER 755.000000 0 FOR 755.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Shaz Kahng DIRECTOR ELECTIONS ISSUER 755.000000 0 WITHHOLD 755.000000 AGAINST GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Miguel A. Lopez Ben DIRECTOR ELECTIONS ISSUER 755.000000 0 FOR 755.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Election of Directors: Susan Lyne DIRECTOR ELECTIONS ISSUER 755.000000 0 WITHHOLD 755.000000 AGAINST GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 755.000000 0 FOR 755.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Approval of the non-binding, advisory resolution on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 755.000000 0 FOR 755.000000 FOR GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Approval of Amendment to the GoPro, Inc. 2024 Equity Incentive Plan with additional 13,000,000 shares. COMPENSATION ISSUER 755.000000 0 AGAINST 755.000000 AGAINST GoPro, Inc. 38268T103 US38268T1034 06/02/2026 Approval, in accordance with Nasdaq Listing Rule 5635(d), of the issuance of the maximum number of shares of Class A Common Stock issuable upon conversion of all Convertible Debentures and removal of the Exchange Cap. CAPITAL STRUCTURE ISSUER 755.000000 0 FOR 755.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Election of Class II Directors: John Duke DIRECTOR ELECTIONS ISSUER 23.000000 0 FOR 23.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Election of Class II Directors: Katherine A. Eade DIRECTOR ELECTIONS ISSUER 23.000000 0 FOR 23.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 23.000000 0 FOR 23.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Approval, by a non-binding advisory vote, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 23.000000 0 FOR 23.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Adoption and approval of an amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance by 120,000 shares of common stock. COMPENSATION ISSUER 23.000000 0 FOR 23.000000 FOR Harvard Bioscience, Inc. 416906204 US4169062043 06/02/2026 Adoption and approval of an amendment to the Harvard Bioscience, Inc. 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance by 400,000 shares of common stock. COMPENSATION ISSUER 23.000000 0 AGAINST 23.000000 AGAINST Kodiak Sciences Inc. 50015M109 US50015M1099 06/02/2026 Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. Bancroft DIRECTOR ELECTIONS ISSUER 399.000000 0 WITHHOLD 399.000000 AGAINST Kodiak Sciences Inc. 50015M109 US50015M1099 06/02/2026 Elect three Class II directors nominated by our board and named in this proxy statement: Bassil I. Dahiyat, Ph.D. DIRECTOR ELECTIONS ISSUER 399.000000 0 FOR 399.000000 FOR Kodiak Sciences Inc. 50015M109 US50015M1099 06/02/2026 Elect three Class II directors nominated by our board and named in this proxy statement: Taiyin Yang, Ph.D. DIRECTOR ELECTIONS ISSUER 399.000000 0 FOR 399.000000 FOR Kodiak Sciences Inc. 50015M109 US50015M1099 06/02/2026 Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 399.000000 0 FOR 399.000000 FOR Kodiak Sciences Inc. 50015M109 US50015M1099 06/02/2026 Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 399.000000 0 FOR 399.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: Howard G. Berger, M.D. DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: A. Gregory Sorensen, M.D. DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: Laura P. Jacobs DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: Lawrence L. Levitt DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: Gregory E. Spurlock DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 Election of Directors until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: David L. Swartz DIRECTOR ELECTIONS ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 An advisory vote to approve the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 8.000000 0 FOR 8.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 The approval of an amendment and restatement to the Company's Equity Incentive Plan. COMPENSATION ISSUER 8.000000 0 FOR 8.000000 FOR Torrid Holdings Inc. 89142B107 US89142B1070 06/02/2026 DIRECTOR NOMINEES TO SERVE FOR A THREE-YEAR TERM EXPIRING AT THE FISCAL YEAR 2029 ANNUAL MEETING: Theophlius Killion DIRECTOR ELECTIONS ISSUER 103.000000 0 WITHHOLD 103.000000 AGAINST Torrid Holdings Inc. 89142B107 US89142B1070 06/02/2026 DIRECTOR NOMINEES TO SERVE FOR A THREE-YEAR TERM EXPIRING AT THE FISCAL YEAR 2029 ANNUAL MEETING: Michael A. Shaffer DIRECTOR ELECTIONS ISSUER 103.000000 0 FOR 103.000000 FOR Torrid Holdings Inc. 89142B107 US89142B1070 06/02/2026 ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 103.000000 0 FOR 103.000000 FOR Torrid Holdings Inc. 89142B107 US89142B1070 06/02/2026 RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING JANUARY 30, 2027. AUDIT-RELATED ISSUER 103.000000 0 FOR 103.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Stephen L. Schlecht DIRECTOR ELECTIONS ISSUER 72.000000 0 WITHHOLD 72.000000 AGAINST Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Stephanie L. Pugliese DIRECTOR ELECTIONS ISSUER 72.000000 0 FOR 72.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: David C. Finch DIRECTOR ELECTIONS ISSUER 72.000000 0 WITHHOLD 72.000000 AGAINST Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Janet H. Kennedy DIRECTOR ELECTIONS ISSUER 72.000000 0 FOR 72.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Brett L. Paschke DIRECTOR ELECTIONS ISSUER 72.000000 0 WITHHOLD 72.000000 AGAINST Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Susan J. Riley DIRECTOR ELECTIONS ISSUER 72.000000 0 FOR 72.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Ronald Robinson DIRECTOR ELECTIONS ISSUER 72.000000 0 FOR 72.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 Election of Directors: Scott K. Williams DIRECTOR ELECTIONS ISSUER 72.000000 0 WITHHOLD 72.000000 AGAINST Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 To approve, by an advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 72.000000 0 FOR 72.000000 FOR Duluth Holdings Inc. 26443V101 US26443V1017 06/03/2026 To ratify the appointment of KPMG LLP as our independent registered public accountants for fiscal 2026. AUDIT-RELATED ISSUER 72.000000 0 FOR 72.000000 FOR Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The election of three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Napoleone Ferrara, M.D. DIRECTOR ELECTIONS ISSUER 7.000000 0 WITHHOLD 7.000000 AGAINST Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The election of three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: David Hallal DIRECTOR ELECTIONS ISSUER 7.000000 0 WITHHOLD 7.000000 AGAINST Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The election of three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Leone Patterson DIRECTOR ELECTIONS ISSUER 7.000000 0 FOR 7.000000 FOR Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The approval of an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 7.000000 0 FOR 7.000000 FOR Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The holding of an advisory vote on the frequency of future executive compensation advisory votes. SECTION 14A SAY-ON-PAY VOTES ISSUER 7.000000 0 ONE YEAR 7.000000 FOR Kalaris Therapeutics, Inc. 482929106 US4829291065 06/03/2026 The ratification of the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 7.000000 0 FOR 7.000000 FOR Neurogene Inc. 64135M105 US64135M1053 06/03/2026 Election of Class III Directors for terms expiring in 2029: Robert Baffi, Ph.D. DIRECTOR ELECTIONS ISSUER 10.000000 0 WITHHOLD 10.000000 AGAINST Neurogene Inc. 64135M105 US64135M1053 06/03/2026 Election of Class III Directors for terms expiring in 2029: Rohan Palekar DIRECTOR ELECTIONS ISSUER 10.000000 0 FOR 10.000000 FOR Neurogene Inc. 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 10.000000 0 FOR 10.000000 FOR Neurogene Inc. 64135M105 US64135M1053 06/03/2026 To ratify on an advisory (non-binding) basis the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 10.000000 0 FOR 10.000000 FOR Neurogene Inc. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the company to its named executive officers should be held every one, two or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 10.000000 0 ONE YEAR 10.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: William Ericson DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: Chris Gibson, Ph.D. DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: Christian O. Henry DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: John F. Milligan, Ph.D. DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: Kathy Ordonez DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 Election of Directors: Christopher M. Smith DIRECTOR ELECTIONS ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 2271.000000 0 FOR 2271.000000 FOR Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2271.000000 0 AGAINST 2271.000000 AGAINST Pacific Biosciences of California, Inc. 69404D108 US69404D1081 06/03/2026 To approve the amendment of our 2020 Equity Incentive Plan. COMPENSATION ISSUER 2271.000000 0 AGAINST 2271.000000 AGAINST Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 Election of one Class III Director: John T. McDonald DIRECTOR ELECTIONS ISSUER 172.000000 0 FOR 172.000000 FOR Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 172.000000 0 FOR 172.000000 FOR Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 172.000000 0 FOR 172.000000 FOR Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 To approve the adoption of an amendment to the Company's Amended and Restated Certificate of Incorporation, to be filed not later than February 24, 2027, to effect a reverse stock split of our common stock at a ratio in the range of 1-for-5 to 1-for-30 (collectively, the "Reverse Split"), with such ratio to be determined in the discretion of the Board and publicly disclosed prior to the effectiveness of the Reverse Split. CAPITAL STRUCTURE ISSUER 172.000000 0 FOR 172.000000 FOR Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 To approve an amendment to the Company's 2024 Omnibus Incentive Plan to increase the number of shares of the Company's common stock reserved for issuance thereunder from 3,200,000 shares to 5,200,000 shares. COMPENSATION ISSUER 172.000000 0 FOR 172.000000 FOR Upland Software, Inc. 91544A208 US91544A2087 06/03/2026 To approve an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are not sufficient votes in favor of Proposal 4 or Proposal 5. CORPORATE GOVERNANCE ISSUER 172.000000 0 FOR 172.000000 FOR Absci Corporation 00091E109 US00091E1091 06/04/2026 The election of the Class II directors nominated by the Board of Directors and named in our Proxy Statement to hold office for a three-year term expiring at our 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified: Prof Sir Menelas Pangalos, Ph.D. DIRECTOR ELECTIONS ISSUER 287.000000 0 WITHHOLD 287.000000 AGAINST Absci Corporation 00091E109 US00091E1091 06/04/2026 The election of the Class II directors nominated by the Board of Directors and named in our Proxy Statement to hold office for a three-year term expiring at our 2029 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified: Daniel Rabinovitsj DIRECTOR ELECTIONS ISSUER 287.000000 0 WITHHOLD 287.000000 AGAINST Absci Corporation 00091E109 US00091E1091 06/04/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm to audit our financial statements for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 287.000000 0 FOR 287.000000 FOR Ameresco, Inc. 02361E108 US02361E1082 06/04/2026 Elect two (2) directors to the Ameresco, Inc. Board of Directors for a three-year term or until their successors are elected and qualified: Claire Hughes-Johnson DIRECTOR ELECTIONS ISSUER 362.000000 0 WITHHOLD 362.000000 AGAINST Ameresco, Inc. 02361E108 US02361E1082 06/04/2026 Elect two (2) directors to the Ameresco, Inc. Board of Directors for a three-year term or until their successors are elected and qualified: Frank V. Wisneski DIRECTOR ELECTIONS ISSUER 362.000000 0 WITHHOLD 362.000000 AGAINST Ameresco, Inc. 02361E108 US02361E1082 06/04/2026 To ratify the selection by the Audit Committee of RSM US LLP as Ameresco's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 362.000000 0 FOR 362.000000 FOR Ameresco, Inc. 02361E108 US02361E1082 06/04/2026 To approve an amendment to Ameresco's 2020 Stock Incentive Plan ("Plan) to increase the number of shares of Ameresco, Inc. Class A Common Stock authorized for issuance under the Plan by 3,200,000 from 5,000,000 to 8,200,000 as described in the Ameresco, Inc. Proxy Statement. COMPENSATION ISSUER 362.000000 0 AGAINST 362.000000 AGAINST Ameresco, Inc. 02361E108 US02361E1082 06/04/2026 To approve on a non-binding advisory basis the compensation of our named executive officer as described in the Ameresco, Inc. Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 362.000000 0 FOR 362.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Robert W. Pittman DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: James A. Rasulo DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Richard J. Bressler DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Samuel E. Englebardt DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Robert Millard DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Cheryl Mills DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Graciela Monteagudo DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The election of the following eight director nominees, each for a one-year term ending at the 2027 Annual Meeting of Stockholders: Kamakshi Sivaramakrishnan DIRECTOR ELECTIONS ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1313.000000 0 FOR 1313.000000 FOR iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The approval, on an advisory (non-binding) basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1313.000000 0 AGAINST 1313.000000 AGAINST iHeartMedia, Inc. 45174J509 US45174J5092 06/04/2026 The approval of the second amendment to the iHeartMedia, Inc. 2021 Long-Term Incentive Award Plan. COMPENSATION ISSUER 1313.000000 0 FOR 1313.000000 FOR Outset Medical, Inc. 690145206 US6901452069 06/04/2026 Election of Class III Directors: Brent D. Lang DIRECTOR ELECTIONS ISSUER 36.000000 0 WITHHOLD 36.000000 AGAINST Outset Medical, Inc. 690145206 US6901452069 06/04/2026 Election of Class III Directors: Karen Prange DIRECTOR ELECTIONS ISSUER 36.000000 0 FOR 36.000000 FOR Outset Medical, Inc. 690145206 US6901452069 06/04/2026 To approve, on a non-binding basis, the 2025 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 36.000000 0 AGAINST 36.000000 AGAINST Outset Medical, Inc. 690145206 US6901452069 06/04/2026 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for fiscal year 2026. AUDIT-RELATED ISSUER 36.000000 0 FOR 36.000000 FOR PMV Pharmaceuticals, Inc. 69353Y103 US69353Y1038 06/04/2026 Election of Class III Directors: David H. Mack, Ph.D. DIRECTOR ELECTIONS ISSUER 156.000000 0 WITHHOLD 156.000000 AGAINST PMV Pharmaceuticals, Inc. 69353Y103 US69353Y1038 06/04/2026 Election of Class III Directors: Laurie Stelzer DIRECTOR ELECTIONS ISSUER 156.000000 0 WITHHOLD 156.000000 AGAINST PMV Pharmaceuticals, Inc. 69353Y103 US69353Y1038 06/04/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 156.000000 0 AGAINST 156.000000 AGAINST PMV Pharmaceuticals, Inc. 69353Y103 US69353Y1038 06/04/2026 Ratification of the appointment of Ernst & Young LLP as our independent public accounting firm. AUDIT-RELATED ISSUER 156.000000 0 FOR 156.000000 FOR Pulmonx Corporation 745848101 US7458481014 06/04/2026 Election of Directors: Thomas W. Burns DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Pulmonx Corporation 745848101 US7458481014 06/04/2026 Election of Directors: Georgia Garinois-Melenikiotou DIRECTOR ELECTIONS ISSUER 155.000000 0 WITHHOLD 155.000000 AGAINST Pulmonx Corporation 745848101 US7458481014 06/04/2026 Election of Directors: Dana G. Mead, Jr. DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Pulmonx Corporation 745848101 US7458481014 06/04/2026 To ratify the selection by the Audit Committee of our Board of Directors of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 155.000000 0 FOR 155.000000 FOR Pulmonx Corporation 745848101 US7458481014 06/04/2026 To conduct a non-binding advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 155.000000 0 AGAINST 155.000000 AGAINST Sana Biotechnology, Inc. 799566104 US7995661045 06/04/2026 To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. Bishop DIRECTOR ELECTIONS ISSUER 1029.000000 0 WITHHOLD 1029.000000 AGAINST Sana Biotechnology, Inc. 799566104 US7995661045 06/04/2026 To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Robert Nelsen DIRECTOR ELECTIONS ISSUER 1029.000000 0 WITHHOLD 1029.000000 AGAINST Sana Biotechnology, Inc. 799566104 US7995661045 06/04/2026 To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Alise S. Reicin, M.D. DIRECTOR ELECTIONS ISSUER 1029.000000 0 WITHHOLD 1029.000000 AGAINST Sana Biotechnology, Inc. 799566104 US7995661045 06/04/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1029.000000 0 FOR 1029.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Ian Bickley DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Ivan Brockman DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Kristina Cashman DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Robert J. Hall DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Andrew Meslow DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To elect six Directors for a one-year term to expire at the 2027 Annual Meeting of Shareholders: Jessica Rodriguez DIRECTOR ELECTIONS ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal 2027. AUDIT-RELATED ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 155.000000 0 FOR 155.000000 FOR Vera Bradley, Inc. 92335C106 US92335C1062 06/04/2026 To approve an amendment to the Company's 2020 Equity and Incentive Plan to increase the number of shares authorized for issuance by 3,000,000 shares. COMPENSATION ISSUER 155.000000 0 AGAINST 155.000000 AGAINST Climb Bio, Inc. 28658R106 US28658R1068 06/05/2026 The election of two Class II directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his respective successor has been duly elected and qualified: Alexander (Bo) Cumbo DIRECTOR ELECTIONS ISSUER 41.000000 0 FOR 41.000000 FOR Climb Bio, Inc. 28658R106 US28658R1068 06/05/2026 The election of two Class II directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his respective successor has been duly elected and qualified: Douglas Williams, Ph.D. DIRECTOR ELECTIONS ISSUER 41.000000 0 WITHHOLD 41.000000 AGAINST Climb Bio, Inc. 28658R106 US28658R1068 06/05/2026 The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; AUDIT-RELATED ISSUER 41.000000 0 FOR 41.000000 FOR Climb Bio, Inc. 28658R106 US28658R1068 06/05/2026 The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, relating to the removal of directors for "cause"; SHAREHOLDER RIGHTS AND DEFENSES ISSUER 41.000000 0 FOR 41.000000 FOR Climb Bio, Inc. 28658R106 US28658R1068 06/05/2026 The approval of an amendment to our 2021 Equity Incentive Plan to amend the provision providing for an automatic share pool increase to include prefunded warrants in the calculation of the annual increase; and COMPENSATION ISSUER 41.000000 0 AGAINST 41.000000 AGAINST CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Linda Baddour DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Daniel Hancock DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Robert Hariri, MD, PhD DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Ram M. Jagannath DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Ramkumar Mandalam, PhD DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To elect six directors: Jerrell W. Shelton DIRECTOR ELECTIONS ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2026; AUDIT-RELATED ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in the Proxy Statement; SECTION 14A SAY-ON-PAY VOTES ISSUER 476.000000 0 FOR 476.000000 FOR CryoPort, Inc. 229050307 US2290503075 06/05/2026 To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares for issuance thereunder from 10,350,000 to 14,625,000; and COMPENSATION ISSUER 476.000000 0 AGAINST 476.000000 AGAINST FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: John S. Fleshood DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: Peter E. Murphy DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: Sam Edelson DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: Henchy R. Enden DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: Benjamin Mackovak DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: C. Allen Parker DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 Election of Directors: Thomas C. Shafer DIRECTOR ELECTIONS ISSUER 45.000000 0 FOR 45.000000 FOR FirstSun Capital Bancorp 33767U107 US33767U1079 06/05/2026 To ratify the appointment of Crowe LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 45.000000 0 FOR 45.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Election of Directors: Xi "Felix" Lin DIRECTOR ELECTIONS ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Election of Directors: Richard Diaz DIRECTOR ELECTIONS ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Election of Directors: Dennis Lam DIRECTOR ELECTIONS ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Election of Directors: Jeffery Taylor DIRECTOR ELECTIONS ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm. AUDIT-RELATED ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Approval, on an advisory basis, of the compensation of our executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 217.000000 0 FOR 217.000000 FOR HF Foods Group Inc. 40417F109 US40417F1093 06/05/2026 Advisory vote on frequency of the advisory approval of the compensation of our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 217.000000 0 ONE YEAR 217.000000 FOR Asana, Inc. 04342Y104 US04342Y1047 06/08/2026 Election of three Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Krista Anderson-Copperman DIRECTOR ELECTIONS ISSUER 853.000000 0 WITHHOLD 853.000000 AGAINST Asana, Inc. 04342Y104 US04342Y1047 06/08/2026 Election of three Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sydney Carey DIRECTOR ELECTIONS ISSUER 853.000000 0 WITHHOLD 853.000000 AGAINST Asana, Inc. 04342Y104 US04342Y1047 06/08/2026 Election of three Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dan Rogers DIRECTOR ELECTIONS ISSUER 853.000000 0 FOR 853.000000 FOR Asana, Inc. 04342Y104 US04342Y1047 06/08/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending January 31, 2027. AUDIT-RELATED ISSUER 853.000000 0 FOR 853.000000 FOR Asana, Inc. 04342Y104 US04342Y1047 06/08/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 853.000000 0 AGAINST 853.000000 AGAINST Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Election of Directors: Timothy A. Springer, Ph.D. DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Election of Directors: Stefan Vitorovic, M.S., M.B.A. DIRECTOR ELECTIONS ISSUER 18.000000 0 FOR 18.000000 FOR Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 18.000000 0 FOR 18.000000 FOR Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Advisory approval of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 18.000000 0 FOR 18.000000 FOR Exagen Inc. 30068X103 US30068X1037 06/09/2026 To elect two directors to serve as Class I directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tina S. Nova, Ph.D. DIRECTOR ELECTIONS ISSUER 61.000000 0 FOR 61.000000 FOR Exagen Inc. 30068X103 US30068X1037 06/09/2026 To elect two directors to serve as Class I directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Scott D. Kahn, Ph.D. DIRECTOR ELECTIONS ISSUER 61.000000 0 WITHHOLD 61.000000 AGAINST Exagen Inc. 30068X103 US30068X1037 06/09/2026 To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and AUDIT-RELATED ISSUER 61.000000 0 FOR 61.000000 FOR Exagen Inc. 30068X103 US30068X1037 06/09/2026 To approve by advisory vote the compensation of our named executive officers, as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 61.000000 0 FOR 61.000000 FOR Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/09/2026 Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Muna Bhanji, R.Ph. DIRECTOR ELECTIONS ISSUER 814.000000 0 FOR 814.000000 FOR Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/09/2026 Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Brian Goff DIRECTOR ELECTIONS ISSUER 814.000000 0 AGAINST 814.000000 AGAINST Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/09/2026 Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Jesse Goodman, M.D., M.P.H. DIRECTOR ELECTIONS ISSUER 814.000000 0 AGAINST 814.000000 AGAINST Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/09/2026 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 814.000000 0 FOR 814.000000 FOR Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 814.000000 0 AGAINST 814.000000 AGAINST OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Lynn O'Connor Vos DIRECTOR ELECTIONS ISSUER 205.000000 0 WITHHOLD 205.000000 AGAINST OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Catherine Klema DIRECTOR ELECTIONS ISSUER 205.000000 0 WITHHOLD 205.000000 AGAINST OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: James Lang DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Patrick Spangler DIRECTOR ELECTIONS ISSUER 205.000000 0 WITHHOLD 205.000000 AGAINST OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Mariyamma Varghese Presti DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Gregory D. Wasson DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Election of each of the seven director nominees listed below: Stephen Silvestro DIRECTOR ELECTIONS ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Advisory (non-binding) approval of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Approval of an amendment to the Company's 2021 Equity Incentive Plan (the "2021 Equity Plan") to increase the aggregate number of shares of Common Stock available for awards by 1,000,000 shares to 5,450,000 shares. COMPENSATION ISSUER 205.000000 0 FOR 205.000000 FOR OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Approval of an amendment to the 2021 Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the 2021 Equity Plan. COMPENSATION ISSUER 205.000000 0 AGAINST 205.000000 AGAINST OptimizeRx Corporation 68401U204 US68401U2042 06/09/2026 Ratification of Grant Thornton LLP as OptimizeRx's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 205.000000 0 FOR 205.000000 FOR Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Election of Class III Directors: Krishna Vaddi, Ph.D. DIRECTOR ELECTIONS ISSUER 64.000000 0 FOR 64.000000 FOR Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Election of Class III Directors: Paul Scherer, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 64.000000 0 WITHHOLD 64.000000 AGAINST Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Election of Class III Directors: Katina Dorton DIRECTOR ELECTIONS ISSUER 64.000000 0 FOR 64.000000 FOR Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 64.000000 0 FOR 64.000000 FOR Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Advisory vote to approve the 2025 compensation for the company's named executive officers (say-on-pay). SECTION 14A SAY-ON-PAY VOTES ISSUER 64.000000 0 FOR 64.000000 FOR Prelude Therapeutics Incorporated 74065P101 US74065P1012 06/09/2026 Advisory vote on the frequency of advisory votes on named executive officer compensation (say-on-frequency). SECTION 14A SAY-ON-PAY VOTES ISSUER 64.000000 0 ONE YEAR 64.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: S. Hoby Darling DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: Robert T. DeMartini DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: Gary T. DiCamillo DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: McNeil S. Fiske Jr. DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: Adam L. Gray DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: Claudia Hollingsworth DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: D. Scott Peterson DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Election of Directors: Erika Serow DIRECTOR ELECTIONS ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Approve, on an advisory basis, the compensation of the Company's Named Executive Officers as set forth in our Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 343.000000 0 FOR 343.000000 FOR Purple Innovation, Inc. 74640Y304 US74640Y3045 06/09/2026 Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm to audit our financial statements for the year ending December 31, 2026. AUDIT-RELATED ISSUER 343.000000 0 FOR 343.000000 FOR Riot Platforms, Inc. 767292105 US7672921050 06/09/2026 Election of Directors: Lance D'Ambrosio DIRECTOR ELECTIONS ISSUER 1226.000000 0 FOR 1226.000000 FOR Riot Platforms, Inc. 767292105 US7672921050 06/09/2026 Election of Directors: Michael Turner DIRECTOR ELECTIONS ISSUER 1226.000000 0 FOR 1226.000000 FOR Riot Platforms, Inc. 767292105 US7672921050 06/09/2026 Ratification on a non-binding advisory basis of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1226.000000 0 FOR 1226.000000 FOR Riot Platforms, Inc. 767292105 US7672921050 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1226.000000 0 FOR 1226.000000 FOR Riot Platforms, Inc. 767292105 US7672921050 06/09/2026 Approve the Seventh Amendment to the 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder. COMPENSATION ISSUER 1226.000000 0 FOR 1226.000000 FOR Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Election of Directors: Stephen A. Berenson DIRECTOR ELECTIONS ISSUER 20.000000 0 WITHHOLD 20.000000 AGAINST Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Election of Directors: Claire M. Fraser, Ph.D. DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Election of Directors: Richard N. Kender DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 20.000000 0 FOR 20.000000 FOR Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 20.000000 0 FOR 20.000000 FOR Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Approval of an amendment and restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan to increase the number of shares available for issuance under the plan. COMPENSATION ISSUER 20.000000 0 AGAINST 20.000000 AGAINST Seres Therapeutics, Inc. 81750R201 US81750R2013 06/09/2026 Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4. CORPORATE GOVERNANCE ISSUER 20.000000 0 AGAINST 20.000000 AGAINST Traeger, Inc. 89269P202 US89269P2020 06/09/2026 Election of Class II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Martin Eltrich DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Traeger, Inc. 89269P202 US89269P2020 06/09/2026 Election of Class II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Steven Richman DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Traeger, Inc. 89269P202 US89269P2020 06/09/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 3.000000 0 FOR 3.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To elect the Board of Directors' three nominees, Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah, for Class Il director to serve until the 2029 Annual Meeting of Stockholders: Imran Alibhai, Ph.D. DIRECTOR ELECTIONS ISSUER 7.000000 0 FOR 7.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To elect the Board of Directors' three nominees, Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah, for Class Il director to serve until the 2029 Annual Meeting of Stockholders: Cynthia Smith DIRECTOR ELECTIONS ISSUER 7.000000 0 FOR 7.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To elect the Board of Directors' three nominees, Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah, for Class Il director to serve until the 2029 Annual Meeting of Stockholders: Sujal Shah DIRECTOR ELECTIONS ISSUER 7.000000 0 FOR 7.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 7.000000 0 FOR 7.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 7.000000 0 ONE YEAR 7.000000 FOR Tvardi Therapeutics, Inc. 140755307 US1407553072 06/09/2026 To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 7.000000 0 FOR 7.000000 FOR ALX Oncology Holdings Inc. 00166B105 US00166B1052 06/10/2026 Election of Directors: Daniel Curran, M.D. DIRECTOR ELECTIONS ISSUER 105.000000 0 FOR 105.000000 FOR ALX Oncology Holdings Inc. 00166B105 US00166B1052 06/10/2026 Election of Directors: Rekha Hemrajani DIRECTOR ELECTIONS ISSUER 105.000000 0 WITHHOLD 105.000000 AGAINST ALX Oncology Holdings Inc. 00166B105 US00166B1052 06/10/2026 Election of Directors: Chris Takimoto, M.D., Ph.D., F.A.C.P. DIRECTOR ELECTIONS ISSUER 105.000000 0 FOR 105.000000 FOR ALX Oncology Holdings Inc. 00166B105 US00166B1052 06/10/2026 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 105.000000 0 FOR 105.000000 FOR ALX Oncology Holdings Inc. 00166B105 US00166B1052 06/10/2026 Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 105.000000 0 FOR 105.000000 FOR Bolt Biotherapeutics, Inc. 097702203 US0977022039 06/10/2026 To elect our two nominees for Class II directors to serve until our 2029 Annual Meeting of Stockholders: William P. Quinn DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST Bolt Biotherapeutics, Inc. 097702203 US0977022039 06/10/2026 To elect our two nominees for Class II directors to serve until our 2029 Annual Meeting of Stockholders: Jakob Dupont, M.D. DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST Bolt Biotherapeutics, Inc. 097702203 US0977022039 06/10/2026 To ratify the selection by the audit committee of the Board of Directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026; and AUDIT-RELATED ISSUER 6.000000 0 FOR 6.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Terry Ledbetter DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Bradford Luke Ledbetter DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Joseph Brecher DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Erik Cohen DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Michael Hotchkiss DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Steven Nigro DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Election of Directors: Jeffrey Weissmann DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Approval of a non-binding advisory resolution to approve the compensation of certain executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 20.000000 0 FOR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Approval of a non-binding advisory resolution on the frequency (whether annual, biennial or triennial) of the advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 20.000000 0 ONE YEAR 20.000000 FOR Kestrel Group Ltd G5260K102 BMG5260K1027 06/10/2026 Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the 2026 fiscal year. AUDIT-RELATED ISSUER 20.000000 0 FOR 20.000000 FOR Korro Bio, Inc. 500946108 US5009461089 06/10/2026 Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Nessan Bermingham DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Korro Bio, Inc. 500946108 US5009461089 06/10/2026 Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Rachel Meyers DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Korro Bio, Inc. 500946108 US5009461089 06/10/2026 Non-Binding advisory vote to approve the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 3.000000 0 FOR 3.000000 FOR Korro Bio, Inc. 500946108 US5009461089 06/10/2026 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; AUDIT-RELATED ISSUER 3.000000 0 FOR 3.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell DIRECTOR ELECTIONS ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 747.000000 0 FOR 747.000000 FOR Lineage Cell Therapeutics, Inc. 53566P109 US53566P1093 06/10/2026 To approve, on an advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 747.000000 0 FOR 747.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Matthew Ehrlichman DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Sean Kell DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Rachel Lam DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Alan Pickerill DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Amanda Reierson DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Maurice Tulloch DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Camilla Velasquez DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To elect eight directors to serve until the 2027 Annual Meeting of Stockholders: Regi Vengalil DIRECTOR ELECTIONS ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for Porch Group, Inc. for the year ending December 31, 2026. AUDIT-RELATED ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To approve of, on an advisory (non-binding) basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 894.000000 0 FOR 894.000000 FOR Porch Group, Inc. 733245104 US7332451043 06/10/2026 To approve and adopt the Porch Group, Inc. Employee Stock Purchase Plan. COMPENSATION ISSUER 894.000000 0 FOR 894.000000 FOR Rocket Companies, Inc. 77311W101 US77311W1018 06/10/2026 Election of Class III Directors: Varun Krishna DIRECTOR ELECTIONS ISSUER 963.000000 0 WITHHOLD 963.000000 AGAINST Rocket Companies, Inc. 77311W101 US77311W1018 06/10/2026 Election of Class III Directors: Matthew Rizik DIRECTOR ELECTIONS ISSUER 963.000000 0 WITHHOLD 963.000000 AGAINST Rocket Companies, Inc. 77311W101 US77311W1018 06/10/2026 Election of Class III Directors: Suzanne Shank DIRECTOR ELECTIONS ISSUER 963.000000 0 WITHHOLD 963.000000 AGAINST Rocket Companies, Inc. 77311W101 US77311W1018 06/10/2026 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026 AUDIT-RELATED ISSUER 963.000000 0 FOR 963.000000 FOR Rocket Companies, Inc. 77311W101 US77311W1018 06/10/2026 Approval of an amendment to the Amended and Restated Rocket Companies, Inc. 2020 Team Member Stock Purchase Plan COMPENSATION ISSUER 963.000000 0 FOR 963.000000 FOR Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To elect the Board's two nominees to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Bob Holmen DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To elect the Board's two nominees to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Kristian Humer DIRECTOR ELECTIONS ISSUER 6.000000 0 WITHHOLD 6.000000 AGAINST Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 6.000000 0 FOR 6.000000 FOR Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To approve the issuance of shares of the Company's common stock, par value $0.0001 per share, upon conversion of the Company's Series B Preferred Stock, which will (a) represent more than 20% of the shares of common stock outstanding and (b) result in the change of control of the Company pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To approve an amendment to the Company's certificate of incorporation to increase the number of authorized shares of the Company's common stock from 12,500,000 to 300,000,000. CAPITAL STRUCTURE ISSUER 6.000000 0 FOR 6.000000 FOR Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To approve the 2026 Equity Incentive Plan. COMPENSATION ISSUER 6.000000 0 AGAINST 6.000000 AGAINST Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To approve the 2026 Employee Stock Purchase Plan. COMPENSATION ISSUER 6.000000 0 AGAINST 6.000000 AGAINST Sensei Biotherapeutics, Inc. 81728A207 US81728A2078 06/10/2026 To approve the adjournment or postponement of the Annual Meeting, if necessary, to continue to solicit votes for Proposals Nos. 3, 4, 5 and/or 6 or if the Nasdaq initial listing application required by Nasdaq Listing Rule 5110(a) has not yet been approved. CORPORATE GOVERNANCE ISSUER 6.000000 0 AGAINST 6.000000 AGAINST SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Brenton L. Saunders DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Pedro Malha DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: E. Scott Beattie DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Stephen J. Fanning DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Michelle Kerrick DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Brian Miller DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Doug Schillinger DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Sachin Shridharani, M.D. DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Election of Directors: Kenneth Tripp DIRECTOR ELECTIONS ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1022.000000 0 FOR 1022.000000 FOR SkinHealth Systems Inc. 88331L108 US88331L1089 06/10/2026 Approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1022.000000 0 FOR 1022.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 Election of Class II Directors: Clare Kahn DIRECTOR ELECTIONS ISSUER 23.000000 0 WITHHOLD 23.000000 AGAINST Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 Election of Class II Directors: Adam Stone DIRECTOR ELECTIONS ISSUER 23.000000 0 WITHHOLD 23.000000 AGAINST Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 Election of Class II Directors: Lynne Sullivan DIRECTOR ELECTIONS ISSUER 23.000000 0 WITHHOLD 23.000000 AGAINST Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 The ratification of the appointment of Ilan Ganot, on an advisory basis, to the Company's Board of Directors as a Class I Director to hold office until the 2028 annual meeting of stockholders. CORPORATE GOVERNANCE ISSUER 23.000000 0 FOR 23.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 23.000000 0 FOR 23.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 The approval of an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 240,000,000 to 480,000,000. CAPITAL STRUCTURE ISSUER 23.000000 0 FOR 23.000000 FOR Solid Biosciences Inc. 83422E204 US83422E2046 06/10/2026 The approval of an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 23.000000 0 AGAINST 23.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Hezy Shaked DIRECTOR ELECTIONS ISSUER 135.000000 0 WITHHOLD 135.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Teresa Aragones DIRECTOR ELECTIONS ISSUER 135.000000 0 FOR 135.000000 FOR Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Doug Collier DIRECTOR ELECTIONS ISSUER 135.000000 0 WITHHOLD 135.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Seth Johnson DIRECTOR ELECTIONS ISSUER 135.000000 0 WITHHOLD 135.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Janet Kerr DIRECTOR ELECTIONS ISSUER 135.000000 0 WITHHOLD 135.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Michael Relich DIRECTOR ELECTIONS ISSUER 135.000000 0 WITHHOLD 135.000000 AGAINST Tilly's, Inc. 886885102 US8868851028 06/10/2026 Election of the following directors for a term expiring at the 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Nathan Smith DIRECTOR ELECTIONS ISSUER 135.000000 0 FOR 135.000000 FOR Tilly's, Inc. 886885102 US8868851028 06/10/2026 Approval of the Fourth Amended and Restated Tilly's 2012 Equity and Incentive Award Plan COMPENSATION ISSUER 135.000000 0 FOR 135.000000 FOR Tilly's, Inc. 886885102 US8868851028 06/10/2026 Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending January 30, 2027. AUDIT-RELATED ISSUER 135.000000 0 FOR 135.000000 FOR Tilly's, Inc. 886885102 US8868851028 06/10/2026 Non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 135.000000 0 FOR 135.000000 FOR Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To elect each of the Class II directors nominated by our Board of Directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director's successor has been duly elected and qualified: Akintunde Bello, Ph.D. DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To elect each of the Class II directors nominated by our Board of Directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director's successor has been duly elected and qualified: Daniel Curran, M.D. DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To elect each of the Class II directors nominated by our Board of Directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director's successor has been duly elected and qualified: Robert Ross, M.D. DIRECTOR ELECTIONS ISSUER 3.000000 0 FOR 3.000000 FOR Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To elect each of the Class II directors nominated by our Board of Directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director's successor has been duly elected and qualified: Yuan Xu, Ph.D. DIRECTOR ELECTIONS ISSUER 3.000000 0 WITHHOLD 3.000000 AGAINST Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 3.000000 0 FOR 3.000000 FOR Xilio Therapeutics, Inc. 98422T209 US98422T2096 06/10/2026 To approve our Amended and Restated 2021 Stock Incentive Plan. COMPENSATION ISSUER 3.000000 0 AGAINST 3.000000 AGAINST Zevia PBC 98955K104 US98955K1043 06/10/2026 Election of Directors: To be elected for terms expiring in 2029: Suzanne S. Ginestro DIRECTOR ELECTIONS ISSUER 61.000000 0 FOR 61.000000 FOR Zevia PBC 98955K104 US98955K1043 06/10/2026 Election of Directors: To be elected for terms expiring in 2029: David J. Lee DIRECTOR ELECTIONS ISSUER 61.000000 0 AGAINST 61.000000 AGAINST Zevia PBC 98955K104 US98955K1043 06/10/2026 Ratification of the selection of Deloitte & Touche LLP as Zevia PBC's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 61.000000 0 FOR 61.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 06/11/2026 To elect as director the one (1) director nominee named in the attached proxy statement as a Class III director to serve for a three-year period until the Annual Meeting of stockholders in the year 2029, and in, until a successor has been elected and qualified: Lucille Salhany DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 06/11/2026 To approve an advisory resolution approving executive compensation for fiscal year 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 1.000000 0 FOR 1.000000 FOR 22nd Century Group, Inc. 90137F707 US90137F7078 06/11/2026 To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accountants for fiscal year 2026. AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 06/11/2026 Election of Class II directors for a three year term expiring in 2029: Alessandro Riva, M.D. DIRECTOR ELECTIONS ISSUER 96.000000 0 WITHHOLD 96.000000 AGAINST Century Therapeutics, Inc. 15673T100 US15673T1007 06/11/2026 Election of Class II directors for a three year term expiring in 2029: Han Lee, Ph.D., M.B.A. DIRECTOR ELECTIONS ISSUER 96.000000 0 FOR 96.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 06/11/2026 Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for 2026. AUDIT-RELATED ISSUER 96.000000 0 FOR 96.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 06/11/2026 Approval of an amendment to the Company's Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 (the "Charter Amendment Proposal"). CAPITAL STRUCTURE ISSUER 96.000000 0 FOR 96.000000 FOR Century Therapeutics, Inc. 15673T100 US15673T1007 06/11/2026 Approval of adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve the Charter Amendment Proposal. CORPORATE GOVERNANCE ISSUER 96.000000 0 FOR 96.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Robert Barrow DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Suzanne Bruhn, Ph.D. DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Roger Crystal, M.D. DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: David Gryska DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Andreas Krebs DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Carol A. Vallone DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 Election of Directors to hold office until the 2027 annual general meeting of shareholders: Roger Adsett DIRECTOR ELECTIONS ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 To appoint KPMG LLP as independent registered public accounting firm (auditor) for the Company until the 2027 annual general meeting of shareholders. AUDIT-RELATED ISSUER 125.000000 0 FOR 125.000000 FOR Definium Therapeutics, Inc. 24477V105 CA24477V1058 06/11/2026 To consider, and if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares. COMPENSATION ISSUER 125.000000 0 FOR 125.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Richard J. Barry DIRECTOR ELECTIONS ISSUER 448.000000 0 FOR 448.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Pierre Gravier DIRECTOR ELECTIONS ISSUER 448.000000 0 FOR 448.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To elect or re-elect three (3) Class II Directors to serve for three-year terms and until their successors are duly elected and qualified: Claude Nicaise, M.D. DIRECTOR ELECTIONS ISSUER 448.000000 0 FOR 448.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To approve Amendment No. 2 to the Company's 2018 Omnibus Incentive Plan, which, among other things, increases the authorized number of shares issuable thereunder by 4,000,000 shares (from 5,000,000 to 9,000,000 authorized shares). COMPENSATION ISSUER 448.000000 0 FOR 448.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 448.000000 0 FOR 448.000000 FOR Filana Therapeutics, Inc. 14817C107 US14817C1071 06/11/2026 To approve, by a non-binding advisory vote, 2025 executive compensation for the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 448.000000 0 FOR 448.000000 FOR Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Election of Directors: Ross Fubini DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Election of Directors: Christian Henry DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Election of Directors: Sri Kosuri DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Election of Directors: Harry E. Sloan DIRECTOR ELECTIONS ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 10.000000 0 FOR 10.000000 FOR Ginkgo Bioworks Holdings, Inc. 37611X209 US37611X2099 06/11/2026 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 10.000000 0 AGAINST 10.000000 AGAINST Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Tom Cusack DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage DIRECTOR ELECTIONS ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To ratify the appointment of Withum as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers during the fiscal year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To approve the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares. COMPENSATION ISSUER 1100.000000 0 AGAINST 1100.000000 AGAINST Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To amend the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares. COMPENSATION ISSUER 1100.000000 0 FOR 1100.000000 FOR Heron Therapeutics, Inc. 427746102 US4277461020 06/11/2026 To ratify, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 1100.000000 0 FOR 1100.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 Election of Directors: Avram A. Glazer DIRECTOR ELECTIONS ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 Election of Directors: Warren H. Gfeller DIRECTOR ELECTIONS ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 Election of Directors: Brian S. Goldstein DIRECTOR ELECTIONS ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 Election of Directors: Amy M. Wilkinson DIRECTOR ELECTIONS ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers (the "Say on Pay Vote"). SECTION 14A SAY-ON-PAY VOTES ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 To approve an amendment to the Company's Second Amended and Restated 2014 Omnibus Equity Award Plan, as amended, to increase the number of shares of Common Stock of the Company available for issuance thereunder (the "Second A&R 2014 Plan Proposal"). COMPENSATION ISSUER 29.000000 0 FOR 29.000000 FOR INNOVATE Corp. 45784J303 US45784J3032 06/11/2026 To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (the "Accounting Firm Proposal"). AUDIT-RELATED ISSUER 29.000000 0 FOR 29.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Joshua Riggs DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Andrew Arno DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Andrew J. Last DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal: Louis E. Silverman DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To ratify the appointment of CBIZ CPAs P.C. as the company's independent registered public accounting firm for the year ending December 31, 2026; AUDIT-RELATED ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To approve, on a non-binding advisory basis, the company's named executive officer compensation for the year ended December 31, 2025; and SECTION 14A SAY-ON-PAY VOTES ISSUER 17.000000 0 FOR 17.000000 FOR Insight Molecular Diagnostics Inc. 68235C206 US68235C2061 06/11/2026 To approve an amendment to the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company's common stock authorized for issuance under such plan by 1,750,000, to a total of 5,550,000 shares. COMPENSATION ISSUER 17.000000 0 FOR 17.000000 FOR Ocugen, Inc. 67577C105 US67577C1053 06/11/2026 The election of Kirsten Castillo and Satish Chandran, Ph.D. as Class III Directors to hold office until the 2029 Annual Meeting: Kirsten Castillo DIRECTOR ELECTIONS ISSUER 2201.000000 0 WITHHOLD 2201.000000 AGAINST Ocugen, Inc. 67577C105 US67577C1053 06/11/2026 The election of Kirsten Castillo and Satish Chandran, Ph.D. as Class III Directors to hold office until the 2029 Annual Meeting: Satish Chandran, Ph.D. DIRECTOR ELECTIONS ISSUER 2201.000000 0 FOR 2201.000000 FOR Ocugen, Inc. 67577C105 US67577C1053 06/11/2026 Ratification of Appointment of PricewaterhouseCoopers LLP as Ocugen, Inc.'s Independent Registered Public Accounting Firm for 2026. AUDIT-RELATED ISSUER 2201.000000 0 FOR 2201.000000 FOR Ocugen, Inc. 67577C105 US67577C1053 06/11/2026 Approval, on an advisory basis, of the compensation of Ocugen, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2201.000000 0 FOR 2201.000000 FOR Ocugen, Inc. 67577C105 US67577C1053 06/11/2026 Approval, on a non-binding advisory basis, of the compensation of Ocugen, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2201.000000 0 ONE YEAR 2201.000000 FOR Quince Therapeutics, Inc. 22053A305 US22053A3059 06/11/2026 To elect one Class I nominee for director to hold office until the 2029 annual meeting of stockholders and until her successor is duly elected and qualified: June Bray DIRECTOR ELECTIONS ISSUER 11.000000 0 WITHHOLD 11.000000 AGAINST Quince Therapeutics, Inc. 22053A305 US22053A3059 06/11/2026 To approve an amendment to our certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio ranging from one-for-ten to one-for-one-hundred. CAPITAL STRUCTURE ISSUER 11.000000 0 FOR 11.000000 FOR Quince Therapeutics, Inc. 22053A305 US22053A3059 06/11/2026 To ratify the selection of BDO USA, P.C. as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 11.000000 0 FOR 11.000000 FOR Quince Therapeutics, Inc. 22053A305 US22053A3059 06/11/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 11.000000 0 FOR 11.000000 FOR Quince Therapeutics, Inc. 22053A305 US22053A3059 06/11/2026 To approve the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the foregoing proposals. CORPORATE GOVERNANCE ISSUER 11.000000 0 AGAINST 11.000000 AGAINST VirnetX Holding Corporation 92823T207 US92823T2078 06/11/2026 Election of our Class I Directors: Kendall Larsen DIRECTOR ELECTIONS ISSUER 18.000000 0 FOR 18.000000 FOR VirnetX Holding Corporation 92823T207 US92823T2078 06/11/2026 Election of our Class I Directors: Gary W. Feiner DIRECTOR ELECTIONS ISSUER 18.000000 0 FOR 18.000000 FOR VirnetX Holding Corporation 92823T207 US92823T2078 06/11/2026 To ratify the appointment of Farber Hass Hurley LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 18.000000 0 FOR 18.000000 FOR VirnetX Holding Corporation 92823T207 US92823T2078 06/11/2026 To approve, on a non-binding advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 18.000000 0 FOR 18.000000 FOR VirnetX Holding Corporation 92823T207 US92823T2078 06/11/2026 To approve an amendment to our Amended and Restated 2013 Equity Incentive Plan to increase the share reserve. COMPENSATION ISSUER 18.000000 0 AGAINST 18.000000 AGAINST Vor Biopharma Inc. 929033207 US9290332074 06/11/2026 To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Andrew Levin, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 5.000000 0 FOR 5.000000 FOR Vor Biopharma Inc. 929033207 US9290332074 06/11/2026 To elect each of the two Class II director nominees set forth in the Proxy Statement to our board of directors, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Fouad Namouni, M.D. DIRECTOR ELECTIONS ISSUER 5.000000 0 WITHHOLD 5.000000 AGAINST Vor Biopharma Inc. 929033207 US9290332074 06/11/2026 To approve the amendment and restatement of our Amended and Restated 2021 Equity Incentive Plan. COMPENSATION ISSUER 5.000000 0 AGAINST 5.000000 AGAINST Vor Biopharma Inc. 929033207 US9290332074 06/11/2026 To ratify the selection by the audit committee of the board of directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 5.000000 0 FOR 5.000000 FOR Cartesian Therapeutics, Inc. 816212302 US8162123025 06/12/2026 Election of Directors: Michael Singer, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Cartesian Therapeutics, Inc. 816212302 US8162123025 06/12/2026 Election of Directors: Timothy A. Springer, Ph.D. DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Cartesian Therapeutics, Inc. 816212302 US8162123025 06/12/2026 Election of Directors: Patrick Zenner, MBA DIRECTOR ELECTIONS ISSUER 18.000000 0 WITHHOLD 18.000000 AGAINST Cartesian Therapeutics, Inc. 816212302 US8162123025 06/12/2026 To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation." SECTION 14A SAY-ON-PAY VOTES ISSUER 18.000000 0 FOR 18.000000 FOR Cartesian Therapeutics, Inc. 816212302 US8162123025 06/12/2026 To ratify the appointment of Ernst & Young LLP as Cartesian Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 18.000000 0 FOR 18.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 Election of Class I Directors: Robert S. Epstein, M.D., M.S. DIRECTOR ELECTIONS ISSUER 948.000000 0 FOR 948.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 Election of Class I Directors: Karin Jooss, Ph.D. DIRECTOR ELECTIONS ISSUER 948.000000 0 FOR 948.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 Election of Class I Directors: Laura J. Hamill DIRECTOR ELECTIONS ISSUER 948.000000 0 FOR 948.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 To approve the ratification of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 948.000000 0 FOR 948.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 948.000000 0 FOR 948.000000 FOR Fate Therapeutics, Inc. 31189P102 US31189P1021 06/12/2026 To approve a proposal to amend and restate the Company's 2022 Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder. COMPENSATION ISSUER 948.000000 0 AGAINST 948.000000 AGAINST LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/12/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders, each until their respective successors are elected and qualified: Evert Schimmelpennink DIRECTOR ELECTIONS ISSUER 22.000000 0 FOR 22.000000 FOR LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/12/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders, each until their respective successors are elected and qualified: Jeff George DIRECTOR ELECTIONS ISSUER 22.000000 0 WITHHOLD 22.000000 AGAINST LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/12/2026 To elect three Class II directors to hold office until our 2029 annual meeting of stockholders, each until their respective successors are elected and qualified: Shelley Thunen DIRECTOR ELECTIONS ISSUER 22.000000 0 FOR 22.000000 FOR LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/12/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 22.000000 0 FOR 22.000000 FOR Q32 Bio Inc. 746964105 US7469641051 06/12/2026 To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kathleen LaPorte DIRECTOR ELECTIONS ISSUER 13.000000 0 WITHHOLD 13.000000 AGAINST Q32 Bio Inc. 746964105 US7469641051 06/12/2026 To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Jodie Morrison DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Q32 Bio Inc. 746964105 US7469641051 06/12/2026 To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Arthur Tzianabos, Ph.D. DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR Q32 Bio Inc. 746964105 US7469641051 06/12/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; AUDIT-RELATED ISSUER 13.000000 0 FOR 13.000000 FOR Q32 Bio Inc. 746964105 US7469641051 06/12/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers; and SECTION 14A SAY-ON-PAY VOTES ISSUER 13.000000 0 FOR 13.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: Eugene I. Davis DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: Lisa Gavales DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: Sue Gove DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: J. Carney Hawks DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: Nikolaj Sjoqvist DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 Election of Directors: Heather Thiltgen DIRECTOR ELECTIONS ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal 2026. AUDIT-RELATED ISSUER 4946.000000 0 FOR 4946.000000 FOR WW International, Inc. 98262P200 US98262P2002 06/12/2026 To approve, on an advisory basis, the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 4946.000000 0 FOR 4946.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Robert Ades DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Michael J. Driscoll DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Prathyusha Duraibabu DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Jon Giacomin DIRECTOR ELECTIONS ISSUER 379.000000 0 WITHHOLD 379.000000 AGAINST Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Gary S. Gillheeney, Sr. DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Michele Korfin DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Arthur S. Leibowitz DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Glenn H. Nussdorf DIRECTOR ELECTIONS ISSUER 379.000000 0 WITHHOLD 379.000000 AGAINST Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Election of Directors: Gilberto Quintero DIRECTOR ELECTIONS ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Approval, on an advisory basis, of the compensation paid to our named executive officers, as disclosed in the Company's proxy statement for its 2026 annual meeting of shareholders. SECTION 14A SAY-ON-PAY VOTES ISSUER 379.000000 0 FOR 379.000000 FOR Organogenesis Holdings Inc. 68621F102 US68621F1021 06/15/2026 Appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2026. AUDIT-RELATED ISSUER 379.000000 0 FOR 379.000000 FOR Par Health, Inc. ZZZZ00272603 06/15/2026 Elect Director Michael Heffernan OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Par Health, Inc. ZZZZ00272603 06/15/2026 Elect Director Joshua Murray OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Par Health, Inc. ZZZZ00272603 06/15/2026 Elect Director Matthew Stober OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Par Health, Inc. ZZZZ00272603 06/15/2026 Elect Director Stephen Welch OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Par Health, Inc. ZZZZ00272603 06/15/2026 Elect Director Jon Zinman OTHER Private company-related matter ISSUER 582.000000 0 FOR 582.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 06/15/2026 The election of three Class II directors named in the proxy statement: Thomas Civik DIRECTOR ELECTIONS ISSUER 62.000000 0 FOR 62.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 06/15/2026 The election of three Class II directors named in the proxy statement: Freda Lewis-Hall, M.D. DIRECTOR ELECTIONS ISSUER 62.000000 0 WITHHOLD 62.000000 AGAINST Pyxis Oncology, Inc. 747324101 US7473241013 06/15/2026 The election of three Class II directors named in the proxy statement: Michael A. Metzger DIRECTOR ELECTIONS ISSUER 62.000000 0 FOR 62.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 06/15/2026 The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and AUDIT-RELATED ISSUER 62.000000 0 FOR 62.000000 FOR American Well Corporation 03044L204 US03044L2043 06/16/2026 To elect two Class III directors to serve until the 2029 annual meeting of stockholders: Dr. Ido Schoenberg DIRECTOR ELECTIONS ISSUER 109.000000 0 WITHHOLD 109.000000 AGAINST American Well Corporation 03044L204 US03044L2043 06/16/2026 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 AUDIT-RELATED ISSUER 109.000000 0 FOR 109.000000 FOR American Well Corporation 03044L204 US03044L2043 06/16/2026 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in executive compensation and the related compensation tables and narrative disclosure in the Company's proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 109.000000 0 FOR 109.000000 FOR comScore, Inc. 20564W204 US20564W2044 06/16/2026 Election of Directors: David Kline DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 06/16/2026 Election of Directors: Brian Wendling DIRECTOR ELECTIONS ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 06/16/2026 The approval, on a non-binding advisory basis, of the compensation paid to the company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 06/16/2026 The ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026 AUDIT-RELATED ISSUER 20.000000 0 FOR 20.000000 FOR comScore, Inc. 20564W204 US20564W2044 06/16/2026 The approval of an amendment to the Amended and Restated 2018 Equity and Incentive Compensation Plan to increase the number of shares of the company's common stock available for grant by 3,000,000 COMPENSATION ISSUER 20.000000 0 AGAINST 20.000000 AGAINST ImageneBio, Inc. 45175G207 US45175G2075 06/16/2026 To elect the Board of Director's two nominees for Class II directors listed below, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until his earlier death, resignation or removal: David P. Bonita, M.D. DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR ImageneBio, Inc. 45175G207 US45175G2075 06/16/2026 To elect the Board of Director's two nominees for Class II directors listed below, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until his earlier death, resignation or removal: Joseph P. Slattery DIRECTOR ELECTIONS ISSUER 13.000000 0 FOR 13.000000 FOR ImageneBio, Inc. 45175G207 US45175G2075 06/16/2026 To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 13.000000 0 FOR 13.000000 FOR ImageneBio, Inc. 45175G207 US45175G2075 06/16/2026 To approve an amendment and restatement of the Company's 2025 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2025 Plan by 850,000 shares and include in the calculation of the annual automatic share reserve increase shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. COMPENSATION ISSUER 13.000000 0 AGAINST 13.000000 AGAINST Inseego Corp. 45782B302 US45782B3024 06/16/2026 Elect two directors to serve until the 2029 Annual Meeting of Stockholders.: James B. Avery DIRECTOR ELECTIONS ISSUER 49.000000 0 FOR 49.000000 FOR Inseego Corp. 45782B302 US45782B3024 06/16/2026 Elect two directors to serve until the 2029 Annual Meeting of Stockholders.: Jeffrey Tuder DIRECTOR ELECTIONS ISSUER 49.000000 0 WITHHOLD 49.000000 AGAINST Inseego Corp. 45782B302 US45782B3024 06/16/2026 Ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 49.000000 0 FOR 49.000000 FOR Inseego Corp. 45782B302 US45782B3024 06/16/2026 Approve, in an advisory vote, the compensation paid to the Company's named executive officers, as presented in the proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 49.000000 0 AGAINST 49.000000 AGAINST Playboy, Inc. 72814P109 US72814P1093 06/16/2026 Election of Directors: Tracey Edmonds DIRECTOR ELECTIONS ISSUER 337.000000 0 WITHHOLD 337.000000 AGAINST Playboy, Inc. 72814P109 US72814P1093 06/16/2026 Election of Directors: James Yaffe DIRECTOR ELECTIONS ISSUER 337.000000 0 WITHHOLD 337.000000 AGAINST Playboy, Inc. 72814P109 US72814P1093 06/16/2026 Approve the amendment of the Playboy, Inc. Amended & Restated 2021 Equity and Incentive Compensation Plan (the "Incentive Plan"), to increase the number of shares of Playboy, Inc. common stock available under the Incentive Plan by 10,000,000 shares. COMPENSATION ISSUER 337.000000 0 AGAINST 337.000000 AGAINST Playboy, Inc. 72814P109 US72814P1093 06/16/2026 Ratify the appointment of RSM US LLP as Playboy, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 337.000000 0 FOR 337.000000 FOR Playboy, Inc. 72814P109 US72814P1093 06/16/2026 An advisory, non-binding vote to approve the compensation of Playboy, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 337.000000 0 AGAINST 337.000000 AGAINST Playboy, Inc. 72814P109 US72814P1093 06/16/2026 Approve the adjournment of the Playboy, Inc. 2026 Annual Meeting, if necessary or appropriate, to continue to solicit votes in favor of Proposal 2 above. CORPORATE GOVERNANCE ISSUER 337.000000 0 AGAINST 337.000000 AGAINST Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To elect five directors to serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Paul Travers DIRECTOR ELECTIONS ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To elect five directors to serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Grant Russell DIRECTOR ELECTIONS ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To elect five directors to serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Timothy Harned DIRECTOR ELECTIONS ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To elect five directors to serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Paula Whitten-Doolin DIRECTOR ELECTIONS ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To elect five directors to serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Alasdair MacKinnon DIRECTOR ELECTIONS ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To ratify the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 349.000000 0 FOR 349.000000 FOR Vuzix Corporation 92921W300 US92921W3007 06/16/2026 To conduct a non-binding advisory vote for the approval of the compensation disclosed in the Proxy Statement of the Company's executive officers who are named in the Proxy Statement Summary Compensation Table. SECTION 14A SAY-ON-PAY VOTES ISSUER 349.000000 0 AGAINST 349.000000 AGAINST Zentalis Pharmaceuticals, Inc. 98943L107 US98943L1070 06/16/2026 Election of each of the Class III Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: David Johnson DIRECTOR ELECTIONS ISSUER 428.000000 0 WITHHOLD 428.000000 AGAINST Zentalis Pharmaceuticals, Inc. 98943L107 US98943L1070 06/16/2026 Election of each of the Class III Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Jan Skvarka, Ph.D. DIRECTOR ELECTIONS ISSUER 428.000000 0 WITHHOLD 428.000000 AGAINST Zentalis Pharmaceuticals, Inc. 98943L107 US98943L1070 06/16/2026 Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 428.000000 0 FOR 428.000000 FOR Zentalis Pharmaceuticals, Inc. 98943L107 US98943L1070 06/16/2026 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 428.000000 0 AGAINST 428.000000 AGAINST Alector, Inc. 014442107 US0144421072 06/17/2026 ELECTION OF DIRECTORS: Elizabeth Garofalo, M.D. DIRECTOR ELECTIONS ISSUER 695.000000 0 FOR 695.000000 FOR Alector, Inc. 014442107 US0144421072 06/17/2026 ELECTION OF DIRECTORS: Errol De Souza, Ph.D. DIRECTOR ELECTIONS ISSUER 695.000000 0 FOR 695.000000 FOR Alector, Inc. 014442107 US0144421072 06/17/2026 ELECTION OF DIRECTORS: Kristine Yaffe, M.D. DIRECTOR ELECTIONS ISSUER 695.000000 0 WITHHOLD 695.000000 AGAINST Alector, Inc. 014442107 US0144421072 06/17/2026 Ratification of the appointment of Ernst & Young, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 695.000000 0 FOR 695.000000 FOR Alector, Inc. 014442107 US0144421072 06/17/2026 Advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 695.000000 0 FOR 695.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: Ellen Beausang DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: Jeffrey Cohen, M.D. DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: John Fraser DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: Cynthia Hundorfean DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: Winfred Parnell, M.D. DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Election of Director Nominees: Jane Pine Wood DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Proposal to approve an amendment to the Aspira Women's Health Inc. 2019 Stock Incentive Plan. COMPENSATION ISSUER 28.000000 0 FOR 28.000000 FOR Aspira Women's Health Inc. 04537Y208 US04537Y2081 06/17/2026 Proposal to ratify the selection of BDO USA PC as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 28.000000 0 FOR 28.000000 FOR Codexis, Inc. 192005106 US1920051067 06/17/2026 Election of the three Class I directors named in the Proxy Statement to hold office for a three-year term expiring at the 2029 Annual Meeting: Stephen G. Dilly, M.B.B.S., Ph.D. DIRECTOR ELECTIONS ISSUER 706.000000 0 FOR 706.000000 FOR Codexis, Inc. 192005106 US1920051067 06/17/2026 Election of the three Class I directors named in the Proxy Statement to hold office for a three-year term expiring at the 2029 Annual Meeting: Raymond De Vre, Ph.D. DIRECTOR ELECTIONS ISSUER 706.000000 0 FOR 706.000000 FOR Codexis, Inc. 192005106 US1920051067 06/17/2026 Election of the three Class I directors named in the Proxy Statement to hold office for a three-year term expiring at the 2029 Annual Meeting: Rahul Singhvi, Sc.D. DIRECTOR ELECTIONS ISSUER 706.000000 0 FOR 706.000000 FOR Codexis, Inc. 192005106 US1920051067 06/17/2026 To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 706.000000 0 FOR 706.000000 FOR Codexis, Inc. 192005106 US1920051067 06/17/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 706.000000 0 FOR 706.000000 FOR Editas Medicine, Inc. 28106W103 US28106W1036 06/17/2026 Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Bernadette Connaughton DIRECTOR ELECTIONS ISSUER 801.000000 0 WITHHOLD 801.000000 AGAINST Editas Medicine, Inc. 28106W103 US28106W1036 06/17/2026 Election of two Class I Directors, each to serve until the 2029 annual meeting of stockholders: Elliott Levy, M.D. DIRECTOR ELECTIONS ISSUER 801.000000 0 FOR 801.000000 FOR Editas Medicine, Inc. 28106W103 US28106W1036 06/17/2026 To approve, on an advisory basis, the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 801.000000 0 AGAINST 801.000000 AGAINST Editas Medicine, Inc. 28106W103 US28106W1036 06/17/2026 To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 801.000000 0 FOR 801.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: Matthew Conlin DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: James P. Geygan DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: David A. Graff DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: Barbara Shattuck Kohn DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: Donald Mathis DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: Richard C. Pfenniger, Jr. DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 To elect seven directors: Ryan Schulke DIRECTOR ELECTIONS ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve, on an advisory basis, the 2025 compensation of the Company's named executive officers (Say-on-Pay). SECTION 14A SAY-ON-PAY VOTES ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve, for the purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(c), warrants and pre-funded warrants issued pursuant to those certain securities purchase agreements dated as of May 15, 2025 to certain of the Company's directors and/or officers and any shares of the Company's common stock issuable upon exercise thereof. CAPITAL STRUCTURE ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve, for the purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(c), warrants and pre-funded warrants issued pursuant to those certain securities purchase agreements dated as of August 19, 2025 to certain of the Company's directors and/or officers and any shares of the Company's common stock issuable upon exercise thereof. CAPITAL STRUCTURE ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve an Amended and Restated Certificate of Incorporation to provide for exculpation of officers as permitted by recent amendments to Delaware law. CORPORATE GOVERNANCE ISSUER 43.000000 0 FOR 43.000000 FOR Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve an amendment to the Fluent, Inc. 2022 Omnibus Equity Incentive Plan to increase the number of shares of common stock reserved thereunder to 5,566,666 shares from 3,666,666 shares. COMPENSATION ISSUER 43.000000 0 AGAINST 43.000000 AGAINST Fluent, Inc. 34380C201 US34380C2017 06/17/2026 Approve the adjournment of the annual meeting, if necessary or advisable, to solicit additional proxies in favor of any of the foregoing proposals if there are not sufficient votes to approve any such proposals. CORPORATE GOVERNANCE ISSUER 43.000000 0 AGAINST 43.000000 AGAINST Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Lindsay A. Rosenwald, M.D. DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Michael S. Weiss DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Jimmie Harvey, Jr., M.D. DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Malcolm Hoenlein DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Dov Klein, CPA DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: J. Jay Lobell DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Election of Directors: Kevin L. Lorenz, J.D. DIRECTOR ELECTIONS ISSUER 28.000000 0 FOR 28.000000 FOR Fortress Biotech, Inc. 34960Q307 US34960Q3074 06/17/2026 Ratification of the appointment of KPMG LLP as Fortress Biotech, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 28.000000 0 FOR 28.000000 FOR MaxCyte, Inc. 57777K106 US57777K1060 06/17/2026 To elect the Board's three nominees as identified in the accompanying Proxy Statement as Class II directors: Patrick J. Balthrop DIRECTOR ELECTIONS ISSUER 563.000000 0 WITHHOLD 563.000000 AGAINST MaxCyte, Inc. 57777K106 US57777K1060 06/17/2026 To elect the Board's three nominees as identified in the accompanying Proxy Statement as Class II directors: Cynthia Collins DIRECTOR ELECTIONS ISSUER 563.000000 0 FOR 563.000000 FOR MaxCyte, Inc. 57777K106 US57777K1060 06/17/2026 To elect the Board's three nominees as identified in the accompanying Proxy Statement as Class II directors: Stanley C. Erck DIRECTOR ELECTIONS ISSUER 563.000000 0 WITHHOLD 563.000000 AGAINST MaxCyte, Inc. 57777K106 US57777K1060 06/17/2026 To ratify the Audit Committee's selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 563.000000 0 FOR 563.000000 FOR Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Election of Class II Directors: Phillip M. Eyler DIRECTOR ELECTIONS ISSUER 112.000000 0 FOR 112.000000 FOR Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Election of Class II Directors: Angus Pacala DIRECTOR ELECTIONS ISSUER 112.000000 0 WITHHOLD 112.000000 AGAINST Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 112.000000 0 FOR 112.000000 FOR Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 112.000000 0 AGAINST 112.000000 AGAINST Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Approval of an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock, par value $0.0001 per share, from 100,000,000 to 200,000,000. CAPITAL STRUCTURE ISSUER 112.000000 0 FOR 112.000000 FOR Ouster, Inc. 68989M202 US68989M2026 06/17/2026 Approval of an amendment to the Company's Certificate of Incorporation, as amended, to provide for exculpation of officers from breaches of fiduciary duty to the extent permitted by the General Corporation Law of the State of Delaware. CORPORATE GOVERNANCE ISSUER 112.000000 0 FOR 112.000000 FOR Recursion Pharmaceuticals, Inc. 75629V104 US75629V1044 06/17/2026 Election of Directors: Najat Khan, Ph.D. DIRECTOR ELECTIONS ISSUER 1343.000000 0 WITHHOLD 1343.000000 AGAINST Recursion Pharmaceuticals, Inc. 75629V104 US75629V1044 06/17/2026 Election of Directors: Franziska Michor, Ph.D. DIRECTOR ELECTIONS ISSUER 1343.000000 0 WITHHOLD 1343.000000 AGAINST Recursion Pharmaceuticals, Inc. 75629V104 US75629V1044 06/17/2026 Advisory vote to approve executive compensation as disclosed in the 2026 Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1343.000000 0 AGAINST 1343.000000 AGAINST Recursion Pharmaceuticals, Inc. 75629V104 US75629V1044 06/17/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1343.000000 0 FOR 1343.000000 FOR Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 Election of Directors: Michael Egholm, Ph.D. DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 Election of Directors: Thomas Carey DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 Election of Directors: Eli Casdin DIRECTOR ELECTIONS ISSUER 454.000000 0 FOR 454.000000 FOR Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 454.000000 0 AGAINST 454.000000 AGAINST Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 454.000000 0 FOR 454.000000 FOR Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 To approve the Standard BioTools Inc. 2026 Equity Incentive Plan. COMPENSATION ISSUER 454.000000 0 AGAINST 454.000000 AGAINST Standard BioTools Inc. 34385P108 US34385P1084 06/17/2026 To approve an amendment to our Amended and Restated 2017 Employee Stock Purchase Plan to increase the number of shares of common stock available for issuance thereunder by 1,200,000 shares. COMPENSATION ISSUER 454.000000 0 FOR 454.000000 FOR Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 Election of Directors: Deborah Messemer DIRECTOR ELECTIONS ISSUER 811.000000 0 WITHHOLD 811.000000 AGAINST Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 Election of Directors: Vicki Sato, Ph.D. DIRECTOR ELECTIONS ISSUER 811.000000 0 WITHHOLD 811.000000 AGAINST Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 Election of Directors: Owen Witte, M.D. DIRECTOR ELECTIONS ISSUER 811.000000 0 WITHHOLD 811.000000 AGAINST Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 811.000000 0 FOR 811.000000 FOR Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 811.000000 0 ONE YEAR 811.000000 FOR Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares. CAPITAL STRUCTURE ISSUER 811.000000 0 FOR 811.000000 FOR Allogene Therapeutics, Inc. 019770106 US0197701065 06/18/2026 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 811.000000 0 FOR 811.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Election of three Class III Directors: Gary P. Fischetti DIRECTOR ELECTIONS ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Election of three Class III Directors: John B. Henneman, III DIRECTOR ELECTIONS ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Election of three Class III Directors: Stephen D. Griffin DIRECTOR ELECTIONS ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Ratification of Deloitte & Touche LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Advisory vote on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Approval of the Amendment to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan. COMPENSATION ISSUER 86.000000 0 FOR 86.000000 FOR Anika Therapeutics, Inc. 035255108 US0352551081 06/18/2026 Approval of the Amendment of the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan COMPENSATION ISSUER 86.000000 0 FOR 86.000000 FOR Douglas Elliman Inc. 25961D105 US25961D1054 06/18/2026 Election of Directors: Michael S. Liebowitz DIRECTOR ELECTIONS ISSUER 449.000000 0 WITHHOLD 449.000000 AGAINST Douglas Elliman Inc. 25961D105 US25961D1054 06/18/2026 Election of Directors: Mark D. Zeitchick DIRECTOR ELECTIONS ISSUER 449.000000 0 WITHHOLD 449.000000 AGAINST Douglas Elliman Inc. 25961D105 US25961D1054 06/18/2026 Approval of ratification of EisnerAmper LLP as independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 449.000000 0 FOR 449.000000 FOR Douglas Elliman Inc. 25961D105 US25961D1054 06/18/2026 Advisory vote on executive compensation (the say-on-pay vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 449.000000 0 AGAINST 449.000000 AGAINST eHealth, Inc. 28238P109 US28238P1093 06/18/2026 Election of Class II Directors: Prama Bhatt DIRECTOR ELECTIONS ISSUER 145.000000 0 FOR 145.000000 FOR eHealth, Inc. 28238P109 US28238P1093 06/18/2026 Election of Class II Directors: Beth A. Brooke DIRECTOR ELECTIONS ISSUER 145.000000 0 FOR 145.000000 FOR eHealth, Inc. 28238P109 US28238P1093 06/18/2026 Ratification of the appointment of Ernst & Young LLP as the Independent registered public accounting firm of eHealth, Inc. for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 145.000000 0 FOR 145.000000 FOR eHealth, Inc. 28238P109 US28238P1093 06/18/2026 Approval, on an advisory basis, of the compensation of the Named Executive Officers of eHealth, Inc. SECTION 14A SAY-ON-PAY VOTES ISSUER 145.000000 0 FOR 145.000000 FOR eHealth, Inc. 28238P109 US28238P1093 06/18/2026 Approval of an amendment and restatement of the eHealth, Inc. Amended and Restated 2024 Equity Incentive Plan to Increase the maximum number of shares of common stock that may be issued thereunder by 1,300,000 shares. COMPENSATION ISSUER 145.000000 0 AGAINST 145.000000 AGAINST GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 Election of Directors: Darren Lampert DIRECTOR ELECTIONS ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 Election of Directors: Michael Salaman DIRECTOR ELECTIONS ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 Election of Directors: Eula Adams DIRECTOR ELECTIONS ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 Election of Directors: Stephen Aiello DIRECTOR ELECTIONS ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 Election of Directors: Starlett Carter DIRECTOR ELECTIONS ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 To provide an advisory vote to approve the compensation paid to the Company's named executive officers pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 647.000000 0 FOR 647.000000 FOR GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 To approve and ratify the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan, as set forth in Exhibit A attached to the Proxy Statement. COMPENSATION ISSUER 647.000000 0 AGAINST 647.000000 AGAINST GrowGeneration Corp. 39986L109 US39986L1098 06/18/2026 To approve and ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm to audit the Company's financial statements as of December 31, 2026 and for the fiscal years then ending. AUDIT-RELATED ISSUER 647.000000 0 FOR 647.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Jeffrey Siegel DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Robert B. Kay DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Jeffrey H. Evans DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Rachael A. Jarosh DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Cherrie Nanninga DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Bruce G. Pollack DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Michael J. Regan DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Michael Schnabel DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 ELECTION OF DIRECTORS: Daniel Siegel DIRECTOR ELECTIONS ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026. AUDIT-RELATED ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE 2025 COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. SECTION 14A SAY-ON-PAY VOTES ISSUER 75.000000 0 FOR 75.000000 FOR Lifetime Brands, Inc. 53222Q103 US53222Q1031 06/18/2026 TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S AMENDED AND RESTATED 2000 LONG-TERM INCENTIVE PLAN. COMPENSATION ISSUER 75.000000 0 FOR 75.000000 FOR MARA Holdings, Inc. 565788106 US5657881067 06/18/2026 Election of Class III directors to serve until our 2029 annual meeting of stockholders: Vicki Mealer-Burke DIRECTOR ELECTIONS ISSUER 1115.000000 0 WITHHOLD 1115.000000 AGAINST MARA Holdings, Inc. 565788106 US5657881067 06/18/2026 Election of Class III directors to serve until our 2029 annual meeting of stockholders: Douglas Mellinger DIRECTOR ELECTIONS ISSUER 1115.000000 0 FOR 1115.000000 FOR MARA Holdings, Inc. 565788106 US5657881067 06/18/2026 Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 1115.000000 0 FOR 1115.000000 FOR MARA Holdings, Inc. 565788106 US5657881067 06/18/2026 A non-binding, advisory vote on the compensation of our Named Executive Officers ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 1115.000000 0 AGAINST 1115.000000 AGAINST MARA Holdings, Inc. 565788106 US5657881067 06/18/2026 Approval of an amendment to our Amended and Restated 2018 Equity Incentive Plan (the "2018 Plan") to increase the number of shares of our common stock reserved under the 2018 Plan by 18 million shares. COMPENSATION ISSUER 1115.000000 0 AGAINST 1115.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Phillip Frost, M.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Jane H. Hsiao, Ph.D., MBA DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Elias A. Zerhouni, M.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Steven D. Rubin DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Gary J. Nabel, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Prem A. Lachman, M.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Roger J. Medel, M.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: John A. Paganelli DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Richard C. Pfenniger, Jr. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Subbarao V. Uppaluri, Ph.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 FOR 2343.000000 FOR OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Alice Lin-Tsing Yu, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To approve the Company's 2026 Equity Incentive Plan; COMPENSATION ISSUER 2343.000000 0 AGAINST 2343.000000 AGAINST OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 To approve a non-binding resolution regarding the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 2343.000000 0 FOR 2343.000000 FOR OPKO Health, Inc. 68375N103 US68375N1037 06/18/2026 The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and AUDIT-RELATED ISSUER 2343.000000 0 FOR 2343.000000 FOR Rackspace Technology, Inc. 750102105 US7501021056 06/18/2026 Nominees: Gajen Kandiah DIRECTOR ELECTIONS ISSUER 324.000000 0 FOR 324.000000 FOR Rackspace Technology, Inc. 750102105 US7501021056 06/18/2026 Nominees: Michael Weston DIRECTOR ELECTIONS ISSUER 324.000000 0 FOR 324.000000 FOR Rackspace Technology, Inc. 750102105 US7501021056 06/18/2026 Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 324.000000 0 FOR 324.000000 FOR Rackspace Technology, Inc. 750102105 US7501021056 06/18/2026 Non-binding advisory vote to approve the compensation of the Company's named executive officers as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 324.000000 0 FOR 324.000000 FOR Rackspace Technology, Inc. 750102105 US7501021056 06/18/2026 Approve an amendment to the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock authorized to be issued under the plan. COMPENSATION ISSUER 324.000000 0 AGAINST 324.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 Election of Class III Directors: Kelly A. Romano DIRECTOR ELECTIONS ISSUER 19.000000 0 WITHHOLD 19.000000 AGAINST LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 Election of Class III Directors: James A. Johnson DIRECTOR ELECTIONS ISSUER 19.000000 0 FOR 19.000000 FOR LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 Election of Class III Directors: Natalie Holles DIRECTOR ELECTIONS ISSUER 19.000000 0 FOR 19.000000 FOR LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 19.000000 0 FOR 19.000000 FOR LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 19.000000 0 FOR 19.000000 FOR LeonaBio, Inc. 04746L203 US04746L2034 06/22/2026 To approve, on an advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 19.000000 0 ONE YEAR 19.000000 AGAINST AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 To elect four directors to serve on our Board of Directors for a one-year term of office until the next annual meeting of stockholders: Graydon Bensler DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 To elect four directors to serve on our Board of Directors for a one-year term of office until the next annual meeting of stockholders: Braeden Lichti DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 To elect four directors to serve on our Board of Directors for a one-year term of office until the next annual meeting of stockholders: Rick Sterling DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 To elect four directors to serve on our Board of Directors for a one-year term of office until the next annual meeting of stockholders: Sylvia Wulf DIRECTOR ELECTIONS ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 Ratify the independent registered public accounting firm for 2026. AUDIT-RELATED ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 Approve amendment to our Third Amended and Restated Certificate of Incorporation, as amended, to approve a Reverse Share Split. CAPITAL STRUCTURE ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 Approve non-binding advisory on compensation to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 17.000000 0 FOR 17.000000 FOR AquaBounty Technologies, Inc. 03842K309 US03842K3095 06/23/2026 Approve adjournment of meeting, if necessary to solicit additional proxies. CORPORATE GOVERNANCE ISSUER 17.000000 0 FOR 17.000000 FOR Hydrofarm Holdings Group, Inc. 44888K407 US44888K4076 06/23/2026 To elect one (1) class III directors to serve three-year terms expiring in 2029: Richard Christopher Yetter DIRECTOR ELECTIONS ISSUER 46.000000 0 FOR 46.000000 FOR Hydrofarm Holdings Group, Inc. 44888K407 US44888K4076 06/23/2026 To approve, on a non-binding advisory basis, the compensation of our named executine officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 46.000000 0 FOR 46.000000 FOR Hydrofarm Holdings Group, Inc. 44888K407 US44888K4076 06/23/2026 To ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 46.000000 0 FOR 46.000000 FOR Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To elect two Class III directors to serve until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Milind Deshpande, Ph.D. DIRECTOR ELECTIONS ISSUER 144.000000 0 WITHHOLD 144.000000 AGAINST Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To elect two Class III directors to serve until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Kathleen Tregoning DIRECTOR ELECTIONS ISSUER 144.000000 0 FOR 144.000000 FOR Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 144.000000 0 FOR 144.000000 FOR Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 144.000000 0 FOR 144.000000 FOR Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares. CAPITAL STRUCTURE ISSUER 144.000000 0 FOR 144.000000 FOR Spero Therapeutics, Inc. 84833T103 US84833T1034 06/23/2026 To approve adoption of the 2026 Spero Therapeutics, Inc. Stock Incentive Plan. COMPENSATION ISSUER 144.000000 0 AGAINST 144.000000 AGAINST Arvinas, Inc. 04335A105 US04335A1051 06/24/2026 Election of two Class II directors: Leslie V. Norwalk, Esq. DIRECTOR ELECTIONS ISSUER 548.000000 0 WITHHOLD 548.000000 AGAINST Arvinas, Inc. 04335A105 US04335A1051 06/24/2026 Election of two Class II directors: Randy Teel, Ph.D. DIRECTOR ELECTIONS ISSUER 548.000000 0 FOR 548.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 06/24/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 548.000000 0 FOR 548.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 06/24/2026 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 548.000000 0 FOR 548.000000 FOR C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Andrew Hirsch DIRECTOR ELECTIONS ISSUER 460.000000 0 WITHHOLD 460.000000 AGAINST C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Stephen Fawell, Ph.D. DIRECTOR ELECTIONS ISSUER 460.000000 0 WITHHOLD 460.000000 AGAINST C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To elect three Class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Utpal Koppikar DIRECTOR ELECTIONS ISSUER 460.000000 0 WITHHOLD 460.000000 AGAINST C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 460.000000 0 FOR 460.000000 FOR C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To ratify the engagement of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 460.000000 0 FOR 460.000000 FOR C4 Therapeutics, Inc. 12529R107 US12529R1077 06/24/2026 To approve an amendment to our 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are issued and outstanding as of each December 31. COMPENSATION ISSUER 460.000000 0 AGAINST 460.000000 AGAINST Lucid Diagnostics Inc. 54948X109 US54948X1090 06/24/2026 Election of Class B Directors: James L. Cox, M.D. DIRECTOR ELECTIONS ISSUER 39.000000 0 WITHHOLD 39.000000 AGAINST Lucid Diagnostics Inc. 54948X109 US54948X1090 06/24/2026 Election of Class B Directors: John R. Palumbo DIRECTOR ELECTIONS ISSUER 39.000000 0 WITHHOLD 39.000000 AGAINST Lucid Diagnostics Inc. 54948X109 US54948X1090 06/24/2026 Election of Class B Directors: Ronald M. Sparks DIRECTOR ELECTIONS ISSUER 39.000000 0 WITHHOLD 39.000000 AGAINST Lucid Diagnostics Inc. 54948X109 US54948X1090 06/24/2026 Approval of an amendment to the Certificate of Incorporation to increase the total number of shares of common stock the Company is authorized to issue by 100,000,000 shares, from 300,000,000 shares to 400,000,000 shares. CAPITAL STRUCTURE ISSUER 39.000000 0 FOR 39.000000 FOR Lucid Diagnostics Inc. 54948X109 US54948X1090 06/24/2026 Ratification of the appointment of the independent registered certified public accounting firm. AUDIT-RELATED ISSUER 39.000000 0 FOR 39.000000 FOR PAVmed Inc. 70387R502 US70387R5028 06/24/2026 Election of Class A Directors: Ronald M. Sparks DIRECTOR ELECTIONS ISSUER 1.000000 0 WITHHOLD 1.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 06/24/2026 Election of Class A Directors: Timothy Baxter DIRECTOR ELECTIONS ISSUER 1.000000 0 WITHHOLD 1.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 06/24/2026 Approval of amendments to the Company's Employee Stock Purchase Plan (the "ESPP") to (i) increase the total number of shares of the Company's common stock available under the ESPP by an additional 200,000 shares, from 15,774 shares to 215,774 shares, and (ii) raise the annual limit for increases under the evergreen provision from 5,556 shares to 500,000 shares. COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST PAVmed Inc. 70387R502 US70387R5028 06/24/2026 Ratification of the appointment of the independent registered certified public accounting firm. AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR Scilex Holding Company 80880W205 US80880W2052 06/24/2026 Election of Director: Dorman Followwill DIRECTOR ELECTIONS ISSUER 14.000000 0 WITHHOLD 14.000000 AGAINST Scilex Holding Company 80880W205 US80880W2052 06/24/2026 Proposal to ratify the appointment of BPM LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 14.000000 0 FOR 14.000000 FOR Scilex Holding Company 80880W205 US80880W2052 06/24/2026 To approve the amendment to the Scilex Holding Company 2022 Equity Incentive Plan (as amended) to (i) increase the number of shares authorized for issuance thereunder by 1,300,000 shares to 2,765,789 shares and (ii) increase the number of shares authorized for issuance thereunder pursuant to the exercise of incentive stock options to 2,765,789 shares. COMPENSATION ISSUER 14.000000 0 AGAINST 14.000000 AGAINST Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To elect two Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Bridget Martell, M.A., M.D. DIRECTOR ELECTIONS ISSUER 5.000000 0 WITHHOLD 5.000000 AGAINST Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To elect two Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Carole Nuechterlein, J.D. DIRECTOR ELECTIONS ISSUER 5.000000 0 WITHHOLD 5.000000 AGAINST Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; AUDIT-RELATED ISSUER 5.000000 0 FOR 5.000000 FOR Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To approve an amendment to the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), in substantially the form attached to the accompanying Proxy Statement as Appendix A, to remove the evergreen provision and increase the number of shares reserved for issuance under the ESPP by 500,000 shares; COMPENSATION ISSUER 5.000000 0 FOR 5.000000 FOR Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"); and SECTION 14A SAY-ON-PAY VOTES ISSUER 5.000000 0 FOR 5.000000 FOR Aligos Therapeutics, Inc. 01626L204 US01626L2043 06/25/2026 To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one year, every two years or every three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 5.000000 0 ONE YEAR 5.000000 FOR Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The election of the two Class III directors and three Class I directors named in the proxy statement: Bruce Felt (Class III) DIRECTOR ELECTIONS ISSUER 63.000000 0 WITHHOLD 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The election of the two Class III directors and three Class I directors named in the proxy statement: Kevin Lynch (Class III) DIRECTOR ELECTIONS ISSUER 63.000000 0 WITHHOLD 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The election of the two Class III directors and three Class I directors named in the proxy statement: Atul Bhatnagar (Class I) DIRECTOR ELECTIONS ISSUER 63.000000 0 WITHHOLD 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The election of the two Class III directors and three Class I directors named in the proxy statement: Alexander Slusky (Class I) DIRECTOR ELECTIONS ISSUER 63.000000 0 WITHHOLD 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The election of the two Class III directors and three Class I directors named in the proxy statement: Morgan Kurk (Class I) DIRECTOR ELECTIONS ISSUER 63.000000 0 WITHHOLD 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026; AUDIT-RELATED ISSUER 63.000000 0 FOR 63.000000 FOR Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The approval, on a non-binding, advisory basis, of the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 63.000000 0 FOR 63.000000 FOR Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The approval, on a non-binding, advisory basis, of the frequency of future advisory votes on the compensation of our named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 63.000000 0 ONE YEAR 63.000000 AGAINST Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The approval of a reverse share split; CAPITAL STRUCTURE ISSUER 63.000000 0 FOR 63.000000 FOR Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The approval of an amendment to our Memorandum and Articles of Association to grant our board of directors the power to deal with any fractional shares resulting from a consolidation or division of our share capital; CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 63.000000 0 FOR 63.000000 FOR Cambium Networks Corporation G17766109 KYG177661090 06/25/2026 The approval of an amendment to our Memorandum and Articles of Association to reflect the reverse share split in accordance with the reverse share split ratio selected by the board of directors; and CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 63.000000 0 FOR 63.000000 FOR Curis, Inc. 231269408 US2312694084 06/25/2026 To adopt and approve amendments to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued shares of common stock, by a ratio ranging from any whole number between 1-for-5 and 1-for-25, as determined by the Company's Board of Directors (the "Board") in its discretion, subject to the Board's authority to abandon such amendments (the "Reverse Stock Split Proposal"). CAPITAL STRUCTURE ISSUER 25.000000 0 FOR 25.000000 FOR Curis, Inc. 231269408 US2312694084 06/25/2026 To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the adoption and approval of the Reverse Stock Split Proposal. CORPORATE GOVERNANCE ISSUER 25.000000 0 FOR 25.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Michael Cohen DIRECTOR ELECTIONS ISSUER 37.000000 0 WITHHOLD 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Maile Naylor DIRECTOR ELECTIONS ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Kayla Dean Obia DIRECTOR ELECTIONS ISSUER 37.000000 0 WITHHOLD 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Gregory Graves DIRECTOR ELECTIONS ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Laird Hamilton DIRECTOR ELECTIONS ISSUER 37.000000 0 WITHHOLD 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Grant J. LaMontagne DIRECTOR ELECTIONS ISSUER 37.000000 0 WITHHOLD 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Jason Vieth DIRECTOR ELECTIONS ISSUER 37.000000 0 WITHHOLD 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Election of Directors: Kristin Patrick DIRECTOR ELECTIONS ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Ratification of the appointment of KPMG LLP as the independent registered public accounting firm. AUDIT-RELATED ISSUER 37.000000 0 FOR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Approval, by non-binding advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 37.000000 0 AGAINST 37.000000 AGAINST Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Approval, by non-binding advisory vote, the frequency of holding a future advisory vote an executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 37.000000 0 ONE YEAR 37.000000 FOR Laird Superfood, Inc. 50736T102 US50736T1025 06/25/2026 Approval of an amendment to the Incentive Plan to increase the number of shares authorized for issuance pursuant to the Incentive Plan and to extend the term of the Incentive Plan. COMPENSATION ISSUER 37.000000 0 AGAINST 37.000000 AGAINST Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Re-elect Christopher Hill as Director DIRECTOR ELECTIONS ISSUER 273.000000 0 AGAINST 273.000000 AGAINST Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Re-elect Garry Menzel as Director DIRECTOR ELECTIONS ISSUER 273.000000 0 AGAINST 273.000000 AGAINST Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Reappoint Grant Thornton LLP as Auditors AUDIT-RELATED ISSUER 273.000000 0 AGAINST 273.000000 AGAINST Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Authorize Board to Fix Remuneration of Auditors AUDIT-RELATED ISSUER 273.000000 0 FOR 273.000000 FOR Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 273.000000 0 FOR 273.000000 FOR Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Authorize Issue of Equity CAPITAL STRUCTURE ISSUER 273.000000 0 FOR 273.000000 FOR Adaptimmune Therapeutics Plc 00653A107 US00653A1079 06/29/2026 Authorize Issue of Equity without Pre-emptive Rights CAPITAL STRUCTURE ISSUER 273.000000 0 FOR 273.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Matthew O'Leary DIRECTOR ELECTIONS ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Scott Griffith DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Pamela S. Mader DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Raymond J. Chess DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Alan S. Henricks DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Paul Savoie DIRECTOR ELECTIONS ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Election of Directors: Desi Ujkashevic DIRECTOR ELECTIONS ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Proposal to approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Proposal to ratify the appointment of Carr, Riggs & Ingram, L.L.C. as the Company's independent auditors for the fiscal year ending December 31, 2026. AUDIT-RELATED ISSUER 1.000000 0 FOR 1.000000 FOR Workhorse Group Inc. 98138J503 US98138J5039 06/29/2026 Approve the Amended and Restated Workhorse Group 2023 Long-Term Incentive Plan. COMPENSATION ISSUER 1.000000 0 AGAINST 1.000000 AGAINST Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Elect four directors to serve on our Board of Directors for a one-year term of office expiring at the 2027 Annual Meeting of Stockholders: Ritsaart J. M. van Montfrans DIRECTOR ELECTIONS ISSUER 428.000000 0 WITHHOLD 428.000000 AGAINST Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Elect four directors to serve on our Board of Directors for a one-year term of office expiring at the 2027 Annual Meeting of Stockholders: Michael C. Battaglia DIRECTOR ELECTIONS ISSUER 428.000000 0 WITHHOLD 428.000000 AGAINST Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Elect four directors to serve on our Board of Directors for a one-year term of office expiring at the 2027 Annual Meeting of Stockholders: Jack Levine DIRECTOR ELECTIONS ISSUER 428.000000 0 WITHHOLD 428.000000 AGAINST Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Elect four directors to serve on our Board of Directors for a one-year term of office expiring at the 2027 Annual Meeting of Stockholders: Glen Moller DIRECTOR ELECTIONS ISSUER 428.000000 0 FOR 428.000000 FOR Blink Charging Co. 09354A100 US09354A1007 06/30/2026 To approve an amendment to the Company's 2018 Incentive Compensation Plan increasing the number of shares of stock reserved for issuance thereunder by common 10,000,000 shares, to a new total of 17,000,000 shares. COMPENSATION ISSUER 428.000000 0 FOR 428.000000 FOR Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Approve, on a non-binding advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 428.000000 0 FOR 428.000000 FOR Blink Charging Co. 09354A100 US09354A1007 06/30/2026 Ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2026. AUDIT-RELATED ISSUER 428.000000 0 FOR 428.000000 FOR